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Abstract 
Post-traumatic stress disorder (PTSD) is increasingly being recognized as a health 
and economic burden. PTSD can develop after witnessing or experiencing severe or life-
threatening trauma and is associated with a number of devastating symptoms that result in 
decreased quality of life.  In addition, PTSD patients have difficulties integrating into 
society and are at greater risk for other neuropsychiatric disorders, including suicide and 
substance abuse.  The prevalence of PTSD ranges from 8% to 12 % in the general 
population with a noticeably higher incidences in the US military (20 % -34 %). Current 
treatment strategies for PTSD are limited and provide only symptomatic relief.  
Furthermore, many military-related PTSD cases are complicated with the presence 
of other comorbidities such as mild traumatic brain injury (mTBI).  Comorbid PTSD and 
mTBI pose particular challenges clinically; the similar symptomatic profiles and unclear 
presentations in the comorbid condition make it difficult to both diagnose and treat.  As 
both military and civilian populations are increasingly exposed to traumatic stress and 
mTBI, establishing criteria that facilitate the discrimination between these conditions and 
developing new effective treatments should be a top priority. Animal models are an 
appropriate platform for conducting such studies.  In Chapter 1, the epidemiology, 
diagnosis and pathophysiology of PTSD and TBI are reviewed.  In addition, a quick 
summary of preclinical animal models of the two conditions is presented.  The thesis then 
focuses on the establishment and validation of a chronic mouse model of PTSD (Chapter 
2) and PTSD with comorbid repetitive mild TBI (Chapters 3).  Chapter 4 investigates the 
key molecular mechanisms implicated in PTSD pathophysiology in a mouse model.  
Finally, the outcomes of a pilot treatment study are presented in Chapter 5. 
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Chapter 1. Introduction 
Incidence of PTSD, TBI and their comorbidity in civilian and combat 
populations 
Posttraumatic stress disorder (PTSD) is typically caused by exposure to a severe 
life-threatening traumatic event that results in a cluster of debilitating neurobehavioral 
symptoms (Kennedy, 2007).  In the United States, it is estimated that about 13% of women 
and 6% of men exposed to traumatic events will develop PTSD (Breslau et al. 1999).  In 
the United Kingdom, 3.7% of men and 5.1% of women exposed to traumatic events 
screened positive for PTSD (Fear et al. 2012). 
The incidence of PTSD ranges from 3 to 30 percent in groups exposed to specific 
traumatic incidents such as war, torture, or rape (Kennedy 2007).  Moreover, PTSD 
prevalence is estimated to increase to over 15% in refugees and conflict-afflicted 
populations because of exposure to torture and potentially traumatic events (Richter-Levin, 
Stork, and Schmidt 2018).  PTSD is also a common neuropsychiatric disorder among 
military populations due to the repeated exposure to horrific combat-related events.  The 
prevalence of PTSD in soldiers returning from Operation Iraqi Freedom (OIF) and 
Operation Enduring Freedom (OEF) ranges from 4% to 17% for those in the United States 
(Hines et al. 2014; Hoge et al. 2008) and 3% to 6% for the returning UK veterans 
(Richardson, Frueh, and Acierno 2010).  The probability of developing PTSD is higher for 
soldiers in combat roles and has been reported to double compared to subjects in 
noncombat roles (Kok et al. 2012).  Furthermore, many soldiers are also exposed to 
various degrees of traumatic brain injuries (TBI), which can further complicate diagnosis 
and treatment outcome (Kennedy 2007; Tanev et al. 2014).  
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 A report from the RAND corporation in 2009 indicated that 19 % of the soldiers 
returning form deployment in Iraq and Afghanistan were diagnosed with TBI and 5% were 
diagnosed with co-morbid PTSD and TBI (Holdeman 2009).  Mild TBI (mTBI) is the most 
common form of TBI (representing more than 80% of all TBI cases) and often co-exists 
with other psychiatric conditions such as depression, PTSD and suicidal ideation (Bigler 
and Tsao 2017; Lindquist, Love, and Elbogen 2017).  A number of studies have suggested 
that risk of developing PTSD increases after mTBI in both civilian (Bryant et al. 2009) and 
military populations (Kennedy et al. 2010). However, contradictory findings were reported 
in a study of 781 injured military service members, showing lower rates of PTSD and 
mood/anxiety disorders in those with mild and moderate-severe TBI (MacGregor et al. 
2010). 
The impact of co-existing TBI and PTSD on symptom severity relative to each 
condition remains elusive.  In one particular study, patients with co-morbid PTSD and mild 
to severe TBI exhibited fewer intrusive memories than patients with PTSD alone (Hibbard 
et al. 1998).  Another study demonstrated that patients with co-morbid PTSD and moderate 
to severe TBI report more re-experiencing and hyperarousal symptoms as compared to 
those with PTSD alone (Simonović, Radisavljević, and Grbeša 2011).  Thus there is a 
heterogeneity and complexity of behavioral phenotypes exhibited by patients with co-
morbid PTSD and TBI, which makes it very difficult for clinicians to accurately diagnose. 
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Clinical Diagnosis of PTSD 
PTSD involves a constellation of symptoms and is diagnosed clinically based on 
the criteria outlined in the Diagnostic and Statistical Manual of Mental Disorders, 5th ed. 
(DSM-5). These criteria include (A) experiencing a traumatic event, (B) intrusions (re-
experiencing the traumatic event), (C) avoidance of traumatic cues, (D) negative 
alterations in cognition and mood and (E) alterations in arousal and reactivity.  All criteria 
must be met, in addition to the persistence of symptoms for more than 30 days following 
the event (F), for a PTSD diagnosis to be established. If symptoms resolve before this time, 
the diagnosis is classified as acute stress disorder (American Psychiatric Association 
2000). 
Patients suspected to have PTSD should be clinically evaluated with a 
comprehensive psychiatric assessment due to the lack of specific and sensitive clinical 
biomarkers.  Various tools are used by physicians to assist with screening for PTSD and 
aiding its diagnosis. However, many of these screening tools rely on subjective self-
reporting of symptoms.  The Primary Care PTSD screening tool is a questionnaire that 
patients may fill out by themselves or with the aid of a clinician (Prins et al. 2016). The 
PTSD checklist (PCL-5), is another tool with high sensitivity and specificity that can be 
used both for screening as well as for monitoring symptom severity and progress (Blevins 
et al. 2015).  With a maximum score of 80, a score of 38 is associated with a diagnosis of 
PTSD (Spoont et al. 2015).  Another assessment tool is the Clinician-Administered PTSD 
Scale (CAPS).  The CAPS involves a structured interview, in which the clinician reads 
prompts verbatim and assigns a pre-defined symptom severity rating based on symptom 
frequency and intensity.  The CAPS is available in different forms, which address the 
19 	
assessment of PTSD symptoms occurring in the past week, month, or throughout the 
lifetime (Nader et al. 1996).  The current CAPS (CAPS-5) consists of 30 questions that 
asses the frequency and intensity of PTSD symptoms. A patient must fulfil the 
requirements in both frequency and intensity score for each item in order to meet the 
criteria for a symptom. Table 1.1 depicts the CAPS-5 scoring criteria. A patient must meet 
these criteria to receive a PTSD diagnosis (Weathers et al. 2013).  
 
Criterion Condition 
 A Has to be met (experiencing a traumatic event) 
B At least one symptom 
C At least one symptom 
D At least two symptoms 
E At least two symptoms 
F Has to be met (disturbance has lasted one month) 
G Has to be met (disturbance causes either clinically significant distress or 
functional impairment 
Table 1.1. CAPS scoring. Adapted from Weathers et al. 2013.  
 
Clinical Diagnosis of TBI 
TBI is caused by a forceful blow or impact to the head that is often accompanied by 
both short-term and long-term neuropsychological symptoms such as confusion, 
irritability, impulsiveness, and depression (Simonović et al. 2011).  Due to the 
heterogeneous nature of traumatic brain injuries, they can be categorized in several ways. 
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Most commonly, the Glasgow Coma Scale (GCS) (Table 1.2) is used to classify the 
severity of TBI based on assessment and grading of patient eye-opening, verbal and motor 
responses.  Higher scores are associated with mild injury, whereas lower scores with a 
more severe injury. While GCS offers a simple and reproducible method, it can also be 
easily influenced by medical interventions (sedation, intubation, etc.), intoxication (e.g. 
EtOH or recreational drug use), as well as patient’s physical limitations (e.g. paralysis) 
(Prins et al. 2016).  In patients where these limitations are suspected to interfere with the 
validity of the GCS score, the Full Outline of UnResponsiveness (FOUR) Score may be 
used. The FOUR Score is based primarily upon neurological examination of the brainstem. 
Although the FOUR score platform is limited by the greater complexity of the exam as 
well as the lack of long-term use when compared to the GCS, it has similar sensitivity and 
specificity for prognosis (Iyer et al. 2009). Low scores are associated with greater hospital 
mortality according to one study (Wijdicks et al. 2015).  In addition to these clinical 
scores, neuroimaging may also be obtained to assess more severe TBI cases especially 
when underlying pathologic injuries are suspected. Computed tomography (CT) is the 
imaging modality of choice in the acute setting.  Other neuroimaging techniques such as 
magnetic resonance imaging (MRI), functional MRI, single-photon emission computed 
tomography (SPECT) and diffusion tensor imaging (DTI) can also be used to investigate 
the structural and functional pathological mechanisms (Lee and Newberg 2005). However, 
limited data is the available on the value of the advanced imaging techniques (functional 
MRI, SPECT and DTI) in routine clinical use at the patient level and therefore are more 
restricted to use in clinical research (Wintermark et al. 2015).  Because of the low 
detection sensitivity and high cost, conventional imaging techniques (such as CTs cans and 
MRI) are rarely used to diagnose mTBI (Lee and Newberg 2005). 
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Criterion Response Score 
Eye Opening Spontaneous  4 
To sound 3 
To pressure 2 
None 1 
Best verbal response Oriented/Normal conversation  5 
Confused/disoriented Conversation 4 
Words 3 
Sounds 2 
None 1 
Best motor response Obeys commands 6 
Localizing response to pain 5 
Normal flexion to pain 4 
Abnormal flexion 3 
Extension 2 
None 1 
 Total  
Table 1.2. Glasgow Coma Scale 
 
Current treatment options for PTSD  
Management of PTSD patients relies on several partially effective treatment 
strategies, which include the use of psychotherapy, such as cognitive behavioral therapy 
(CBT), sleep modulation, lifestyle interventions and/or pharmacotherapy. These 
pharmacological interventions mainly rely on few antidepressant drugs, such as selective 
serotonin reuptake inhibitors (SSRIs) and serotonin noradrenaline reuptake inhibitors 
(SNRIs) (Tanev et al. 2014).Despite some of the beneficial effects reported using some of 
these therapies, in most cases patients are typically refractory to treatment (Krystal et al. 
2017). The effectiveness of SSRI in treating PTSD was reported to be marginal and 
comparable to placebo (Ragen et al. 2015).  Moreover, in those patients who initially show 
signs of improvement, there is a high incidence of relapse of clinical symptoms after many 
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months (Bernardy & Friedman, 2017).  Together these underscore the vital need to develop 
new perspectives regarding the biological responses to PTSD and to identify new and 
novel therapeutic approaches. 
 
Pathophysiology of PTSD 
PTSD is a complex disorder that involves multiple system dysregulation.  Patients 
show reduced hippocampal volume, decreased responses of the prefrontal cortex and 
increased amygdala activity (Fragkaki, Thomaes and Sijbrandij 2016; Sherin and Nemeroff 
2011). In addition to these structural and activity changes in the brain, the involvement of 
the hypothalamic-pituitary-adrenal (HPA) axis, brain-derived neurotrophic factor (BDNF) 
and neurotransmitters such as glutamate and gamma-aminobutyric acid (GABA) have also 
been routinely reported.  A survey among experts in the field of PTSD research has 
suggested that the glutamatergic system and HPA axis are among the most promising 
targets for PTSD treatment and thus will be discussed in more detail in the following 
sections (Krystal et al. 2017).  
 
Hypothalamic-pituitary-adrenal axis dysregulation 
The physiological response to an acute stressor or danger involves the activation of 
the HPA-axis and the immediate activation of the autonomic nervous system (Mifsud and 
Reul 2016).The HPA axis (Figure 1.1) receives excitatory signals from the amygdala and 
inhibitory signals from the hippocampus. In the hypothalamus, the paraventricular nucleus 
responds to stress by releasing corticotropin releasing hormone (CRH), which acts on the 
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anterior pituitary triggering the release of adrenocorticotropic hormone (ACTH) into the 
bloodstream. ACTH stimulates the adrenal cortex to synthesize and release the 
glucocorticoids cortisol (humans) or corticosterone (rodents). Binding of glucocorticoid to 
its central receptors in the hippocampus, hypothalamus, and pituitary prevents excess 
activation of the HPA axis (which constitutes the negative feedback system; Steven E. 
Hyman 2009). 
 
 
Figure 1.1. The HPA axis. After exposure to stress, the PVN of the hypothalamus releases 
corticotropin-releasing factor (CRF) which acts on the anterior pituitary to release ACTH 
into the bloodstream. ACTH will then stimulate the adrenal cortex to synthesize and 
release glucocorticoids to regulate peripheral and central functions in response to stress. Reprinted	from “How adversity gets under the skin”(Hyman 2009). Copyright 2018 by 
Springer Nature. Reprinted with permission.  
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Dysregulation of HPA axis feedback mechanisms is implicated in the pathogenesis 
of  PTSD (Leistner and Menke 2018).  Several studies have reported lower baseline 
cortisol levels in PTSD patients, (Yehuda 2001), albeit there is some disagreement, with 
some reports showing no changes in cortisol levels (Meewisse et al. 2007). The 
discrepancies between studies may be attributed to differences in sample collection 
procedures (such as sample type and time of the day in which samples were obtained), the 
ratio of female to male subjects in patient cohorts, and the type of trauma examined 
(Matthew J. Girgenti et al. 2017). Moreover, PTSD patients also show increased sensitivity 
to dexamethasone suppression (Yehuda et al. 1993), which has led to the suggestion that 
glucocorticoid negative feedback sensitivity is enhanced in PTSD (Yehuda et al. 1993, 
1995). As dexamethasone acts mainly on glucocorticoid receptor (GR) in the pituitary, 
these findings may indicate compromised pituitary function in PTSD. Additional evidence 
pointing towards impaired glucocorticoid negative feedback regulation in PTSD is the 
decreased expression of GR co-chaperone FK506 binding protein 5 (FKBP5) in red blood 
cells and the prefrontal cortex (Averill et al. 2017; Yehuda et al. 2009). 
GR located in the in the hippocampus, hypothalamus, and pituitary is the main 
regulator of glucocorticoids negative feedback (Abdallah, Southwick, and Krystal 2017; 
Hyman 2009). In the absence of stress (normal glucocorticoid levels), GR is mainly 
localized in the cytoplasm in an inactive complex containing co-chaperones heat shock 
protein 90 (HSP90) and FKBP5. After HPA axis activation, plasma glucocorticoid levels 
increase, dissociate from the bound plasma proteins and passively diffuse across plasma 
membranes to bind glucocorticoid receptor in the cytoplasm. Glucocorticoids can diffuse 
easily through the blood-brain barrier (BBB) because of their small size and lipid 
solubility. Binding of glucocorticoids to the GR complex results in the dissociation of 
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FKBP5 and HSP90 allowing the activation and translocation of GR to the nucleus (Figure 
1.2).  Once in the nucleus, GR binds to glucocorticoid response elements (GRE) initiating 
gene expression of a number of proteins such as FKBP5 and CRH (Figure 1.2) (Matthew 
J. Girgenti et al. 2017). Because FKBP5 bound GR is inactive in the cytoplasm, low levels 
of cytoplasmic FKBP5 would result in decreased inhibitory control of GR and enhanced 
GR sensitivity. Enhanced GR sensitivity would subsequently result in a reduction in basal 
glucocorticoid levels. Alternatively, it was suggested that the change in FKBP5 levels is an 
adaptation to low cortisol levels in PTSD subjects rather than being a risk factor or a cause 
of HPA axis dysregulation (Figure 1.2). 
Interestingly, FKBP5 genotype has been reported to contribute to risk for PTSD. 
The interaction between polymorphisms in the FKBP5 gene and exposure to child abuse 
could predict the severity of PTSD symptoms in adult life (Binder et al. 2008; Watkins et 
al. 2016). In particular, the FKBP5 rs9470080 genotype was shown to moderate that risk 
(Xie et al. 2010). In addition, early trauma victims who carry the risk allele showed 
decreased DNA methylation in intron 7 of FKBP5 leading to increased gene expression 
and glucocorticoid receptor resistance (Klengel et al. 2013).  
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Figure 1.2. A hypothesized mechanism for the regulation of glucocorticoid signaling 
in PTSD. After HPA axis activation, cytoplasmic GR binds to glucocorticoids (e.g. 
cortisol) and translocates to the nucleus increasing gene expression of target gens such as 
FKBP5.  Increased FKBP5 expression creates an ultra-short intracellular feedback loop 
that limits excessive GR activation. The chronic decrease in baseline cortisol levels in 
PTSD patients may result in decreased GR activation as an adaptive mechanism which in 
turns lead to decreased expression of GR target genes such as FKBP5.  Reprinted 
from “Molecular and Cellular Effects of Traumatic Stress: Implications for PTSD” 
(Matthew J. Girgenti et al. 2017). Copyright 2018 by Springer Nature. Reprinted with 
permission. 
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GABAergic and glutamatergic abnormalities 
Disturbances in GABA and glutamate levels in PTSD patients have been examined 
in several human studies.  The majority of studies report a decrease in GABA levels in the 
serum and in multiple cortical regions (Geuze et al. 2008; Pennington et al. 2014; Rosso et 
al. 2014), and an increase in serum glutamate levels (Nishi et al. 2015).  Some 
contradictory findings have also been reported (Averill et al. 2017). Additionally, multiple 
preclinical and clinical studies have demonstrated the potential of ketamine (a glutamate 
N-methyl-D-aspartate (NMDA) receptor antagonist) in the treatment of mood and anxiety 
disorders (Costi, Van Dam, and Murrough 2015). In a randomized clinical trial, ketamine 
was shown to be effective in the rapid reduction of symptom severity in chronic PTSD 
patients (Feder et al. 2014).  Figure 1.3 depicts a proposed mechanism for the role of 
GABA and glutamate system in mediating PTSD pathophysiology. 
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Figure 1.3. A schematic for the proposed role of GABAergic and glutamatergic 
abnormalities in PTSD pathophysiology. The interaction between predisposing 
vulnerabilities (risk factors) and traumatic stress results in a dysregulation in glutamatergic 
signaling,  inflammatory processes and the HPA axis ultimately leading to increased brain 
glutamate levels and excitotoxicity.  These events are followed by synaptic 
dysconnectivity in brain regions responsible for emotional regulation and stress response 
and the subsequent emergence of some PTSD symptoms.  Reprinted from “Glutamate 
Dysregulation and Glutamatergic Therapeutics for PTSD: Evidence from Human 
Studies”(Averill et al. 2017). Copyright 2018 by Elsevier. Reprinted with permission.  
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Alterations in Brain-Derived Neurotrophic Factor 
BDNF is a member of the neurotrophin family of nerve growth factors. The mature 
form of BDNF influences several fundamental brain functions including neuronal survival, 
growth and synaptic plasticity (Phillips 2017). 
PTSD patients show lower serum BDNF levels (Angelucci et al. 2014) relative to 
non-traumatized control subjects. In animal studies, exposure to acute or chronic stress is 
associated with a decrease in hippocampal BDNF levels in the hippocampus (Lee and Kim 
2010; Yu and Chen 2011).  
A BDNF gene polymorphism has been reported to confer risk for a number of 
psychiatric disorders including PTSD. A single nucleotide polymorphism (SNP) in the 
BDNF gene resulting in a valine to methionine substitution (V66M) is associated with 
reduced hippocampal volume (Brooks et al. 2014) and altered fear extinction and 
hyperarousal symptoms in PTSD subjects (Soliman et al. 2010; Zhang, Li, and Hu 2016). 
In animal studies, V66M was also associated with increased anxiety-related behaviors 
(Chen et al. 2007). Furthermore, long-term epigenetic changes in hippocampal BDNF 
DNA were reported after chronic psychosocial stress in rats (Roth et al. 2011).  
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Pathophysiology of TBI 
Primary and secondary injuries occur after sustaining a TBI. Primary injuries are 
the result of direct physical or mechanical damage at the initial moment of impact.  
Secondary injuries are a number of delayed pathological and biochemical disturbances that 
occur over the course of hours to months after injury (Marklund and Hillered 2011). The 
cascade of secondary injuries is initiated by an increase in the release of excitatory 
neurotransmitters such as glutamate and aspartate, which in turn activate glutamate 
receptors and increase Ca+2influx. The increased influx of Ca+2 results in increased 
production of reactive oxygen species, mitochondrial damage, an increase in the release of 
chemokines and cytokines, and changes in gene expression. These cytotoxic events will 
eventually lead to blood-brain barrier damage, cell death, axonal injury and impaired 
cognitive functions (Xiong, Mahmood, and Chopp 2013). Changes in synaptic plasticity 
are also implicated in TBI-related cognitive dysfunction especially in mild to moderate 
cases where cell death and neuronal degeneration are not obvious (Walker and Tesco 
2013). The goals of TBI therapeutic interventions are to prevent or alleviate secondary 
injuries, since primary injuries can be only prevented by taking precautionary measures 
(Marklund and Hillered 2011). 
The majority of patients who endure a single concussion (mild TBI) will have a 
complete recovery after receiving proper management (Kamins and Giza 2016). One of the 
main aims of care in concussion patients is to decrease the risk of exposure to a second 
concussion, since multiple concussions are well known to increase symptom severity and 
prolong recovery times (Barkhoudarian, Hovda, and Giza 2011). Recently, the 
consequences of enduring multiple concussions in athletes and military personnel have 
31 	
received a lot of attention because of its implications in the development of Chronic 
Traumatic Encephalopathy or CTE (Omalu et al. 2011). CTE is a neurodegenerative 
disease characterized by the accumulation of hyperphosphorylated Tau protein in different 
brain regions, and has been associated with severe alterations in mood, behavior and 
cognition (McKee et al. 2015; Omalu et al. 2011). 
 
Preclinical animal models for PTSD 
Although the impact of neuropsychiatric disorders on public health is enormous, 
the progress in understanding their pathophysiology, and consequently developing new 
treatment strategies, has been very slow and yielded very little success. The ethical and 
technical challenges surrounding examining the living human brain are likely responsible 
for the lack of advancement (Nestler and Hyman 2010).  Heterogeneity of trauma type and 
exposure, lack of prospective design studies and available autopsy tissue material also 
preclude our ability to adequately interrogate the pathophysiological mechanisms in 
humans.  Animal models provide an alternative platform to conduct more invasive and 
controlled longitudinal studies in response to different stressors, but to be of value such a 
model must be ethologically valid and demonstrate relevance to the human condition. 
Several criteria have to be established when assessing the validity of animals models 
including: (1) Face validity which assesses the similarities between the symptoms 
produced by the animal model and the human condition,  (2) Construct validity which 
accounts for the accuracy of the model to measure what it was designed for, and (3) 
Predictive validity which examines the ability of the model to predict treatment outcomes 
(Belzung and Lemoine 2011; Goswami et al. 2013). 
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Modeling PTSD in animals is complex, given the limitations in our ability to model 
and assess certain neurobehavioral human patterns in animals such as guilt and shame. 
However, most studies attempt to recapitulate some behavioral traits similar to the cluster 
of symptoms experienced in human PTSD patients as defined by the DSM-5 criteria, such 
as anxiety, startle response, deficits in social interaction, depression, avoidance-like 
behavior, reduced exploration and reconsolidation of traumatic memories (American 
Psychiatric Association, 2000). Typically, these PTSD-like symptoms are induced in 
animals by exposing them to one or more aversive stimuli for variable durations to 
establish the face validity of the model (Bowers and Ressler 2015; Matar et al. 2013; 
Sambasivarao 2013). 
 
Summary of the most widely used stress procedures to model PTSD in Animals 
Stressors used in PTSD animal models can be broadly divided into three categories; 
1) physical such as inescapable foot-shocks, forced swim, and restraint stress, 2) social 
such as unstable housing, social isolation, maternal separation and social defeat, and 3) 
psychological stressors involving physical exposure to a predator or exposure to a predator 
odor (Blanchard and Caroline Blanchard 1977; Matar, Zohar, and Cohen 2013; 
Sambasivarao 2013). Most of these stressors have been used alone or in combination to 
produce PTSD-like behavioral and neurobiological changes. The challenge, however, in 
developing an ethologically relevant animal model of PTSD lies in the ability to 
demonstrate face, construct, and predictive validity (Goswami et al. 2013; Matar et al. 
2013). Most preclinical studies to date have not been able to fully satisfy all these 
combinatory criteria, perhaps most important of which is the persistence of symptoms at 
33 	
chronic time points (many months) after trauma; thus, more studies need to be conducted 
in vivo to improve on currently available animal models. A brief summary of the most 
widely used PTSD animal models (Figure 1.4) will be presented in the following section. 
 
Social defeat  
Social defeat is a well-established model for depression and PTSD (Blanchard and 
Caroline Blanchard 1977). In this model, test mice can interact with an aggressive 
dominant mouse, typically of a different genetic background (example CD1 or BALB/c 
mice if the test mouse is C57BL/6), and they are subsequently transferred to a cage that 
allows for olfactory and auditory but not visual communication (Figure 1.4F). The 
auditory and olfactory communication is used as a reminder of the defeat sessions (Hollis 
and Kabbaj 2014).  Animals in this model can then be tested for social dominance by 
placing them in a box that contains two cages, one empty and one containing the 
aggressive mouse. Defeated mice will tend to spend more time around the empty cage 
(Brachman et al. 2016). This social avoidance behavior has been reported 10 days after the 
social defeat procedures (Toth and Neumann 2013).  Additional behavioral changes such 
as hyperarousal and anhedonia (decreased sucrose preference) have also been reported at 
around 3 weeks after the last stress (Wood et al. 2015). Mice exposed to the social defeat 
paradigm typically show increased baseline plasma corticosterone at 12 days after stress 
(Page, Opp, and Kozachik 2016). 
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Response to predator stress 
In the predator stress model, animals receive single or multiple exposures to a 
physical predator or a predator scent such as cat feces, fox urine or their components 
(Figure 1.4B). Studies have shown anxiety-like behavior and freezing in response to 
trauma reminders (3 months after predator stress) (Zoladz et al. 2015). The impact of 
predator stress on other behavioral domains such as anhedonia and stress-coping is not 
clear (Deslauriers et al. 2018). While elevated baseline plasma corticosterone levels are 
observed at 7 days after exposure to predator scent (Cohen et al. 2010), low baseline 
plasma corticosterone levels were reported in the predator based psychosocial stress model 
(PPS) involving exposure to a predator and daily unstable social housing (Zoladz, 
Fleshner, and Diamond 2012). The PPS model also shows increased sensitivity to 
dexamethasone suppression in stressed rats; a finding that has been documented in 
multiple studies of PTSD patients (de Kloet et al. 2007; Nijdam et al. 2015; Yehuda 2001; 
Yehuda et al. 1993).  
 
Single prolonged stress 
Single prolonged stress (SPS) relies on a single episode of intense stressful events 
to trigger several PTSD-related phenotypes (Liberzon, Krstov and Young 1997). The 
procedures of SPS are quite standard and involves a 2-hour immobilization or restraint, 
followed by 20 minutes of forced swimming, and finally exposure to diethyl ether for 2 to 
3 minutes (Figure 1.4C). The SPS model shows a number of behavioral deficits such as 
passive stress-coping, anxiety-like and impaired fear extinction 7-21 days after the last 
stress (Borghans and Homberg 2015; Deslauriers et al. 2018). A key limitation to the SPS 
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model is that baseline corticosterone levels are elevated at day 7 after exposure 
(Deslauriers et al. 2018; Kohda et al. 2007). However, the model is succesful in 
demonstrating enhanced glucocorticoid negative feedback possibly due to overexpression 
of GR in brain regions mediating activity of the HPA-axis during stress (Yamamoto et al. 
2009).   
 
Unpredictable variable stress 
Unpredictable variable stress (UVS) or chronic unpredictable stress (CUS) is 
generally considered a model of depression, since it involves prolonged exposure to mild 
to moderate stressors. Prolonged exposure to life-stress is implicated in stress-induced 
depression in contrast to PTSD which usually emerges from a sudden intense exposure to a 
single trauma. However, it is argued that the repetitive nature of this paradigm is relevant 
to combat-related PTSD where the exposure to trauma is recurrent and prolonged (Richter-
Levin et al., 2018).  In this paradigm, animals are exposed to multiple stressors over the 
period of 4 to 8 weeks in an unpredictable manner (Monteiro et al. 2015). The stressors 
used in this paradigm can vary in intensity between paradigms as depicted in Figure 1.4E. 
Changes in body weight, avoidance and stress-coping have been robustly reported at the 
end of the stress procedures (Monteiro et al. 2015). However, few studies have 
investigated the persistence of behavioral deficits after CUS cessation possibly because of 
its common use as a stress-induced depression models where it is suitable for the stress 
procedures to be ongoing. CUS mice have been demonstrated to show elevated baseline 
corticosterone levels at 1-7 days after the last stressor (Cordner and Tamashiro 2016). 
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Figure 1.4. A number of the most widely used PTSD animal models. In fear 
conditioning experiments (A), animals are exposed to inescapable footshocks that are often 
paired with a cue or reminder. Predator stress models involve single or multiple exposures 
to a predator (e.g. cat) or a predator scent (e.g. fox urine) (B). Panel (C) depicts the three 
consecutive stressors implemented in the single prolonged stress model. Restraint or 
immobilization stress procedures (D). Examples for the stressors used in unpredictable 
variable stress (UVS) or chronic unpredictable stress (CUS) models are depicted in panel 
(E). The social defeat model involving multiple encounters with a dominant aggressive 
mouse is depicted in panel (F). Reprinted from “Current Status of Animal Models of 
Posttraumatic Stress Disorder: Behavioral and Biological Phenotypes, and Future 
Challenges in Improving Translation”(Deslauriers et al. 2018). Copyright 2018 by 
Elsevier. Reprinted with permission. 
 
Experimental approaches to evaluate PTSD-related behavior in animal models. 
The main experimental tools used to test the Face validity of animal behavior in 
PTSD models are briefly summarized in the following section.  
 
Fear Conditioning 
Pavlovian fear conditioning is among the methods commonly used to evaluate 
abnormal fear (Maren 2001). Briefly, animals receive an unconditioned stimulus (aversive 
stimulus) paired with a conditioned stimulus (a tone) in a particular context. The 
conditioned stimulus serves as a predictor of traumatic aversive stimulus.  Animals are 
then tested for freezing behavior (a measure of fear) in the same (or novel) context with or 
without the conditioned stimulus, determining “cued” or “contextual” fear responses. 
Animals with intensified fear will show greater freezing behavior even in the absence of 
aversive stimuli (Bowers and Ressler 2015). Preclinical models using foot-shocks of 
various intensities, frequency and duration are routinely applied to investigate the 
underlying neurobiology of adaptive and pathological fear (Bowers and Ressler 2015).  
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Social behavior 
Alterations in social functioning (e.g. social anxiety and avoidance and 
occupational impairments) have been noted in PTSD patients (Frueh et al. 2001). Social 
behavior can be investigated in animals using the three-chamber test, which evaluates the 
time spent by a mouse interacting between an empty chamber and a chamber holding a 
new novel stranger mouse (Egashira et al. 2007). Animals exposed to trauma, with 
impaired social behavior, tend to spend less time interacting with a new novel mouse 
compared to their control counterparts (Egashira et al. 2007).  
 
Anxiety-like behavior 
Anxiety is another PTSD-related behavior that is frequently evaluated in animal 
models (Tanev et al. 2014). The Elevated Plus Maze (EPM) is a traditional test used to 
assess anxiety in animal models (Bailey and Crawley 2009; Handley and Mithani 1984).  
The apparatus consists of two open and two closed arms forming a plus shape. Normal 
animals tend to spend a proportion of time exploring the open arms of the maze while 
animals with symptoms of anxiety tend to spend most of their time in the closed arms. On 
the contrary, animals with impulsive-like behavior (disinhibition) tend to spend more time 
exploring the open arms (Bortolato et al. 2009).  The Open Field is another routinely used 
behavioral test used to assess anxiety and general locomotor activity (Hall and Ballachey 
1932). The test field is a simple enclosure (circular, rectangular or, square) surrounded by 
walls to prevent escape. Healthy animals will typically spend time exploring the border of 
the field in contact with the walls but will also spend a percentage of their time exploring 
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the unshielded center zone. Spending significantly less time exploring the center zone is 
used as an index of anxiety (thigmotaxis), while spending relatively more time exploring 
the center zone implies increased exploratory behavior and/or disinhibition (Bailey and 
Crawley 2009). 
 
Stress-coping behavior 
The Forced Swim Test is usually implemented to assess stress-coping behavior. 
The test procedures involve placing the animal for 6 min in a cylindrical vessel (20cm X 
20 cm) containing water at room temperature. In response to the forced swim stress, 
animals either swim, float, or struggle (climb the walls of the container). The time spent 
swimming and struggling is interpreted as positive stress-coping strategy, while the time 
spent floating (immobile) is interpreted as a passive stress-coping strategy. Antidepressant 
medications are successful in decreasing rodents’ immobility time in the FST, therefore the 
passive stress-coping behavior is often referred to as depression-like behavior in the 
literature (Brachman et al. 2016). However, recent articles have considered the “stress-
coping strategy” terminology to be more accurate in describing the behaviors assessed by 
the FST (Commons et al. 2017; Molendijk and de Kloet 2015). 
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Preclinical animal models of mTBI. 
Because of TBI heterogeneity and the ethical and technical limitations of human 
studies noted above, preclinical animal models provide a valuable platform to examine the 
pathobiological mechanism of TBI in a focused and well-controlled setting (Xiong et al. 
2013). Several procedures have been developed to model different types and severities of 
TBI in rodents. In the context of mild TBI, closed head injury models (such as the weight-
drop and pneumatic impactor models) and blast injury models are often used (Shultz et al. 
2017). 
Our group has ample experience in developing single and repetitive mTBI mouse 
models that have been characterized at 24 hours and up to 24 months after injury. In 
agreement with clinical findings in concussion patients, we have shown that exposure to 
repetitive mTBI results in progressive cognitive deficits and behavioral impairments at 12 
months after the last injury (Mouzon et al. 2014, 2012; Ojo et al. 2013). These impairments 
were absent after a single mTBI. In addition, the behavioral alterations after repetitive TBI  
(5 hits with intra-hit 48-hours interval) were accompanied by progressive 
neuroinflammation and persistent white matter degeneration (Mouzon et al. 2014). 
Furthermore, increasing the number of hits to 24-32 hits with 48-hours interval resulted in 
the accumulation of hyperphosphorylated tau and cognitive deficits in mice expressing 
humanized tau 3 months post-injury (Ojo et al. 2016). 
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Summary of preclinical models for PTSD and co-occurring TBI. 
Very few studies have investigated the effects of both mTBI and PTSD in animal 
models. A study by Kwon and colleagues, supporting a synergistic relationship between 
TBI and traumatic stress, investigated the long-term consequences of unpredictable stress 
in combination with a blast injury. These studies reported impairment in memory function 
in blast injured mice exposed to chronic and unpredictable predator odor (Kwon et al. 
2011). In another study, Klemenhagen et al. found that repetitive concussive traumatic 
brain injury and post-injury foot shocks had synergistic effects in tests of social recognition 
and depression-like behavior, compared to non-shocked injured mice or shocked but 
uninjured mice that were less impaired (Klemenhagen, O’Brien, and Brody 2013). On the 
other hand, some recent studies have reported that mTBI may mitigate the PTSD-related 
behavior. Genovese et al. studied the effect of mTBI from a blast overpressure (BOP) on 
the expression of a conditioned fear in rats. Interestingly, BOP injuries decreased the 
expression of a conditioned fear response in rats exposed to inescapable electric shocks 
relative to rats receiving shocks only (Genovese et al. 2013).  A study from our laboratory 
has found that mTBI abrogates both contextual fear and impairments in social behavior, 
seen in PTSD animals  (Ojo et al. 2014).  Finally, a study by Sierra-Mercado et al. has 
shown that controlled cortical impact (CCI) injury had no influence on fear learning and 
extinction irrespective of when it was applied before or after fear conditioning (Sierra-
Mercado et al. 2015) 
A different topic that has been more extensively examined in the literature is the 
risk of developing PTSD-like symptoms after mTBI alone in animals. Six weeks after 
mTBI in rats, Elder al. found a decrease in open-field center activity following exposure to 
42 	
a predator cue and a decrease in the exploratory activity in an elevated plus maze (Elder et 
al. 2012). These changes, together with increased acoustic startle response (a rapid and 
involuntary muscle reflex to auditory stimuli), and conditioned fear were interpreted as 
PTSD-like traits (Elder et al. 2012). Another study by Reger et al. reported an overall 
increase in fear conditioning in rats several days after a fluid percussion injury (Reger et al. 
2012). Similarly, Meyer et al. observed an increase in conditioned fear (8 days post-injury) 
and a decrease in open-arm time in a plus maze after a weight drop injury (Meyer et al. 
2012).  
 
Hypotheses and Synopsis of the following chapters 
Developing a preclinical model that captures the complexity of both PTSD and r-
mTBI, either individually or comorbidly, is crucial to understand the underlying 
pathophysiology and to identify targets for therapeutic intervention.  However, as 
presented in this Introduction, there are innumerable potential paradigms that could be 
conceived to model PTSD and PTSD with comorbid TBI.  While these paradigms have 
been successful in probing several acute PTSD-related or mTBI-related phenotypes, 
studies exploring the long-lasting behavioral effects in correlation with the key biological 
outcomes of PTSD and/or TBI are lacking. When designing a new model, it is important to 
recapitulate multiple symptoms and pathologies in a manner and timescale that will be 
relevant to the human population. In addition, these models have limitations in modeling 
specific phenotypes such as HPA axis dysregulation in PTSD. For instance, CUS and SPS 
paradigms often result in an increase in basal plasma glucocorticoid levels after stress 
43 	
cessation, while they appear to be low or unchanged in PTSD patients (Deslauriers et al. 
2018; Yehuda 2001).  
Our group has previously developed a mouse model of PTSD with comorbid TBI, 
which unlike other models that examine the effects of TBI and traumatic stress at different 
timepoints, couples both events at around the same time. This approach is relevant to a 
large population of PTSD patients (such as the combat veteran population) who experience 
an emotional trauma around the same time that they also experience TBI. In our previous 
model, a combination of unpredictable exposure to psychological stressors 
(trimethylthiazoline—TMT, a component of fox urine), a physical stressor (one foot-
shock), and one mTBI were employed. This paradigm resulted in distinct and overlapping 
effects in neurobehavioral, neuropathological and biochemical profiles subacutely at 14 
days after exposures (Ojo et al. 2014). However, these effects did not persist at a chronic 
timepoint.  The goal for this new body of research was to overcome the limitations of our 
previous model and advance towards a valid model both for PTSD and PTSD with 
coincident TBI that shows long-lasting behavioral and neurobiological alterations.  Such a 
model could then be utilized to advance the understanding of the pathophysiology of the 
condition, and in accelerating the drug discovery process.  
My hypothesis was that with a new chronic stress exposure paradigm that combines 
physical, social and psychological stressors, I would develop a novel mouse model of 
PTSD with face and construct validity and a persistent phenotype. After establishing the 
PTSD model, the addition of our well-characterized r-mTBI protocol to the stress 
procedures would then show altered outcomes.  
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In chapter 2, I first focused on establishing a PTSD mouse model that showed 
chronic stress-related effects at a chronic timepoint. To accomplish that, I used a more 
intensified stress procedure than that previously employed, including repeated 
unpredictable stress (RUS) and social isolation. To validate the model, I examined the 
behavioral outcomes at extended timepoints (acute to chronic). In addition, I explored the 
impact of the stress procedure on a number of PTSD-related pathobiological mechanisms 
such as the HPA axis and hippocampal structure and plasticity. 
I then examined the effects of repeated exposure to mild TBI in addition to stress in 
chapter 3, to explore the impact of repetitive mild TBI (r-mTBI) on stress-related 
phenotypes. The procedures of r-mTBI and RUS will be delivered twice to resemble the 
multiple traumatic events and injuries that are usually sustained by soldiers receiving 
multiple deployments and to address a possible dose-response relationship of trauma, TBI 
and their interaction.  
In chapter 4, I specifically interrogated the role of the HPA axis in our stress model 
using different challenges and molecular tools. Finally, I present the findings of a pilot 
treatment study in chapter 5, involving supplementing GR signaling using low dose 
dexamethasone and replenishing BDNF levels using 7,8 dihydroxyflavone (A TrkB 
receptor agonist), individually or as a combined therapy, in this mouse model of PTSD. 
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Chapter 2. Chronic hippocampal abnormalities and blunted 
HPA axis in an animal model of repeated unpredictable stress 
Introduction 
Upon exposure to an acute stressor, the brain initiates “fight or flight” responses 
involving the cardiovascular, endocrine and immune systems to prepare the body for the 
possible danger. After dismissal of the stressor, physiological homeostatic mechanisms 
restore normal baseline functions. However, a single exposure to a particularly severe 
traumatic stressor or prolonged exposure to milder stressors, can lead to maladaptive 
responses within the brain neurocircuitry regulating these homeostatic mechanisms (Bonne 
et al. 2004; Roth et al. 2012; Sambasivarao 2013; Sherin and Nemeroff 2011). Theses 
maladaptive responses are involved in the pathophysiology of various stress-related 
psychiatric illnesses such as anxiety disorders, post-traumatic stress disorder (PTSD) and 
depression (MCEWEN 2004).  
As described in chapter 1, the symptoms of PTSD are marked by the uncontrolled re-
experiencing of traumatic events triggered by intrusive memories, avoidance of traumatic 
cues, negative alterations in cognition and mood and dynamic fluctuation in arousal and 
reactivity states (DSM-5, 2013) (American Psychiatric Association 2000). A diagnosis of 
PTSD requires that these clusters of symptoms must last for at least one month to 
demonstrate clinical impact, and they have to significantly influence the functional ability 
of the individual in several domains.  
It has previously been shown that exposure to a single footshock with repeated 
exposure to TMT under restraint induces acute PTSD-like behavior including anxiety-like 
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behavior, social avoidance and recall of fear memory in C57BL/6 mice (Ojo et al. 2014). 
One of the major limitations of our previous model was the lack of chronic and persistent 
behavioral and neurobiological changes. The presence of acute symptoms after a traumatic 
incident is not an accurate hallmark feature for PTSD diagnosis, as they can be attributed 
to a normal adaptive stress response or acute stress disorder (Flandreau and Toth 2017).  
While acute stress disorder and PTSD share a number of diagnostic criteria, in PTSD, 
symptoms are primarily persistent (> 1 month) and may also develop after a delay 
(American Psychiatric Association 2000). Therefore, a chronic and long-lasting behavioral 
and biological outcome in a mouse model is essential to more accurately reflect the human 
PTSD experience. 
To overcome this limitation in our earlier model, I intensified our previous 21-day 
repeated unpredictable stress (RUS) paradigm to include 10 unpredictable exposures to 
TMT under restraint, 5-inescapable foot shocks and daily unstable social housing that was 
followed by social isolation. The presence of chronic social stress in our model is a unique 
feature in comparison with traditional CUS paradigms.  
Here, I show that such repeated exposures to intense physical, psychological and 
psychosocial stressors resulted in PTSD-like symptomology and biological responses as 
presented in the following sections.  
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Materials and Methods 
Animals 
C57BL/6 male mice (aged 8–10 weeks) were purchased from Jackson Laboratories 
(Bar Harbor, Maine) and housed in standard cages under a 12-h light/12-h dark schedule at 
ambient temperature. A two-weeks habituation period was followed before the start of any 
experimental procedures. All procedures were performed in accordance with OLAW 
guidelines under an approved protocol by the Roskamp Institute IACUC. 
 
The 21-day RUS paradigm 
Animals were randomly assigned to either a control group (n=15) or the stress 
group (n=17).  The 21-day repeated unpredictable stress (RUS) paradigm is shown in 
Figure 2.1, and involved (i) daily unstable social housing with an alternate congener; (ii) 
unpredictable repetitive exposure to a psychological stressor of predator odor (TMT) while 
in a decapicone restrainer for 30 mins in a dark room (1 exposure per day, 10 exposures 
within 21 days); (iii) physical trauma in the form of five repeated inescapable foot-shocks; 
and (iv) lack of social support (i.e. singly housed) post-traumatic stress. Animals in the 
stress group were housed individually after the 21 days, whereas animals in the control 
group were housed in groups of 2-3 throughout the study.  Animals in the control group 
were never subjected to the decapicone restraint or TMT exposure, but were exposed to the 
fear-conditioning chamber for the same frequency and duration as the stressed mice, 
without administration of foot shock or auditory cues. 4-5 animals per group were 
euthanized at 10 days after RUS (acute timepoint) for molecular studies without receiving 
any behavioral testing. The remaining animals (10-12) per group received a behavioral test 
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battery at one day (acute timepoint) after RUS and then were retested using a similar 
battery at 3 months and 6 months after RUS. Details about the timeline of the behavioral 
test battery can be found in Figure 2.2 After the last behavioral experiment, all animals 
(11-12) were euthanized and brain and plasma were collected for molecular studies (6 
months timepoint).  
 
 
Figure 2.1. Study timeline and experimental procedures for the stress paradigm. 
Stress paradigm involved 21 days of daily unstable social housing with an alternate 
congener (i), unpredictable repetitive exposures to danger-related predator odor (Fox urine, 
TMT), while under a decapicone restrainer for 30 mins (ii), and physical trauma in the 
form of five repeated inescapable footshocks (iii).  After 21 days of stress, animals in the 
stress group were singly housed (social isolation) until the end of the study (iv). A battery 
of behavioral testing was conducted at an acute timepoint (1-14 days), 3 months, and 6 
months after the last footshock. Brain tissue and plasma were collected only at the acute 
timepoint (10 days) and 6 months after the last footshock. 
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Figure 2.2. Timeline of behavioral test batteries. The same animals tested in behavioral 
test battery 1 were retested at behavioral test batteries 2 and 3.  
 
TMT  
Trimethylthiazoline (TMT, SRQ Bio, Florida) is a component of fox urine, which I 
and others have previously used as a predator odor stressor (Endres and Fendt 2009; 
Janitzky et al. 2015).  TMT was diluted 1:10 (v/v) in double distilled water before being 
used as a predator odor stressor.  50 ul of 10% TMT were dispensed on a tissue paper then 
placed next to the restrained animal. 
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Behavioural testing 
At least two baseline body weight measurements were taken during the acclimation 
period and before administering the stress paradigm. After exposure to the stress, body 
weight was measured on a weekly basis for each mouse.  
 
Fear conditioning, contextual and cued fear testing. 
Fear conditioning was delivered in the form of 5 footshocks on days 2, 4, 6, 9, and 
12 of the stress exposures paradigm. This involved placing animals in a shuttle box-
chamber for 3min, with a pure tone (70 dB, 2.9 kHz) introduced during the last 30 s. At the 
end of the auditory cue, animals received a single 1mA of uncontrollable/inescapable 
footshock for 4s and were allowed to recover for 1min in the same context before returning 
to their home cages. The control group was allowed to explore the fear-conditioning 
context for 3 min without introducing a tone or electric shock. To determine retention of 
contextual/cued fear memory animals were tested at the acute timepoint, 3 months, and 
then 6 months after RUS. This involved placing animals in the fear-conditioning spatial 
context for 3 min and measuring the freezing response using automated video tracking 
system (Ethovision; Noldus—Netherlands). Freezing responses were calculated by 
Ethovision Software using the immobility time (2.5 % immobility threshold, 20 frames per 
second) (Ojo et al. 2014). A cued memory test was conducted 1 h after the contextual fear 
memory test and involved placing animals in a novel context for 3 min without the tone 
and a further 3 min with the tone. Freezing response was measured throughout the entire 6 
min period. 
51 	
Open field test 
Anxiety and sensorimotor behavior were further assessed by the open field test 
(Hall and Ballachey 1932). This test was conducted in a circular maze (120cm diameter) 
setup in a dim lit room (80 Lux). Animals were placed in the center of the maze and the 
time spent in a predefined center zone and around the walls of the maze was recorded over 
a 15 min trial.  
 
Elevated plus maze 
Anxiety behavior was evaluated using the elevated plus maze (Pellow et al. 1985). 
The apparatus consists of two open and two closed arms forming a plus shape. The arms 
are elevated 70cm from the floor. Each mouse was placed on the junction of the four arms 
of the maze, facing the open arm. The mouse was allowed to freely explore the maze for 
5min in a dark light (~1 Lux). The percentage of time spent in the open arms was 
calculated using Ethovision video tracking system. Animals were retested in a different 
room at 6 months after RUS.  
 
Forced swim test 
The test was performed in a cylindrical container (20 cm height x 20 cm diameters) 
filled with water at room temperature. Animals were placed in the container for 6 min with 
video recording from the top. The time spent floating (not swimming nor climbing) was 
calculated using Ethovision immobility parameter (7.5% immobility threshold, 20 frames 
per second) as a measure of depression–like behavior. The immobility time measured by 
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our automated detection settings was comparable to manually calculated floating times by 
a blinded observer (data not shown). 
 
Radial arm water maze (RAWM) 
The RAWM test for spatial learning and memory was conducted as described by 
Park et al. (2008) (Park et al. 2008). In brief, the test was conducted in a radial arm water 
maze pool (120cm diameter and 30–40cm height), containing six swim paths extending 
from an open central arena. A hidden escape platform was placed beneath the end of the 
target arm and each of the arms was marked with a unique visual cue. Animals were 
trained for 5 days with 12 trials per day to locate the hidden goal arm. Each trial lasted for 
60s. Each entry to a wrong arm was scored as a memory error. The number of errors per 
block trial, across the entire length of the training session was recorded using a video-
tracking system (Ethiovision, Noldus - Netherlands).  All animals were subjected to the 
test at three time points after the traumatic stress (i.e. 2 weeks and 3 months and 6 months 
after traumatic stress).  
 
Social interaction and novelty recognition tests (Three-chamber test) 
The three-chamber test was used to evaluate social behavior. The testing apparatus 
consists of a rectangular box with three chambers separated by two doors. Each of the 
outer chambers contains a cage enclosure. The mice were habituated to the testing box for 
5 min prior to testing.  Testing occurred in two sessions. In the first session, a new intruder 
mouse (Stranger1) was placed in one cage, while the other cage was left empty. The tested 
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mouse was placed in the middle chamber and left to explore the three chambers for 10min. 
The time spent in the Stanger1 chamber versus the empty cage is used to evaluate social 
interaction of the test subject. In the second session, another intruder mouse (Stranger2) 
was placed in the second cage along with the previous intruder mouse (Stranger1) still held 
in the first cage, and the test subject was allowed to freely explore both chambers for 
10min.    The time spent in the Stanger2 versus Stranger1 chamber was used to evaluate 
the social memory of the tested animal. 
 
Enzyme-linked immunosorbent assay (ELISA) 
To obtain blood specimens, animals were anesthetized with isoflurane, and 
approximately 500 μl of blood were collected into EDTA tubes by cardiac puncture 
immediately prior to euthanasia. Samples were centrifuged at 3000g for 3 min, and plasma 
samples (clear supernatant fraction) were flash frozen in liquid nitrogen and stored at 
−80 °C. Plasma Corticotropin-releasing hormone (CRH) levels were measured using an 
enzyme-linked immunosorbent assay (ELISA) purchased from Life-Span biosciences 
(Seattle, Washington). The Adrenocorticotropic Hormone (ACTH) ELISA was purchased 
from Cloud-Clone Corp (Katy, Texas). Tissue and plasma corticosterone levels were 
measured using an ELISA from Arbor Assays (Ann Arbor, Michigan) and tissue Brain-
derived neurotrophic factor (BDNF) levels were measured using an ELISA from Boster 
Bio (Pleasanton, California).  ELISA kits were used as per manufacturers’ instructions.  
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Brain tissue preparation and western blotting 
Brains from 6 animals per group were used for biochemical analysis while the 
brains form the remaining animals were used for hippocampal volume estimation 
(histopathology). Western blot experiments were conducted as described previously (Ojo 
et al. 2016). In brief, 6 animals from the stress group and 6 control animals were used for 
all western blot and ELISA experiments from brain tissue. Tissue was collected following 
transcardial perfusion by gravity drip with phosphate-buffered saline (PBS). Both 
hemispheres were extracted and dissected into multiple regions (hippocampus, amygdala, 
and hypothalamus); these were flash frozen in liquid nitrogen and kept at −80 °C.   
For western blotting analyses, the hippocampi or amygdalae from both hemispheres 
were homogenized in 200 µl of M-PER protein extraction reagent containing proteinase 
and phosphatase inhibitors (Thermofisher) using a probe sonicator. Samples received 2-s 
long sonication pulse followed by incubation on ice for 10 s, this process was repeated 3 
times. Homogenized samples were spun in a centrifuge at 15000g for 10 minutes (min) and 
tissue supernatants were collected. Supernatant fractions were denatured at 99 °C by 
boiling in Laemmli buffer (Bio-Rad) containing DDT. Samples were then subsequently 
resolved on 4% to 15% gradient polyacrylamide criterion gels (Bio-Rad). After 
electrotransferring, polyvinylidene difluoride membranes were blocked in 5% milk made 
in Tris-buffered saline and subsequently immunoprobed for different brain-specific 
primary antibodies overnight (Table 2.1). After three washing steps, membranes were 
probed with horseradish peroxidase-linked secondary antibodies (Table 2.1). Anti-
GAPDH antibody was used as a housekeeping gene to quantify the amount of proteins 
electrotransferred, and signal intensity ratios were quantified by chemiluminescence 
imaging with the ChemiDocTM XRS (Bio-Rad). 
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Table 2.1.  Summary of antibodies (ab) used in western blot experiments 
Target 1ry ab 
dilution 
Source Catalogue #  Host 2ry ab$ 
dilution 
MR 1:1000 Milipore Sigma MABS496 Mouse 1:2000 
GR 1:1000 Cell Signaling 
Technology 
12041 Rabbit 1:2000 
FKBP51 1:1000 abcam ab2901 Rabbit 1:2000 
CRH 1:1000 abcam ab184238 Rabbit 1:2000 
TrkB 1:2000 abcam Ab187041 Rabbit 1:2000 
P75NTR 1:1000 Cell Signaling 
Technology 
8238 Rabbit 1:2000 
ProBDNF 1:500 Milipore Sigma MABN110 Mouse 1:2000 
GluN1 1:1000 GeneTex GTX133097 Rabbit 1:2000 
GluN2A 1:500 Thermo Fisher 
Scientific 
PA5-27921 Rabbit 1:2000 
GluN2B 1:1000 GeneTex GTX109713 Rabbit 1:2000 
PSD95 1:2000 Thermo Fisher 
Scientific 
MA1-046 Mouse 1:2000 
CAMKIIα 1:1000 GeneTex GTX27939 Rabbit 1:2000 
NF-κB 
 
1:1000 Cell Signaling 
Technology 
8242 Rabbit 1:2000 
pNF-κB 
 
1:500 Cell Signaling 
Technology 
3031 
 
Rabbit 1:2000 
GAPDH 1:1000 Cell Signaling 
Technology 
5174S Rabbit 1:2000 
$Anti-mouse and anti-rabbit secondary antibodies were ordered from Cell Signaling Technology 
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Multiplex enzyme-linked immunosorbent assay (ELISA) 
Levels of 9 cytokines; interferon γ (IFN-γ), interleukin (IL)-1β, IL-2, IL-4, IL-6, 
IL-10, IL-12p70, IL-13, and tumor necrosis factor α (TNFα) were measured from a single 
plasma sample (12.5 μL) using the MSD proinflammatory Panel I multiplex assay 
(MesoScale Discovery, Gaithersburg, Maryland).  
 
Neuropeptide magnetic bead panel from hypothalamus  
Levels of six neuropeptides (α-MSH, β-Endorphin, Neurotensin, Orexin A, 
Oxytocin, Substance P) were measured in the hypothalamus using MILLIPLEX MAP 
Rat/Mouse Neuropeptide Magnetic Bead Panel. The following procedures were 
implemented to extract neuropeptides from the hypothalamic tissue. Each dissected 
hypothalamus was dissolved in 200 μL deionized water and homogenized using a probe 
sonicator on ice. Immediately after homogenization, 100 μL of the hypothalamus lysates 
were mixed with 200 μL acetonitrile and incubated for 10 min at room temperature then 
centrifuged at 17,000 g for 5 min. Clear supernatants were collected and dried using speed-
vac without sample heating then solubilized in 100 μL of the manufacture’s assay buffer. 
The rest of multiplex assay steps were carried out as instructed by the manufacturer’s 
guide. Phosphatase and protease inhibitors were added to the remainder of the original 
lysates and stored for western blot experiments. 
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Hippocampal volume estimation 
5 control animals and 6 stressed animals where used for volume estimation from 
the hippocampus using Cavalieri principal. At 6 months after last stress exposure, mice 
were anesthetized with 3% isoflorane and transcardially perfused with a 4% 
paraformaldehyde phosphate buffered saline (PBS) solution. Brain hemispheres were post-
fixed overnight in 4% paraformaldehyde–PBS solution. The volume of the right 
hippocampus as guided by bregma coordinates (−0.94 to −3.28mm) was determined by 
quantitative light microscopy using the Cavalieri method as described elsewhere (Ojo et al. 
2014). In brief, sagittal sections from the extent of the right hippocampus of each animal 
(taking every twentieth serial section) were mounted onto superfrost plus slides. An 
average of 10–15 sections were collected per animal. Mounted sections were air-dried and 
stained with a solution of 0.1% cresyl fast violet (Tedpella, Reading, CA) and were viewed 
at low magnification using a DP72 digital camera attached to a motorized Olympus BX63 
digital photomicroscope (Olympus, Center Valley, PA). Analyses were carried out blind 
and were made via the Cell SENS Olympus software package. Digital images were 
captured electronically and the boundaries of the total dorsal hippocampal compartment 
and its subfields (DG, CA1, and CA2/CA3) were digitally outlined on each section from 
the series of sagittal sections of the right hemisphere. For each animal, the total volume of 
the right hippocampus and its subfields were subsequently derived by multiplying the 
calculated total surface area by the mean distance between the series of sections. Data are 
expressed as mean volume (in mm3) ± SEM. 
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Statistical Analysis 
The relationships between stress and control animals for Western blotting, ELISA, 
and neurobehavioral data were assessed using a t-test predefined criterion of p < 0.05 to 
assess group differences, while experiments examining stress effects over time were 
assessed using a RM-ANOVA.  Pearson correlation and Spearman correlation were used 
for parametric and nonparametric data sets, respectively.   The choice of the appropriate 
statistical test was made after assessment of normal distribution using the Shapiro-Wilk 
normality test. All analyses were performed with Graph Pad prism version 7.0a statistical 
software (La Jolla, California). Statistical outliers were identified using Grubbs’ test and 
excluded.  
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Results 
Mice exposed to the 21-day stress paradigm show attenuation of bodyweight gain and 
anxiety-like behavior immediately after stress.  
Stress is usually associated with changes in bodyweight and food intake (Harris 
2015). Therefore, I obtained the weekly bodyweight for each mouse to examine the effects 
of the RUS paradigm (Figure 2.3A). Stressed mice showed reduced weight gain in the first 
3 weeks of stress (RM-ANOVA: interaction F(4, 116) = 12.54, p<0.0001, with the Sidak post 
hoc test) compared to their unexposed group. The changes in bodyweight are mainly 
driven by an intense decrease in their growth rate during the first week of stress (RM-
ANOVA: interaction F(3, 87) = 10.58, p<0.0001, with the Sidak post hoc test,  Figure 2.3B).   
In addition, stressed mice showed an anxiety–like behavior as evident by reduced 
center zone entries per 3 min time bins (RM-ANOVA: Stress effect F(1, 18) = 27.87, 
p<0.0001, with the Sidak post hoc test) and throughout the entire 15 min (t-test: t(18) 
=5.174, p<0.0001) in the open field test (Figure 2.3C and 2.3D) at the acute timepoint.  
However, assessment in the elevated plus maze (EPM) in the same timepoint showed no 
significant differences between groups in the open arm duration (t-test: t(18) =1.8, p=0.083, 
Figure 2.3E) or open arm entries (t-test: t(18) =1.8, p=0.99, Figure 2.3F). 
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Figure 2.3 Effect of RUS on bodyweight gain and anxiety-like behavior.  During the 
21-day stress paradigm, stressed mice showed a reduction in body weight gain when 
compared to control mice (A). Growth rate was significantly lower only during and after 
the first week of stress (day7) (B). Exposure to stress increased anxiety-like behavior at the 
acute timepoint as evident by reduced center zone entries per a 3- min time bin (C) and in 
the total 15 min (D) in the open field test.  No significant changes were observed in the 
EPM open arm time (E) and entries (F) at the acute timepoint. Data in (A, B) were 
analyzed using repeated measures Two-Way ANOVA followed by post-hoc Tukey's test (n 
= 14-17), while data in (C-F) were analyzed using a student t-test (n=8-9). Asterisks denote 
statistical significance as follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001.  
 
Stressed mice recall fear memory and show passive stress coping behavior at 6 
months after RUS.  
Fear conditioning using electric footshocks was used as a stressor in the RUS 
paradigm and also as a tool to evaluate the recall of contextual and cued fear memory 
responses (Ojo et al. 2014). Stressed mice showed a significant increase in their freezing 
(Immobility time) when placed in the same trauma context at the acute timepoint (t-test: 
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t(21) =8.4, p<0.0001, Figure 2.4A). However, stressed mice were not able to recall 
contextual fear memory when examined at 3 months and 6 months after RUS (Figure 2.4B 
and 2.4C, p>0.05). I also examined recall of cued fear memory at the same timepoints. 
Mice were placed in a novel context for 3 minutes, and then exposed to a trauma related 
cue (auditory tone) lasting an additional 3 minutes. While all animal groups showed 
minimal freezing during the first 3 min in the novel context (without a tone), stressed 
animals showed an increased % freezing upon tone introduction at the acute timepoint 
(Two-way ANOVA, interaction F(1, 40) =111.8, p<0.0001, Figure 2.4D), 3 months (Two-
way ANOVA, interaction F(1, 40) =8.7, p<0.0052, Figure 2.4E) and 6 months (Two-way 
ANOVA, interaction F(1, 40) =5.4, p<0.025, Figure 2.4F) after RUS. Chronic changes in 
stress-coping strategies and anxiety-like behavior were also examined at 6 months after 
RUS using the forced swim test and the elevated plus maze, respectively. As depicted in 
Figure 2.4G and 4H, stressed animals showed negative stress coping behavior as evident 
by increased immobility time in the forced swim test (t-test: t(20) =2.5, p=0.02, Figure 
2.4H).  No significant differences were observed between control and stressed mice at 3 
months and 6 months after RUS in the number of open arm entries in the elevated plus 
maze (p>0.05, Figure 2.5A and Figure 2.5I) or center zone entries in the open field test 
(p>0.05, Figure 2.5B). It is important to note that the performance of mice in the EPM test 
and the suitability of the EPM and Open field for retesting is questionable (Hussin et al. 
2012; Walf and Frye 2007). Control mice in the EPM always performed poorly (spending 
only few seconds in the open arms) which reduced the window for detecting a significant 
effect between sham and stressed mice. Additionally, although some studies suggested 
changing the retesting room and separating the trials by four weeks to improve retesting 
reliability (Schneider et al. 2011), our data indicated that control mice show fewer entries 
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to the open arms of EPM and center zone of the Open Field upon retesting at different 
rooms 3 months and 6 months after RUS. (Figure 2.5A, and 2.5B).  
	
Figure 2.4. Recall of contextual and cued fear memory at the acute timepoint, 3 and 6 
months after RUS. Stressed animals recalled contextual fear memories only at the acute 
timepoint as evident by increased freezing time compared to controls at the acute timepoint 
(A), but not at 3 months (B) or 6 months (C) after RUS. Panels E-G depict % freezing 
scores in the first minute of the cued memory test in absence and presence of a cue (tone) 
at the acute , 3-month and 6-month timepoints, respectively.  There was no significant 
freezing for all treatment groups when tested in a new context without cues (no tone) at all 
timepoints (D-F). After tone introduction, RUS mice showed a significant increase in % 
freezing at the acute timepoint, 3 months and 6 months after RUS (D-F). Stressed mice 
displayed increased immobility time in min 4 and 6 of the FST when compared to a control 
group (G). Average immobility time in the last 4 min was increased in stressed mice 
compared to the control group (H). RUS didn’t alter open arm entries in the elevated plus 
maze test at 6 months after stress. Data in (A-C, H, I) were analyzed using a student t-test 
(n=6-12), while data in D-F were analyzed using repeated measures Two-Way ANOVA 
followed by post-hoc Sidak test (n=10-12). Asterisks denote statistical significance as 
follows: ∗p < 0.05; ∗∗p < 0.01; ∗∗∗p < 0.001. 
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Figure 2.5.  Effect of repeated testing on mice performance in the EPM and Open 
Field tests. (A) Control mice made fewer entries to the open arm of the EPM upon 
retesting at 6 months after RUS. In the Open field test (B), control mice made fewer entries 
to the center zone when retested at 3 months and 6 months after RUS.  No significant 
differences were observed between control and stressed animals in both tests at the 3 
month and the 6 month timepoints. Data were analyzed using Two-Way ANOVA. 
Contextual memory retrieval is thought to be a hippocampal-dependent task 
(Maren and Holt 2000). Since stressed mice were able recall cued fear memory, but not 
contextual fear memory at 3 months and 6 months after RUS, I examined the effect of 
stress on other hippocampal-related tasks such as social memory and spatial learning. Mice 
exposed to RUS did not show any impairment in social memory at the acute timepoint, 3 
months or at 6 months after RUS when tested using social novelty recognition tests 
(p>0.05, Figure 2.6). Our findings in the social memory test at the chronic timepoints are 
inconclusive because control mice did not show any preference to the novel mouse, 
(Stranger2), possibly due to retesting (Figure 2.6B). There were however no impairments 
in spatial learning and memory in stressed animals at any timepoint when tested using the 
radial arm water maze (p>0.05, Figure 2.7).  
64 	
 
Figure 2.6. Effect of stress on social interactions and social memory at the acute 
timepoint, 3 months and 6 months after RUS. No differences in social interactions (A) 
or social memory (B) were observed between RUS animals and controls at the acute 
timepoint, 3 months or 6 months after RUS. In (A), the ratio between time spent around 
stranger1 cage to total time spent around stranger1 and the empty cage was calculated for 
each animal to evaluate social interactions, while in (B), the ratio between time spent 
around stranger2 cage (new never seen mouse) to the total time around both strangers was 
calculated to evaluate social memory (social novelty recognition).  
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Figure 2.7.  Effect of stress on spatial learning and memory at the acute timepoint, 3 
months and 6 months after last stress. Panels A, B and C depict the performance of each 
group during three separate training sessions in a radial arm water maze (RAWM) at the 
acute timepoint, 3 months and 6 months after last stress. All the animal groups 
demonstrated a learning curve at all timepoints after trauma. No significant differences 
between the tested groups were observed at any timepoint. Data were analyzed using 
repeated measures Two-Way ANOVA. Tukey’s multiple comparisons post-hoc test was 
performed in all cases. 
 
Stressed mice display lower plasma corticosterone levels 6 months after RUS; 
suggesting blunted HPA-axis reactivity. 
In order to examine the effect of stress on the HPA axis, baseline plasma 
corticosterone levels were measured at the end of the light cycle 6 months after RUS.  I 
found that mice exposed to stress showed significantly lower plasma corticosterone levels 
(t-test: t(21) =2.9, p=0.009, Figure 2.8A) compared to control mice. Similarly, ACTH levels 
were significantly lower in stressed mice compared to controls (t-test: t(14) =2.3, p=0.04, 
Figure 2.8B). No significant change was seen in plasma CRH at 6 months (p>0.05, Figure 
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2.8C). I subsequently examined glucocorticoid signaling in the hypothalamus by 
measuring the expression levels of glucocorticoid receptors and regulatory proteins 
(Figure 2.8D-H). While there was no change in expression levels of glucocorticoid 
receptor (GR), mineralocorticoid receptor (MR) or CRH levels, the levels of FK506 
binding protein 51 (FKBP51) were downregulated in the hypothalamus of stressed mice 
relative to controls (t-test: t(9) =2.4, p=0.042, Figure 2.8D and 2.8G). To explore the 
relationship between abnormalities in the HPA axis function and behavioral outcomes in 
our model, I assessed the statistical correlation between individual mouse corticosterone 
plasma levels and their corresponding neurobehavioral scores in both control and stress 
groups. I found a significant negative correlation between plasma corticosterone levels and 
freezing scores in the cued fear memory test (Spearman correlation: r= -0.749, p=0.001, 
Figure 2.8I) and the immobility time in the forced swim test (Pearson correlation: r= -
0.63, p=0.0022, Figure 2.8J). Furthermore, cued fear memory freezing scores correlated 
positively with the immobility time in the forced swim test (Pearson correlation: r= -0.479, 
p=0.0278, Figure 2.8H). 
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Figure 2.8. Effect of stress on HPA axis regulation at 6 months after RUS. Mice 
exposed to stress showed lower plasma levels of corticosterone (A) and ACTH (B), but not 
CRH (C) when compared to a control group at 6 months after RUS (n=8-12). 
Representative western blot images for markers of glucocorticoid signaling in the 
hypothalamus (D). Quantification of mineralocorticoid Receptor (E), glucocorticoid 
receptor (F), FKBP5 (G) and CRH (H) levels in the hypothalamus (n=5-6). Only the levels 
of FKBP5 (G) were significantly reduced after RUS. Plasma corticosterone levels were 
inversely correlated with the % freezing scores in the cued fear memory test (I) and the 
immobility time in the forced swim test (J) (n=21). There was a positive correlation 
between % freezing scores in the cued fear memory test and the immobility time in the 
forced swim test (K). Each solid black triangle represents an animal in the stress group, 
while white circles represent control animals. Asterisks denote statistical significance as 
follows: ∗p < 0.05; ∗∗p < 0.01. 
 
Previous studies have suggested interplay between the endocrine and 
inflammatory/immune systems in the pathophysiology of depression (Griffin, Charron, and 
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Al-Daccak 2014) and PTSD (Griffin et al. 2014), owing partly to the immunoregulatory 
role of corticosterone. To examine the effect of our RUS paradigm on the peripheral 
immune system, I evaluated the levels of plasma cytokines at 6 months after stress. I found 
a 2-fold increase in plasma levels of pro-inflammatory IL1β (t-test: t(8) =2.4, p=0.04, Table 
2.2) and IFNγ (t-test: t(7) =3.9, p=0.006, Table 2.2), while the levels of other cytokines 
were not significantly altered (Table 2.2).  
 
Table 2.2.  Effect of stress on plasma cytokines at 6 months after RUS 
Cytokine Fold Change$ ± SD p-value n Time after 
stress 
IFNγ * 1.97 ± 0.26 0.04* 5 6 months 
TNFα 1.02 ± 0.82 0.88 5 6 months 
IL1β** 1.94 ± 0.07 0.006** 5 6 months 
IL2 1.15 ± 0.27 0.688 5 6 months 
IL5 0.84 ± 0.57 0.613 5 6 months 
IL6 1.25 ± 1.37 0.431 5 6 months 
IL10 0.83 ± 1.30 0.132 5 6 months 
IL12 1.65 ± 4.96 0.276 5 6 months 
$Plasma cytokines levels in stressed animals relative to controls ± standard deviation 
 
As the hypothalamus secretes numerous neuropeptides that regulate several 
autonomic functions implicated in regulating neurocircuitry pathways involved in stress 
management, I measured the expression levels of various neuropeptides in the 
hypothalamus using a magnetic bead multiplex assay. As shown in Figure 2.9, there was 
no significant difference in the expression levels of Oxytocin, β-endorphin, Neurotensin, α-
MSH, and Substance P (Figure 2.9, P>0.05). Interestingly, Orexin-A levels were 
significantly elevated in stressed mice compared to controls (t-test: t(10) =2.437, p=0.035, 
Figure 2.9A). 
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Figure 2.9. Exposure to stress elevates Orexin-A levels in the hypothalamus. Magnetic 
beads multiplex assay showed an increase in the hypothalamic levels of Orexin-A at 6 
months after RUS. No significant changes were observed in the levels of Oxytocin (B), β-
endorphin (C), Substance P(E), α-MSH (F), and Neurotensin (G). Data in Figure 2.9 were 
analyzed using a student t-test (n=5-6). Asterisks denote statistical significance as follows: ∗p < 0.05. 
 
Effect of stress on the hippocampus at 6 months after RUS 
The hippocampus is prone to negative consequences of stress (McEwen, Nasca, 
and Gray 2016) and it is postulated that corticosteroids are primary mediators of these 
stress effects (Roth et al. 2012). Consistent with our plasma findings, corticosterone levels 
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were also reduced in the hippocampal tissue lysates of stressed mice compared to controls 
(t-test: t(10) =2.34, p=0.044, Figure 2.10A). To further examine the chronic effect of RUS 
on the hippocampus, I estimated the volume of the hippocampus and its subfields and 
measured the levels of a number of synaptic plasticity markers. Using the Cavalieri 
sterology principle for volume estimation, I found that the volume of the CA1 region of the 
dorsal hippocampus (t-test: t(9) =2.34, p=0.044, Figure 2.10B) was significantly reduced in 
stressed animals compared to controls at 6 months after stress. In addition, there was a 
trend towards reduced total dorsal hippocampus volume (t-test: t(9) =2.13, p=0.061, Figure 
2.10C) in stressed animals, and no significant change in CA2 and CA3 or Dentate gyrus 
regions (p>0.05, Figure 2.10B). I then examined the expression levels of notable 
markers/mediators of neuroplasticity using immunoblot analysis of hippocampal lysates. 
BDNF levels were downregulated in mice exposed to RUS (t-test: t(9) =3.55, p=0.006, 
Figure 2.10D), while the levels of other markers such as PSD95, CAMKII, NGF, TRKB, 
ProBDNF and NMDA receptors were not significantly altered after RUS (P> 0.05, Figure 
2.11). Interestingly, CRH levels were elevated in animals exposed to stress (t-test: t(10) 
=2.4, p=0.037, Figure 2.10I) at 6 months after RUS. Moreover, I did not observe any 
significant change in glucocorticoid signaling receptors (GR and MR) or related binding 
proteins (FKBP51) at 6 months (Figure 2.10E-I). 
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Figure 2.10. Effect of stress on the hippocampal volume and HPA axis markers at 6 
months after RUS. Effect of stress on the volume of the dorsal hippocampus (A) and the 
volume other hippocampal regions (B). Stress resulted in a volume reduction only in the 
CA1 region (B).  Hippocampal BDNF (C) and corticosterone (D) levels were also reduced 
at 6 months after stress. Representative western blot images for markers of glucocorticoid 
signaling in the Hippocampus (E). Quantification of mineralocorticoid receptor (F), 
glucocorticoid Receptor (G), FKBP5 (H) and CRH (I) levels in the hippocampus at 6 
months after RUS. Only the levels of CRH (I) were significantly increased after RUS. Data 
were analyzed using a student t-test (n=5-6). Asterisks denote statistical significance as 
follows: ∗p < 0.05; ∗∗p < 0.01. 
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Figure 2.11. Effect of stress on synaptic plasticity markers in the hippocampus at the 
acute time point and at 6 months after RUS. Quantification of western blot images of 
TRKB (A), P75NTR (B), ProBDNF (C), GluN2B (D), GluN2A (E), GluN1 (F), PSD95 
(G), CAMKIIa (H), and pNF-κB/NF-κB (I),  levels in the hippocampus at the acute 
timepoint and at 6 months after RUS. All Data were analyzed using a student t-test (n=4-
6). 
 
Effect of stress on markers of neuroplasticity in the amygdala 
The amygdala is associated with emotional learning and cued fear memory and is 
also prone to negative consequences of stress(McEwen et al. 2016). Therefore, I probed for 
the levels of a number of markers associated with neuroplasticity using immunoblotting. 
No significant changes were observed in amygdala lysates at 6 months after stress (p> 
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0.05, Figure 2.12). However, I observed that lysates from the acute timepoint showed 
significant changes in several markers associated with neuroplasticity.  
 
Figure 2.12.  Effect of stress on synaptic plasticity markers in the amygdala at 6 
months after RUS.  Representative western blot images from amygdala lysates for 
neurotrophic markers, NMDA receptors and other synaptic plasticity markers are shown in 
panels (A), and (B). Quantification of western blot images of TRKB (C), P75NTR (F), 
ProBDNF (F), pNF-κB/NF-κB (G), GluN2B (H), GluN2A (I), GluN1 (J), PSD95 (K), and 
CAMKII (L) levels in the amygdala at 6 months after RUS. All Data were analyzed using 
a student t-test (n=5-6). 
 
As shown in Figure	2.13, there was a significant reduction in the levels of 
ProBDNF (t-test: t(7) =2.64, p=0.034, Figure 2.13E) and its signaling receptor, P75NTR (t-
test: t(7) =4.02, p=0.0052, Figure 2.13D). In addition, levels of NMDA receptor type1 
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(GluN1) were reduced (t-test: t(7) =6.15, p=0.0003, Figure 2.13I), including downstream 
signaling kinase, CAMKII (t-test: t(7) =4.5, p=0.003, Figure 2.13L) and spine density 
protein marker, Post Synaptic Density protein 95 (PSD95) (t-test: t(7) =3.17, p=0.016, 
Figure 2.13J) in animals exposed to stress compared to controls. No significant changes 
were observed in the amygdalar levels of BDNF or its receptor, Trkb (p>0.05, Figure 
2.13B and 2.13C); neither were there any changes in other NMDA receptor subunits such 
GluN2B and GluN2A (p>0.05, Figure	2.13G	and	2.13H) or in the ratio of 
phosphorylated nuclear factor κB to nuclear factor κB (pNF-κB/NF-κB).  
	
Figure 2.13. Effect of stress on synaptic plasticity markers in the amygdala at the 
acute timepoint. Representative western blot images from amygdala lysates for 
neurotrophic markers, NMDA receptor subunits and other synaptic plasticity markers are 
shown in panels (A), (F) and (K), respectively. Quantification of western blot images of 
TRKB (B), P75NTR (D), ProBDNF (E) and GluN2B (G), GluN2A (H), GluN1 (I), PSD95 
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(J), CAMKII (L), and pNF-κB/NF-κB (M) levels in the amygdala at the acute timepoint. 
All Data were analyzed using a student t-test (n=5-6). Asterisks denote statistical 
significance as follows: ∗p < 0.05; ∗∗p < 0.01. 
 
Effect of stress on the hippocampus and the hypothalamus at the acute timepoint.  No	significant	changes	were	observed	in	GR,	FKBP,	CRH,	and	BDNF	in	the	hypothalamus	and	the	hippocampus	at	the	acute	timepoint	(p>0.05,	Figure	2.14).	There	was	a	trend	towards	decreased	hippocampal	BDNF	levels	and	increased	hypothalamic	FKBP5	levels	in	stressed	animals	at	the	acute	timepoint.	However,	these	findings	were	not	statistically	significant.	A summary of the findings presented in 
this study is depicted in Figure 2.15.		
	
Figure 2.14. Effect of stress on the hippocampal and the hypothalamic HPA axis 
markers at the acute timepoint. Quantification GR (A), FKBP5 (B) and CRH (C), and 
(D) BDNF levels in the hippocampus at the acute timepoint. The lower panels depict the 
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quantification of different markers from the hypothalamus at the same timepoint; GR (E), 
FKBP5 (F), CRH (G), and (H). BDNF levels was measured using a commercial ELISA, 
while the rest of the markers were measured using western blotting. Data were analyzed 
using a student t-test (n=5-6). Asterisks denote statistical significance as follows: ∗p < 
0.05; ∗∗p < 0.01. 
 
 
	
Figure 2.15. A summary of stress effects on the amygdala, hippocampus and HPA 
axis at different timepoints after RUS. 
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Discussion  
In our new RUS paradigm, I assessed the chronic neurobehavioral, neuroendocrine 
and neurobiological consequences of a repeated unpredictable stress (RUS) paradigm in 
mice. The purpose of our study was to develop a mouse model of stress with relevance to 
PTSD that demonstrates chronic behavioral deficits (face validity) with validated 
pathophysiological measures (construct validity). Using a battery of behavioral tests, I 
showed that animals exposed to RUS demonstrate traits similar to the human condition; 
particularly acute anxiety (Figure 2.3C-D), recall of traumatic memory cues (Figure 2.4D-
F) and negative alterations in stress coping strategies (Figure 2.4G-H) at 6 months after 
RUS. 
 Blunted HPA axis responsiveness (Yehuda 2001; Yehuda et al. 1993) (measured 
as lower cortisol levels compared to control subjects) and reduced hippocampal volume 
(Bremner et al. 1995; Levy-Gigi et al. 2013) have been frequently reported in PTSD 
human subjects. Our findings of lower plasma corticosterone levels and reduced 
hippocampal CA1 volume 6 months after RUS (Figures 2.8A and 2.10B) support the 
construct validity of our model. 
Because I have utilized a prolonged unpredictable repeated stress paradigm in this 
study, a caveat of this work is the ability to distinguish between PTSD and other related 
neuropsychiatric conditions such as depression. Although there is a considerable symptom 
overlap between PTSD and depression the nature of HPA axis dysregulation is quite 
different (Schöner et al. 2017). Increased plasma cortisol levels is a common finding in 
human patients with melancholic depression (a form of major depressive disorder),  (Gold, 
Machado-Vieira, and Pavlatou 2015; Palazidou 2012). Interestingly, normal or decreased 
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HPA axis function is found in atypical depression patients suggesting that the HPA axis 
activity in dependent on depression subtypes (Juruena et al. 2018).  In animal studies, 
exposure to chronic mild to moderate stress is commonly used to study depression 
(MCEWEN 2004; Strekalova et al. 2004). For example, chronic unpredictable stress 
(CUS) paradigms involve random, unpredictable exposure to variable daily stressors such 
as restraint, cage tilting and shaking for 4 to 8 weeks.  CUS models typically show anxiety, 
depression-like behavior and increased plasma corticosterone levels at one, 6 and 18 days 
after stress cessation (Abd El Wahab, Ali, and Ayuob 2018; Monteiro et al. 2015). 
Interestingly, C57BL/6 mice appear to be more resilient to CUS compared to other mouse 
strains and longer stress durations are usually needed to show depression-like behavior 
(Monteiro et al. 2015). Blunted HPA axis reactivity to acute stressors has been reported in 
repeated immobilization (Harvey et al. 2006; Liberzon et al. 1997), social defeat (Beitia et 
al. 2005) and predator exposure models (Zoladz et al. 2015). In addition, social isolation 
has been linked to reduced plasma baseline corticosterone levels in mice (Arndt et al. 
2009; Martin and Brown 2010), therefore the incorporation of repeated stress and social 
isolation to our RUS paradigm may have contributed to the decreased basal corticosterone 
levels in our model as compared to the traditional CUS paradigms. Future studies 
including earlier timepoints and control groups receiving CUS and SPS are needed to 
explore the differences between these paradigms and RUS. In contrast to depression, 
PTSD patients typically show lower plasma cortisol levels compared to healthy controls 
(Yehuda 2001; Yehuda et al. 1993). While one possible interpretation of our behavioral 
results is stress induced depression, the blunted HPA axis reactivity is consistent with 
observations in PTSD and thus the lower plasma corticosterone levels observed at 6 
months after RUS suggest that our model has more relevance for PTSD.	
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The blunted HPA axis response in PTSD is thought to be due to increased negative 
feedback sensitivity via enhanced GR responsiveness (Hartmann et al. 2012; Schöner et al. 
2017; Yehuda et al. 2009). FK506 binding protein 5 (FKBP5) is thought to be a regulator 
of GR sensitivity.  FKBP5 gene knockout mice show increased GR sensitivity resulting in 
decreased corticosterone levels after restraint stress (Touma et al. 2011). Previous reports 
have shown that FKBP5 expression levels are reduced in white blood cells and brains of 
trauma-exposed patients (Levy-Gigi et al. 2013; Yehuda et al. 2009; Young et al. 2015). 
FKBP5 levels were also reduced in the prefrontal cortex of post-mortem PTSD human 
subjects (Matthew J Girgenti et al. 2017). In addition, FKBP5 gene polymorphism and 
epigenetic methylation patterns are associated with GR sensitivity and have also been 
linked to early-childhood trauma and risk of PTSD (Yehuda et al. 2009; Zovkic and Sweatt 
2012). I found the levels of FKBP5 to be reduced in the hypothalamus of RUS mice the 6 
months timepoint, supporting a central role for FKBP5 in HPA axis dysregulation in our 
model (Figure 2.8D). These findings together with the reductions in plasma corticosterone 
and ACTH levels (Figure 2.8A and 2.8B) at 6 months after RUS, implicates a dysfunction 
in the intrinsic homeostatic mechanisms regulating the HPA axis and also highlights the 
presence of possible molecular abnormalities in the hypothalamus as a contributing factor 
underlying this dysfunction. Previous reports have also suggested a role for the pituitary 
gland in dysregulation of HPA axis sensitivity in PTSD patients (Cooper et al. 2017; 
Ströhle et al. 2008), however a full understanding of the nature of this dysregulation 
remains elusive. Further chronic studies involving challenging the hypothalamus, pituitary 
and/or adrenal glands after exposure to our stress exposure paradigm will be needed to 
explore these possibilities.  
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HPA axis activation is involved in negative feedback control of the immune 
response as a natural protective mechanism to prevent excessive inflammation (Gill et al. 
2009; Koelsch et al. 2016). The uncontrolled and excessive activation of HPA axis in 
stress disorders is associated with chronic immune system dysregulation (Gill et al. 2009). 
Indeed, peripheral inflammation has been reported in a number of psychological disorders 
such as depression (Deslauriers et al. 2018) and PTSD (Gill et al. 2009; Wang, Caughron, 
and Young 2017). Specifically, IL1β levels were elevate in combat PTSD males compared 
to non-traumatized controls (Spivak et al. 1997). In addition, plasma levels of IFNγ were 
elevated in PTSD veterans when compared to a healthy control group (Zhou et al. 2014). 
The low baseline corticosterone levels in our model may underlie a failure of the HPA axis 
to regulate immune response and therefore explain the elevation in plasma cytokine levels 
which may contribute towards a primed inflammatory state (Table 1).  
Exposure to severe traumatic stress is associated with reduced hippocampus 
volume (Ahmed-Leitao et al. 2016; Fragkaki et al. 2016; Kim, Pellman, and Kim 2015; 
McEwen et al. 2016). A recent large-scale multisite neuroimaging study involving 1868 
subjects found smaller hippocampi volumes in subjects with PTSD compared to trauma-
exposed controls (Logue et al. 2018). In addition, a meta-analysis of magnetic resonance 
imaging studies of adults with PTSD found hippocampal volume reductions in subjects 
with PTSD (n=846) compared to traumatized controls (n=624) with the left-hippocampi 
showing greater reductions (O’Doherty et al. 2015). For the majority of these PTSD 
subjects, MRI scans were taken more than 10 years since the last trauma (O’Doherty et al. 
2015). However, a number of studies have suggested that smaller hippocampal volume is a 
risk factor for the development of PTSD rather than a trauma consequence (Gilbertson et 
al. 2002; van Rooij et al. 2015). In animals, chronic restraint stress has been shown 
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to selectively reduce hippocampal volume in rats (when compared to the pre-stress 
volume) (Gilbertson et al. 2002). A recent study showed that chronic unpredictable 
restraint stress or diminished adult neurogenesis can contribute to reduced volumes of both 
dorsal and ventral hippocampus in rats (Schoenfeld et al. 2017). Our results showed a trend 
towards reduction in the dorsal hippocampus and a statistically significant reduction in the 
CA1 of the right dorsal hippocampus 6 months after exposure to RUS.  The pyramidal 
cells of the CA1 subfield of the dorsal hippocampus is involved in processing and retrieval 
of visuospatial cues or memories (Ji and Maren 2008), and it relays information received 
from other hippocampal subfields to neocortical areas for higher cognitive processing. The 
impact of stress on different subfield regions within the hippocampus remains 
inconclusive. A study on rats found a reduction in the volume of CA1 after two weeks of 
chronic unpredictable mild stress, while a number of studies found a reduction in the CA3 
volume after CUS (McEwen et al. 2016; Morey et al. 2016; Schoenfeld et al. 2017).  
Impairments within the hippocampal neurocircuitry could contribute towards abnormalities 
in the encoding, retrieval and processing of memory in PTSD pathobiology; specifically, 
with regard to the ability to discriminate between safe and aversive contexts, i.e. fear 
generalization.  
Additional experiments in this current model will be required to explore this further 
using context specific cues that are needed to evaluate fear generalization. In addition, 
examining the effect of RUS on fear memory recall compared to a control group receiving 
only fear conditioning is necessary to understand the effect of extinction on recall of 
contextual and cued fear memories in the current model. These experiments will be 
essential to understanding the impact of RUS on fear memory recall (i.e. normal vs. 
abnormal fear memories).  
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Recent evidence suggests that the ventral hippocampus is involved in emotional 
memory retrieval and stress reactivity, therefore future studies should also examine the 
effect of RUS on the volume of the ventral hippocampus (Ritov, Ardi, and Richter-Levin 
2014).  
The BDNF/TrkB system has been implicated in the pathophysiology of a number 
of psychiatric disorders, such as schizophrenia (Autry and Monteggia 2012), 
depression(Autry and Monteggia 2012), and PTSD(Angelucci et al. 2014; Dretsch et al. 
2016; Grassi-Oliveira et al. 2008). A single nucleotide polymorphism (SNP) in the BDNF 
gene, causing a valine to methionine substitution (V66M) is linked to poor working 
memory, reduced hippocampal volume (Brooks et al. 2014) and alterations in fear 
extinction in humans (Soliman et al. 2010). In animal studies, V66M was associated with 
increased anxiety and depression-like behavior (Chen et al. 2007). In a rat model of PTSD, 
exposure to psychosocial stress was linked long-term epigenetic changes in hippocampal 
BDNF DNA (Roth et al. 2011). In addition, several types of stressors, including restraint 
stress, social defeat, and electric foot shocks, result in a decrease in BDNF levels in the 
hippocampus (Lee and Kim 2010; Yu and Chen 2011). Consistent with our data showing 
abnormal passive stress coping behavior in animals exposed to RUS, BDNF levels were 
significantly reduced in the hippocampus of mice exposed to stress (Figure 2.10D). Given 
that I did not observe any impairments in hippocampal-related tasks, such as spatial 
learning, and recall of reference memory (Figure 2.7), and taken together, the lower 
BDNF levels and the reduced CA1 volume observed herein, suggest that exposure to RUS 
interferes with a unique yet unknown function of the hippocampus in regulating aspects of 
fear memory expression and alterations in stress coping strategies (Figure 2.4). Regions 
such as the prefrontal cortex, amygdala and hypothalamus which are associated with these 
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functions, can receive and project their connections to the hippocampus, and therefore 
future studies investigating this complex neurocircuitry may help elucidate the role played 
by this critical brain region in PTSD. 
Acute stress exposure and fear learning are associated with immediate (mins to 
hrs.) increase in amygdala activity as detected by imaging studies, and neuroplasticity 
(increased NMDA receptors and downstream synaptic signaling partners) (Balu et al. 
2017; Yasmin et al. 2016). I did not examine the immediate effects (mins to hrs.) of stress 
on amygdala activity, however, the reduced expression levels of NMDA receptors and 
related neuroplasticity markers observed at the acute timepoint (Figure 2.12) may suggest 
the presence of compensatory mechanisms to the initial hyperactivity in the amygdala 
neurocircuitry. The hypothalamus is rich in neurons that secrete numerous neuropeptides 
that regulate several autonomic functions implicated in regulating neurocircuitry pathways 
involved in mood and stress management. I conducted molecular profiling of regulatory 
neuropeptides within the hypothalamus and observed a significant increase in Orexin-A 
levels at 6 months after stress (Figure 2.9). Orexin-A is a key regulator of the 
sleep/wakefulness cycle(Bee 2009; Tsujino and Sakurai 2013). Sleep disturbance and 
occurrence of traumatic nightmares is a common feature of PTSD in humans. A number of 
studies have drawn a critical link between Orexin system dysregulation and stress/anxiety 
disorders(Johnson et al. 2010; P. L. Johnson et al. 2012). Orexins are also believed to be an 
emerging target for treatment of PTSD (Krystal et al. 2017), however, further examination 
of Orexin signaling and circuitry is needed to understand their role in PTSD 
pathophysiology. This finding suggests the suitability of this model as a platform to 
explore the role of Orexins in stress disorders. 
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Retesting animals using very similar behavioral test batteries is one of the 
limitations in this study since most of the behavioral tests are sensitive to retesting. Future 
experiments should utilize different behavioral tools to examine the same behavioral at 
different timepoints domain.  For example, the Open Field, EPM, and the light-dark box 
can be used to examine anxiety-like behavior at different time points instead of examining 
all animals in the Open field multiple times. The anxiety scores of each particular animal 
can then be correlated with different molecular markers and also can be used to evaluate 
the progression of stress-related behavior over time.  
Using the t-test to evaluate statistical differences between control and stressed 
animals at each timepoint independently is another limitation of the current study. To 
correct for multiple comparisons at different timepoints, a posthoc test should have been 
used after the analysis. These procedures would have granted better control of the false 
discovery rate. However, since the results presented in this chapter are primarily 
exploratory, I used a less stringent test (t-test) to avoid overlooking any significant 
discoveries.	  
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Chapter 3. Impact of r-mTBI on behavioral and hippocampal 
deficits in a mouse model of chronic PTSD 
Introduction  
The consequences of post-traumatic stress disorder (PTSD) and mild traumatic 
brain injury (mTBI) have become a prime research focus in the past decade.  The issue 
received attention with the increasing number of returning veterans from Iraq and 
Afghanistan experiencing one or both conditions.  The prevalence of PTSD in soldiers 
returning from Operation Iraqi Freedom (OIF) and Operation Enduring Freedom (OEF) 
ranges from 4% to 17% for those in the United States (Hines et al. 2014; Hoge et al. 2008).  
In addition, 18% of returning veterans suffered mild TBI largely due to exposures to blast 
waves from improvised explosive devices (Hoge et al. 2008).  
 While the number of PTSD and TBI patients is still growing, many questions 
concerning comorbid PTSD and TBI remain unanswered.  For example, would a history of 
TBI increase the likelihood of developing PTSD after exposure to a traumatic event? Does 
the timing of TBI relative to the traumatic event affect PTSD-related outcomes? The 
complexity of these questions increases when considering the different severities of TBI 
(i.e. mild, moderate or severe). Attempting to answer these questions using human studies 
is challenging as there are several variables to account for, and because of the clinical 
heterogeneity and overlapping symptoms of mTBI and PTSD.  Therefore, developing a 
preclinical model that captures the complexity of both conditions, either individually or co-
morbidly, is crucial in order to understand the underlying neurobiological mechanisms and 
establish better healthcare strategies.  
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In our TBI research, we have focused on the chronic effects of repetitive mild TBI 
(r-mTBI), utilizing a mild injury delivered on the midline of a closed skull, administered 5 
times over a 9 day period (Mouzon et al. 2014).  With this model we have demonstrated 
that, in contrast to single mTBI, repetitive mTBI was associated with ‘chronic’ spatial 
memory deficits, axonal injury, and glial activation long after the last injury (Mouzon et al. 
2014, 2012).  Because the trauma-related symptoms are persistent in human PTSD, the 
presence of long-lasting behavioral alterations in a PTSD mouse model is crucial for its 
validity.  As demonstrated in Chapter 2, I have shown that exposure to a repeated 
unpredictable stress (RUS) was associated with several PTSD-like phenotypes including 
passive stress-coping behavior and long-lasting abnormalities in the HPA axis and the 
hippocampus.  Since both the r-mTBI and RUS models were associated with chronic 
outcomes, they represent a suitable platform in which to investigate comorbid PTSD and 
mTBI.  
I first conducted a preliminary study to examine the impact of their combined 
exposure on behavioral outcomes. The integration of the two paradigms was achieved by 
administering a single mTBI one hour after the foot-shock on five different days.  
Interestingly, I found that r-mTBI abrogated the stress-related phenotype in the cued fear 
memory and the forced swim tests (Experiment 1).  This preliminary study was developed 
to resemble a single military deployment, where soldiers are exposed to multiple repeated 
stressful events in addition to concussions (mTBI).  
Given the moderate effects observed with the RUS paradigm on chronic measures 
at 6 months post-exposure in chapter 2, these findings further led to the idea that a dose 
response of stressful exposures (and injuries) experienced by individuals who are exposed 
to multiple and repeated traumatic events on separate occasions over their life time, may 
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elicit a worse outcome. This is demonstrated by epidemiological studies showing a positive 
correlation between number of deployments and higher risk for PTSD diagnosis (Kline et 
al. 2010) and also increased risk for mental health disorders in civilian population exposed 
to repeated multiple non-combat trauma sources (Tanskanen et al. 2004). 
To that end, in this chapter, I explore the consequences of double exposure to our 
RUS and r-mTBI procedures on behavioral and biological outcome.  I hypothesized that 
both stress-dependent and r-mTBI-dependent phenotypes will be more prominent after 
repeated exposure compared to a single exposure paradigm.  The comprehensive 
characterization of the long-lasting behavioral and neurobiological outcomes of repeated 
RUS and r-mTBI exposure that will be presented in this chapter, are particularly relevant 
to active duty soldiers receiving several combat deployments and multiple traumatic 
events.  I anticipate that this model will be a good platform to untangle the complex 
comorbid pathophysiology in the heterogeneous population of PTSD patients who 
experience different history of traumatic events and enable further exploration of new 
treatment strategies to address comorbid PTSD and repetitive mTBI. 
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Materials and Methods 
Animals 
12-week-old C57BL/6 male mice were purchased from Jackson Laboratories (Bar 
Harbor, Maine) and housed in standard cages under a 12-h light/12-h dark schedule at 
ambient temperature.  All procedures were performed in accordance with OLAW 
guidelines under a protocol approved by the Roskamp Institute IACUC. Animals were 
randomly assigned to four groups: Controls, Stress,  r-mTBI or  Stress+r-mTBI 
(N=15/group).   
 
Experiment 1. The 21-day repeated unpredictable stress (RUS) and repetitive mild 
traumatic brain injury (r-mTBI) paradigm. 
Our repeated unpredictable stress (RUS) paradigm was implemented as described 
previously and as depicted in Figure 3.1.  In brief, 12-week-old mice received 21 days of 
RUS involving (i) unstable social housing with a different mouse every day, (ii) 30 
minutes of unpredictable exposure to a predator odor (TMT) under restraint on 10 different 
days, and (iii) five inescapable foot-shocks.  Animals assigned to the stress+r-mTBI group 
received (iv) a mild traumatic brain injury an hour after exposure to each foot-shock, while 
animals in the r-mTBI group received the five mTBIs only and no foot-shocks. The one-
hour delay was introduced to allow for consolidation of fear memory.  Closed head injuries 
were conducted using our previously established model involving a 1mm depth impact 
delivered to the closed skull using a 5mm flat tip electromagnetic stereotaxic impactor at a 
velocity of 5m/s with a dwell time of 200 milliseconds (Mouzon et al. 2012).  Mice were 
anesthetized using 1.5L/min of oxygen and 3% isoflurane and maintained under anesthesia 
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through a nose cone throughout the injury procedure. Foot-shocks and head injuries were 
administered at 48-72 hour intervals to replicate our previous characterization of the r-
mTBI model. Control and r-mTBI-only animals were exposed to the fear-conditioning 
chamber for the same frequency and duration as the stressed mice, without administration 
of foot-shocks or auditory cues, and were never restrained or exposed to TMT. 
 
Figure 3.1. Study timeline and experimental procedures in Experiment 1.  The stress 
paradigm involved 21 days of daily unstable social housing (i), unpredictable repetitive 
exposures to predator odor (Fox urine, TMT), while under restraint for 30 mins (ii), and 
five repeated inescapable foot-shocks (iii).  Animals receiving repeated mild traumatic 
brain injury (r-mTBI) in addition to stress (stress+r-mTBI group) were exposed to (iv) five 
closed head injuries an hour after exposure to inescapable foot-shocks. Closed head 
injuries were conducted using our previously established model involving a 1mm depth 
impact to the closed skull using a 5mm flat tip electromagnetic impactor at a velocity of 
5m/s with a dwell time of 200ms. All animals in the stress groups were singly housed 
(Social isolation) after RUS until the end of the study (v). 
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 Experiment 1. Behavioral testing 
All behavioral experiments were conducted as described in the materials and methods 
section in Chapter 2. I did not perform any molecular studies on the cohort of animals used 
in Experiment 1. Control and stress-only animals examined in this study were a subset of 
the animals tested previously in Chapter 2. The behavioral test batteries are identical to the 
ones described in Chapter 2 (Figure 2.2). 
 
Experiment 2. The 21-day repeated unpredictable stress (RUS) and repetitive mild 
traumatic brain injury (r-mTBI) paradigm. 
The same RUS and r-mTBI procedures described in Experiment 1 were repeated 
again 3 months after the first RUS (i.e. when animals were 27 weeks old) as depicted in 
Figure 3.2.  Animals in the stress and stress+r-mTBI groups were housed individually 
after RUS procedure, whereas animals in the control and r-mTBI groups were housed in 
groups of 2-3 mice throughout the study. 
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Figure 3.2. Study timeline and experimental procedures in Experiment 2. The RUS 
procedure was implemented as described in Experiment 1.  C57BL/6J mice (12-week-old) 
were exposed to the RUS paradigm at 3 months and at 6 months of age.  A battery of 
behavioral testing was conducted at an acute timepoint (Days1-19) and again at 3 months 
after the second RUS.  Brain tissue and plasma were collected at the acute timepoint and at 
the 3-month timepoint. 
 
 A separate group of animals (n=4-5 per group) were euthanized at 10 days after the 
second RUS (acute timepoint) for molecular studies.  To increase the animal number of 
animals in the anxiety tests, these animals received the Open Field test and the Elevated 
Plus Maze only once at the acute timepoints with no additional testing.  The remaining 
animals (10-11) per group received a behavioral testing battery beginning at day 1 after the 
second RUS (acute timepoint) and then were retested using a similar battery at 3 months 
after the second RUS.  The timeline of the behavioral test batteries is shown in Figure 3.3.  
All animals (10-11) were euthanized one week after the last behavioral experiment for 
molecular studies (3 months after the second RUS). 
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Figure 3.3.  Timeline of behavioral test batteries. The same animals were retested at 
behavioral test battery 2. 
 
Experiment 2. Fear conditioning and behavioral testing 
All fear conditioning and behavioral experiments were conducted as described in 
the materials and methods section in Chapter 2.  
 
Experiment 2. Blood collection and ex-vivo LPS stimulation of whole blood  
To obtain blood samples, animals were anesthetized with isoflurane, and 
approximately 500μL of blood were collected into heparin tubes by cardiac puncture 
immediately prior to euthanasia. 400μL of blood from each animal were kept aside for the 
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ex-vivo LPS stimulation studies. The remaining blood was centrifuged at 3000g for 3 min, 
and plasma samples (clear supernatant fraction) were flash frozen in liquid nitrogen and 
stored at −80°C.  For the ex-vivo LPS challenge, 400μL blood samples from each animal 
were divided into two 200μL samples and incubated with either RPMI (1% glutamine, 1% 
pyruvate, 1% garamycin) or RPMI containing 1μg/mL LPS at 37°C. After 6 hours at 
37 °C, all blood samples were centrifuged for 3 min at 3000g for plasma collection. 
 
Experiment 2. Enzyme-linked immunosorbent assay (ELISA) and Multiplex ELISA 
Commercially available ELISA kits were used to measure the concentration of 
several plasma markers as follows; the neuropeptide Y (NPY) ELISA kit was purchased 
from Life-Span biosciences (Seattle, Washington), the norepinephrine ELISA kit was 
purchased from Eagle biosciences (Amherst, New Hampshire), and the corticosterone 
ELISA kit was purchased from Arbor Assays (Ann Arbor, Michigan).  Tissue brain-
derived neurotrophic factor (BDNF) levels were measured using an ELISA from Boster 
Bio (Pleasanton, California).  All ELISA kits were used as per manufacturers’ instructions.  
Brain and plasma cytokine levels were measured using the MSD proinflammatory Panel I 
for the following cytokines: interferon γ (IFN-γ), interleukin (IL)-1β, IL-2, IL-4, IL-5, IL-
6, IL-10, IL-12p70, and tumor necrosis factor α (TNFα) (MesoScale Discovery, 
Gaithersburg, Maryland). A single plasma sample (12.5μL) from each mouse was used for 
the detection of plasma cytokines, while 25μL of hippocampal homogenate in M-PER 
protein extraction reagent (~8 mg/mL total protein) was used for the measurements of 
hippocampal cytokine levels. 
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Experiment 2. Brain tissue preparation and western blotting 
Brains from 4-6 animals per group were used for biochemical analysis while the 
brains from the remaining animals were used for immunohistochemical experiments.  
Western blot experiments were conducted as described previously (Ojo et al. 2016). In 
brief, following transcardial perfusion by gravity drip with phosphate-buffered saline 
(PBS), brain tissue was collected and the hippocampus and hypothalamus were dissected 
and frozen immediately in liquid nitrogen and kept at −80°C.  For western blotting 
analyses, the hypothalamus  or hippocampi from both hemispheres were homogenized in 
200µL of M-PER protein extraction reagent containing proteinase and phosphatase 
inhibitors (Thermofisher) using a probe sonicator. Samples were sonicated with a 2 s pulse 
followed by incubation on ice for 10 s, and this process was repeated 3 times. 
Homogenized samples were centrifugated at 15,000g for 10 minutes (min) followed by 
collection of the supernatants.  Diluted supernatant fractions (2mg/mL) were then mixed 
with Laemmli buffer (Bio-Rad) containing dithiothreitol (DTT) and denatured by boiling 
at 99°C. Samples were then subsequently resolved on 4% to 15% gradient polyacrylamide 
criterion gels (Bio-Rad). After electrotransferring to polyvinylidene difluoride membranes, 
membranes were blocked in 5% milk made in Tris-buffered saline and subsequently 
incubated with different primary antibodies overnight (Table 2.1).  After three washing 
steps using TBST, membranes were probed with horseradish peroxidase-linked secondary 
antibodies (Table 2.1).  Signal intensity ratios were quantified by chemiluminescence 
imaging with the ChemiDocTM XRS (Bio-Rad) with Anti-GAPDH antibody used as a 
housekeeping protein. 
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Experiment 2. Golgi-Cox staining and Immunohistochemistry 
5-6 animals per group were used in Golgi-Cox staining and immunohistochemistry 
experiments. At 3 months after the second RUS exposure, mice were anesthetized with 3% 
isoflurane and transcardially perfused with PBS solution.  Right brain hemispheres were 
extracted and immediately processed according to FD Rapid Golgi stain Kit instructions 
(FD NeuroTechnologies, Baltimore, MD), while the other hemispheres (left side) were 
fixed in 4% paraformaldehyde for 24–48 hours followed by embedding in paraffin for 
subsequent immunohistochemistry (IHC) experiments.   
For the Golgi experiments, 100μm sections of impregnated tissue were cut using a 
cryostat at -20°C, mounted onto positively charged glass slides (Fisher, Superfrost Plus, 
Pittsburgh, Pennsylvania) and analyzed using an Olympus BX63 upright microscope at 
100x magnification.  The following three criteria were met by a dendrite to be chosen for 
spine density analysis: 1) it had to be emerging either from an apical neuron in the 
hippocampal CA1 region or layer II/III in the frontal cortex, 2) the neuron had to be fully 
stained including the cell body with no cuts in the axons, and 3) the origin of the dendrite 
should not be obscured by any nearby overlapping neurons. 
For IHC experiments, a series of 6µm-thick sagittal sections were cut throughout 
the extent of the cortex and hippocampus guided by known bregma coordinates using a 
microtome (2030 Biocut, Reichert/Leica, Buffalo Grove, Illinois). Cut sections were 
mounted onto positively charged glass slides (Fisher, Superfrost Plus, Pittsburgh, 
Pennsylvania). Before the IHC procedure, all sections were deparaffinized in xylene and 
rehydrated in a gradient of ethanol solutions of decreasing concentrations.  Sections were 
then rinsed in distilled water and subsequently incubated at room temperature in a solution 
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of hydrogen peroxide (3% in water) for 15 minutes to block endogenous peroxidase 
activity.  Antigen retrieval was necessary for Iba1 staining and included treatment with 
boiling citrate buffer solution (pH 6) for 8 minutes in the microwave. Following antigen 
retrieval, sections were blocked for 30 minutes to 1 hour in normal blocking serum, using 
the same serum in which the secondary antibody was raised. Next, sections were 
immunostained in batches with primary antibodies diluted in supersensitive wash buffer 
(BioGenex, Fremont, CA).  The primary antibodies used are listed in Supplementary Table 
1. After overnight incubation at 4°C, sections were washed in PBS and then incubated with 
the appropriate secondary antibody (Vectastain Elite ABC Kit, Vector Laboratories) at 
room temperature for 30 minutes to 1 hour, depending on the specific requirement of the 
antibody protocol.  After rinsing in water, sections were incubated with avidin-biotin 
horseradish peroxidase or alkaline phosphatase enzyme solution (Vector Laboratories) for 
30 minutes at room temperature. Immunoreactivity was visualized with 3,3′-
diaminobenzidine (DAB) peroxidase solution (0.05% DAB - 0.015% H2O2 in 0.01M PBS, 
pH 7.2) (Vector Laboratories). Development with the chromogen was timed and applied 
consistently across batches to limit technical variability before progressing to quantitative 
image analysis.  Reactions were terminated by rinsing sections in distilled water. Sections 
were counterstained with hematoxylin, dehydrated through a gradient of ethanol of 
increasing concentrations, cleared in xylene, and coverslipped with permanent mounting 
medium. Immunoreacted sections were viewed using a motorized Olympus BX63 upright 
microscope and photographs were taken using the high-resolution DP72 color digital 
camera. 
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Experiment 2. Image Analysis  
Immunoreactivity for glial fibrillary acidic protein (GFAP) and ionized calcium 
binding adaptor molecule 1 (Iba1) was measured by quantitative image analysis (optical 
segmentation) by an observer blinded to experimental grouping.   Multiple regions of 
interest were analyzed in standardized fashion for each cell marker/antibody.  A survey of 
immunostained tissue sections was first performed independently to verify specific 
immunoreactivity that was subsequently progressed to quantitative image analysis.  
Briefly, nonoverlapping red, green, blue (RGB) images were digitally captured randomly 
within the defined areas from each section (comprising an average of 5 sections per animal 
for each marker), providing a systematic survey of each region of interest for each animal 
within a group.  A minimum of 10 microscopic fields (60x magnification) were analyzed 
per region per animal. The total microscopic field analyzed for each brain region was an 
area of 3.5 mm2 per animal. Immunoreactive profiles that were optically segmented were 
analyzed using CellSens morphometric image analysis software (Olympus, Center Valley, 
Pennsylvania).  A semiautomated RGB histogram-based protocol (specified in the image 
analysis program) was used to determine the optimal segmentation (threshold setting) for 
immunoreactivity for each antibody.  Immunoreactive profiles discriminated in this 
manner were used to determine the specific immunoreactive percentage area. Data were 
separately plotted as the mean percentage area of immunoreactivity per field (% area) ± SE 
for each region and grouping.  
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Statistical Analysis 
The choice of the appropriate statistical test was made after assessment of normal 
distribution using the Shapiro-Wilk normality test.  Repeated Measures-Two-way ANOVA 
was used to examine statistical significance in bodyweight measurements, fear memory 
testing, EPM, Open Field, RAWM training trials, Immunohistochemical data for GFAP 
and Iba1, and cytokine levels in the ex-vivo LPS challenge. One-Way ANOVA was used 
to analyze total immobility time in the forced swim test, RAWM one-day trials, profiling 
of plasma and brain markers using ELISA and western blotting.  All ANOVA experiments 
were followed by pairwise comparisons with correction for multiple comparisons using the 
two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli (BKY) to control 
the false discovery rate.  The three-chamber test was analyzed using one-sample t-tests.  
All analyses were performed with Graph Pad prism version 7.0 statistical software (La 
Jolla, California). Grubbs’ test was applied to identify statistical outliers.  
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Results 
Experiment 1. Effect of single exposure to RUS and/or r-mTBI on fear memory recall  
Data for control and stressed animals in this section has been previously used in to 
generate the data presented in Chapter 2. Stress-only animals showed a significant increase 
in their freezing responses to both the context (Figure 3.4A) and the auditory cue (Figure 
3.4D) compared to control animals when examined at the acute timepoint. However, only 
the response to the auditory cue persisted at 3 months and 6 months after RUS (Figure 
3.4E and 3.4F). Exposure to r-mTBI abrogated contextual fear memory observed at the 
acute timepoint (Figure 3.4A). On the other hand, no significant r-mTBI effect is observed 
with cued fear memory at this time point (Figure 3.4D). Interestingly, r-mTBI inhibited 
the retrieval of the cued fear memory response at 3 months and 6 months after RUS 
(Figure 3.4E and 3.4F).  
 
100 	
Figure 3.4. Recall of contextual and cued fear memory after single exposure to RUS 
and/or r-mTBI.  Animals in the stress and stress+r-mTBI groups showed a significant 
increase in their % of freezing to the context compared to control animals only at the acute 
timepoint (A-C).  Stress+r-mTBI animals showed reduced freezing times in the fear 
conditioning context relative to the stress group only at the acute timepoint (A). In the cued 
fear memory test, no difference between stress-only and stress+r-mTBI groups was 
observed at acute timepoint (D).  However, at the 3-months (E) and 6-months (F) 
timepoints, stress+r-mTBI animals showed reduced freezing times relative to the stress-
only animals in the cued fear memory test.  Data in A-C were analyzed using One- Way 
ANOVA, while data in D-F were analyzed with Two-way ANOVA. (n=5-6) 
 
Experiment 1. Effect of single exposure to RUS and/or r-mTBI on anxiety-like 
behavior  
In order to test anxiety related behavior in our animal groups, we conducted the 
elevated plus maze and the open field tests (Figure 3.5). In the open field test, stress, r-
mTBI only and stress+r-mTBI groups had fewer mean numbers of entries to the center 
zone compared to the control mice at the acute and 3-month timepoints (Figure 3.5A and 
3.5B), but this observation was not statistically significant. In the EPM tes at the acute 
timepoint, mice receiving r-mTBI only, showed a significant increase in the mean number 
of entries to the open arms, consistent with a disinhibitory like behavior (Figure 3.5D). On 
the contrary, stress and stress+r-mTBI animals’ examination of the open arms was similar 
to the control group at this timepoint (Figure 3.5). No significant changes were observed 
in the EPM test at 3 months or 6 months after RUS (Figure 3.5E and 3.5F) 
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Figure 3.5. The performance of each study group in the Open Field and the EPM.  
Panels A, B, and C shows the mean number of entries to the center zone in an open field at 
the acute time point, 3 months, and 6 months after RUS, respectively.  The performance of 
each study group in the EPM at acute time point, 3 months, and 6 months after RUS is 
depicted in panel D, E, and F, respectively. There was an increase in EPM open arm entries 
in the r-mTBI group compared to controls at the acute timepoint (D).  The EPM test was 
performed in bright-light conditions at the acute timepoint and in dark (1Lux) conditions at 
3, and 6 months after RUS.  Data were analyzed using with one-way ANOVA test (n-5-6).  
 
Experiment 1. Effect of single exposure to RUS and/or r-mTBI on spatial memory 
The performance of each group during training sessions in a radial arm water maze 
(RAWM) is depicted in Figure 3.6. Mice received 3 sets of acquisition training sessions. 
The first set started 3-weeks after RUS followed by a second set at 3 months after RUS and 
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a third set at 6 months after RUS. No significant learning impairments were observed for 
any of the groups at acute, 3-month or 6-month timepoints (Figure 3.6A-C). Animals 
receiving r-mTBI-only showed increased memory errors at 3-month and 6 months 
timepoints when compared to control mice at the last day trial (RM-Two-Way ANOVA: 
interaction F(12, 60) = 1.19, p>0.05, main stress and/or r-mTBI effect F(3, 60) = 8.8, p<0.003 
with correction for multiple comparisons, Figure 3.6B) and (RM-Two-Way ANOVA: 
interaction F(6, 45) = 1.4, p>0.05, main stress and/or r-mTBI effect F(3, 45) = 3.56, p<0.02 
with correction for multiple comparisons, Figure 3.6C).  
 
Figure 3.6. Effect of single exposure to RUS and/or r-mTBI on the performance of 
each group in the Radial Arm Water Maze.  No significant differences between groups 
were observed at the acute timepoints.  In the last day of training at 3 months and 6 months 
after RUS, r-mTBI animals showed increased mean memory errors relative to all other 
groups. Data were analyzed using repeated measures RM-Two-Way ANOVA.  
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Experiment 1. Effect of single exposure to RUS and/or r-mTBI on stress-coping 
strategies 
At 6 months after RUS, animals in the stress-only group showed increased 
immobility time relative to stress+r-mTBI group in the Forced Swim Test (FST) (One-way 
ANOVA, F(3, 17) =4.02, p=0.025, with correction for multiple comparisons, Figure 3.7).  
 
Figure 3.7. Effect of single exposure to RUS and/or r-mTBI on the performance of 
each group in the Forced Swim Test.  Stress animals showed increased immobility time 
in the forced swim test relative to the stress+-r-mTBI group at 6 months after RUS. Data 
were analyzed using with one-way ANOVA test (n-5-6).  
 
Experiment 2. Repeated exposure to stress and/or mTBI results in acute bodyweight 
loss.  
I have previously shown that a single exposure to the RUS paradigm results in a 
reduction in normal bodyweight gain in young adult mice (Algamal et al. 2018). In 
experiment 2, I examined the effect of repeated exposure to stress and mTBI on 
bodyweight.  During the first RUS exposure body weight was only affected by stress 
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alone, as evidenced by reduced weight gain in the stress and stress+r-mTBI groups in the 
first 3 weeks of stress compared to controls (RM-ANOVA: interaction F(9, 102) = 2.835, 
p0.005, with correction for multiple comparisons, Figure 3.8A). No significant r-mTBI 
effects on bodyweight were observed during the first RUS (Figure 3.8A).  Stress and/or r-
mTBI procedures were repeated again 3 months after initial stress (second RUS), during 
which animals in the r-mTBI, stress and stress+r-mTBI groups showed significant weight 
loss at days 14 and 21 of RUS when compared to the control group (RM-ANOVA: 
interaction F(9, 111) = 3.816, p<0.0001, with correction for multiple comparisons, Figure 
3.8B).  The TBI-related weight loss during the second RUS was worsened by stress as 
evidenced by increased weight loss in the stress+r-mTBI group relative to the r-mTBI 
group (Figure 3.8B).  The changes in bodyweight in all groups were driven by an intense 
decrease in their growth rate during the first week of RUS or r-mTBI (RM-ANOVA: 
interaction F(9, 105) = 3.816, p=0.0003, with correction for multiple comparisons,  Figure 
3.8C and 3.8D).   
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Figure 3.8. Effect of double exposure to RUS on bodyweight gain.  (A) During the first 
exposure to stress and/or r-mTBI (1st RUS), animals in the stress and stress+r-mTBI 
groups showed a significant reduction in their bodyweight gain throughout the 21 days of 
stress. Stress and/or r-mTBI procedures were repeated 3 months after initial stress (2nd 
RUS).  (B) During the second RUS, all treatment groups showed significant weight loss at 
days 7, 14 and 21 of the 2nd RUS compared to the control group.  Animals in the stress+r-
mTBI group showed a greater weight loss when compared to the r-mTBI-only group at 
days 7 and 14 of the 2nd RUS (B).  Changes in growth rate after the first and second RUS 
are depicted in panels C and D, respectively.  Data in A-D were analyzed using repeated 
measures Two-Way ANOVA followed by two-stage linear step-up procedure of 
Benjamini, Krieger and Yekutieli (BKY) (n = 9-11). Statistically significant discoveries 
versus the control group are denoted by “*”, while statistically significant discoveries 
versus the r-mTBI group are denoted by “&”. 
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Experiment 2. Effect of r-mTBI on overall locomotion and recall of fear memory.  
I next examined the effect of r-mTBI on several stress-related behaviors (Recall of 
fear memory, and stress-coping strategies) at the acute timepoint and at 3 months after the 
second RUS (Figure 3.9).  All animals receiving RUS, independent of r-mTBI, showed a 
significant increase in their freezing (immobility time) when placed in the same trauma 
context at the acute and 3-month timepoints (RM-Two-Way ANOVA: interaction F(3, 39) 
= 0.5347, p>0.05, main stress/r-mTBI effect F(3, 39) = 23.75, p<0.0001 with correction for 
multiple comparisons, Figure 3.9A). In the cued fear memory test at the acute timepoint, 
stress and stress+r-mTBI groups showed similarly increased freezing responses to the cue 
compared to their respective control groups in the total test duration (Two-way ANOVA, 
interaction F(3, 78) =16.22, p<0.0001, Figure 3.9B), and in the 30 s time-bin analysis 
(RM-Two-Way ANOVA: interaction F(15, 228) = 0.4668, p>0.05, main stress/r-mTBI 
effect F(15, 228) = 86.23, p<0.0001 with correction for multiple comparisons, Figure 
3.9D).  However, at the 3-month timepoint, the stress+r-mTBI group showed reduced 
immobility time relative to the stress-only group in the cued fear memory test (Two-way 
ANOVA, interaction F(3, 78) =6.57, p<0.0011, with correction for multiple comparisons, 
Figure 3.9C). Interestingly, stress+r-mTBI animals showed an increased average 
immobility time relative to controls in the contextual fear memory test, but not in the 3-
min cued fear memory test at the 3-month timepoint.  A decreased startle response in r-
mTBI animals at 3 months after the last injury is a possible explanation to this observation. 
However, a closer inspection of the freezing behavior in 30 s time-bins (Figure 3.9E) 
shows that stress+r-mTBI and stress-only animals exhibited a similar increase in their 
immobility time during the first 60 s of the test (RM-Two-Way ANOVA: interaction F(15, 
234) = 1.53, p>0.05, main stress/r-mTBI effect F(15, 234) = 36.63, p<0.0001 with 
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correction for multiple comparisons, Figure 3.9E).  Therefore, stress+r-mTBI animals do 
not appear to show a reduced startle response relative to the stress-only group.  The 
immobility time parameter relies on animals’ inactivity or lack of body movement to score 
freezing.  To examine the overall locomotor activity, I first checked the total distance 
travelled by different study groups in a safe new context and in the absence of any stress-
related cues.  As depicted in Figure 3.9F, stress+r-mTBI and r-mTBI-only animals 
travelled longer distances in the 3-min-long test relative to the control animals and stress-
only animals respectively (RM-Two-Way ANOVA: interaction F(3, 38) = 0.518, p>0.05, 
main stress/r-mTBI effect F(3, 38) = 8.9, p<0.0001 with correction for multiple 
comparisons, Figure 3.9F).  Remarkably, stress-only animals travelled a shorter distance 
relative to the controls at the acute timepoint (Figure 3.9F), suggesting fear generalization 
or anxiety-like behavior shortly after RUS exposure. 	
108 	
 
Figure 3.9. Effect of stress and r-mTBI on fear memories, anxiety and stress-coping 
behavior at the acute and 3-month timepoints.  (A) Stress and stress+r-mTBI groups 
demonstrated similar increases in freezing time relative to controls at the acute and 3-
month timepoints. r-mTBI didn’t affect recall of cued fear memories in animals exposed to 
RUS at the acute timepoint, as stress and stress+r-mTBI animals showed similar freezing 
time relative to control animals (B) and (D).  However, at the 3-month timepoint, stress+r-
mTBI animals showed an attenuation in recall of cued fear memories compared to stress-
only animals in the total test duration (3 min) as demonstrated by reduced freezing times 
relative to the stress-only group (C). The stress group showed increased freezing time 
relative to controls in the first 150 seconds of the test, while the stress+r-mTBI group 
showed an increased freezing time only during the first 60 seconds (E).  The distance 
travelled (G) and velocity (H) in the open field were increased in the r-mTBI-only group 
and reduced in the stress and stress+r-mTBI groups relative to their respective control 
groups at the acute timepoint (A).  At the chronic timepoint, animals in the stress+r-mTBI 
group showed distance travelled and velocity (B) and decreased not-moving time (I) 
relative to the control group All data were analyzed using repeated measures Two-Way 
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ANOVA followed by two-stage linear step-up procedure of BKY to correct for multiple 
comparisons (n=10-11).  Statistically significant discoveries versus the control group are 
denoted by “*”, while statistically significant discoveries versus the stress+r-mTBI group 
are denoted by “+”. Statically significant discoveries versus the r-mTBI group are denoted 
by “&” .  
 
The Open Field test has been widely used  to evaluate overall locomotion and 
exploratory behavior in rodents (Hall and Ballachey 1932). The test can also be used to 
examine anxiety-like behavior as long as the total ambulatory distance covered by all study 
groups is the same (Seibenhener and Wooten 2015).  At the acute timepoint, the overall 
locomotion activity was reduced after stress and increased by r-mTBI as demonstrated by 
decreased distance travelled in stress-only mice and increased distance travelled in the r-
mTBI-only mice relative to control mice (Two-Way ANOVA: interaction F(3, 94) = 8.6, 
p<0.0001, main stress/r-mTBI effect F(3, 94) = 3.38, p=0.024 with correction for multiple 
comparisons, Figure 3.9G). Stress+r-mTBI mice showed a reduction in the total distance 
travelled in the Open Field relative to r-mTBI-only mice, but not relative to the control 
group, possibly due to opposing effects of stress and r-mTBI on locomotion at the acute 
timepoint.  Interestingly, at the 3-month timepoint, stress+r-mTBI groups showed 
increased locomotion relative to controls, r-mTBI-only and stress-only groups (Two-Way 
ANOVA: interaction F(3, 94) = 8.6, p<0.0001, main stress/r-mTBI effect F(3, 94) = 3.38, 
p=0.024 with correction for multiple comparisons, Figure 3.9G).  Examination of Open 
Field average velocity (Figure 3.9H) and inactivity time (Figure 3.9I) showed additional 
evidence of the altered ambulatory behavior after stress and/or r-mTBI. The distance 
travelled in the Open Field correlated negatively with the immobility time only in stress+r-
mTBI group (Pearson correlation: r = –0.71, p = 0.022, Figure 3.10D).  No changes in the 
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time spent in the Open Field center zone (p>0.05, Figure 3.11A) or center zone entries 
(p>0.05, Figure 3.11B) were observed at any timepoint. 
 
 
Figure 3.10. Correlations between the distance travelled in the open field and the % 
time freezing in the cued fear memory test in different study groups at 3 months after 
second RUS.  The distance travelled by each animal in the open field correlated negatively 
with freezing scores in the cued fear memory test in the stress+r-mTBI group (D), but not 
in control (A), r-mTBI (B) or stress-only (C) groups.  All data were analyzed using 
Pearson correlations.  
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Figure 3.11. Effect of stress and r-mTBI on performance in the Elevated Plus Maze 
and Forced Swim Test.  No changes in the Open Field center zone time (A) or entries (B) 
were observed at any timepoint. Stressed animals spent less time in the EPM open arms 
(C) and made less open arm entries (D) at the acute timepoint.  Average immobility time in 
the last 4 min was increased in stress-only mice compared to the controls, r-mTBI and 
stress+r-mTBI groups (E) at 3 months after second RUS.  Animals in the stress-only group 
displayed increased immobility time in minutes 3 to 6 of the FST when compared to the r-
mTBI and stress+r-mTBI groups (F). There was a trend towards increased distance 
travelled in r-mTBI animals relative to controls in the FST (G).  Data in A-D, F were 
analyzed using RM-Two-Way ANOVA (n = 10-15). Data in E, G were analyzed using a 
One-Way ANOVA followed by two-stage linear step-up procedure of BKY to correct for 
multiple comparisons (n=10-11).  Statistically significant discoveries versus the control 
group are denoted by “*”, while statistically significant differences between the stress-only 
and stress+r-mTBI groups are denoted by “+”. 
 
Experiment 2. Effect of r-mTBI on anxiety-like behavior and stress-coping strategies.  
I examined the effect of r-mTBI on anxiety-like behavior and stress-coping 
strategies using the Elevated Plus Maze (EPM) and the Forced Swim Test (FST), 
respectively. Animals exposed to stress-only showed anxiety-like behavior at the acute 
timepoint as demonstrated by reduced time spent in the open arms (RM-Two-Way 
ANOVA: interaction F(3, 34) = 1.137, p>0.05, main stress/r-mTBI effect F(3, 34) = 2.968, 
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p=0.054 with correction for multiple comparisons, Figure 3.11C) and arm entries in the 
EPM (RM-Two-Way ANOVA: interaction F(3, 35) = 1.53, p>0.05, main stress/r-mTBI 
effect F(3, 35) = 2.96, p=0.045 with correction for multiple comparisons, Figure 3.11D).  
No significant stress or r-mTBI effects were observed at the 3-month timepoint in the 
elevated plus maze (p>0.05, Figure 3.11C and 3.11D).  The validity of retesting at the 3-
month timepoint is questionable since control animals showed a reduction in time spent in 
the open arms and number of entries into the open arms after retesting (Figures 3.11C and 
3.11D).  At 3 months after the second RUS, animals in the stress-only group showed 
negative stress-coping behavior (increased immobility time relative to controls in the FST) 
(One-way ANOVA, F(3, 37) =8.024, p=0.0003, with correction for multiple comparisons, 
Figure 3.11E) and (RM-Two-Way ANOVA: interaction F(15, 185) = 1.55, p>0.05, main 
stress/r-mTBI effect F(15, 158) = 62.66, p=0.003 with correction for multiple comparisons, 
Figure 3.11F).  r-mTBI ameliorated the effects of RUS on stress-coping behavior as 
evidenced by decreased immobility time in the stress+r-mTBI group compared to the 
stress-only group (Figure 3.11E). The total distance travelled in the FST is depicted in 
Figure 3.11G.  A trend towards increased total distance travelled was observed for r-mTBI 
relative to controls. Similar to our findings in the cued fear memory test, the increased 
locomotor activity after r-TBI may account for the reduced immobility time in the stress+r-
mTBI group relative to stress-only group in the FST.   
 
Stress modulates acute r-mTBI impairments in spatial learning and memory.  
Our r-mTBI mouse model is associated with persistent and progressive deficits in 
spatial memory and learning, evaluation of which has previously utilized the Barnes Maze  
113 	
(Mouzon et al. 2014).  The performance of each group during training sessions in a radial 
arm water maze (RAWM) is depicted in Figures 3.12A.  Mice received two sets of 
acquisition training sessions (5 days each).  The first set started at the acute timepoint 
followed by a second set 3 months after. All groups demonstrated a learning curve during 
the two sets of training (Linear regression, slopes >0, P<0.0001, Figures 3.12A).  The 
mean number of memory errors at training day 5 was used to evaluate spatial memory at 
the acute timepoint (Figures 3.12B), while the mean number of memory errors at training 
day 10 was used to assess spatial memory at the 3-month timepoint (Figures 3.12D).  In 
addition, the first day of the second training session (Day 6) was used to evaluate the long-
term recall of spatial memory (Figures 3.12C).  At the acute timepoint, only the r-mTBI 
group showed increased mean memory errors relative  to the control group (One-way 
ANOVA, F(3, 34) =5.75, p=0.003, with correction for multiple comparisons, Figures 
3.12A), while at the chronic timepoint both r-mTBI-only and stress+r-mTBI groups 
showed increased mean memory errors when compared to control mice (One-way 
ANOVA, F(3, 34) =7.23, p=0.0007, with correction for multiple comparisons, Figures 
3.12D). Mice in stress, r-mTBI and stress+r-mTBI groups made more memory errors 
during the 3-month recall when compared to the control group (One-way ANOVA, F(3, 
34) =3.76, p=0.0031, with correction for multiple comparisons, Figures 3.12C). 
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Figure 3.12. Effect of stress and r-mTBI on spatial learning and memory. The 
performance of each group during two separate 5-day training sessions in a radial arm 
water maze (RAWM) is depicted in panel (A).  In the last trial at the acute timepoint 
(Day5), only animals in the r-mTBI group showed spatial memory deficits as evidenced by 
a significant increase in the mean memory errors relative to controls (B).  All treatment 
groups showed increased mean memory errors relative to controls in the 3-month recall of 
learned memories (Day6) (C).  A main r-mTBI effect was observed in the last trial at the 3-
month timepoint (Day10) as animals in the r-mTBI and stress+r-mTBI groups showed 
increased mean memory errors relative to controls (B).  Data in A were analyzed using 
repeated measures Two-Way ANOVA followed by two-stage linear step-up procedure of 
BKY to correct for multiple comparisons (n=10-11), while data in C-D were analyzed 
using a One-Way ANOVA followed by two-stage linear step-up procedure of BKY to 
correct for multiple comparisons (n=10-11).  In panel A, statistically significant 
discoveries for the r-mTBI group versus the control group are denoted by “*”, while 
statistically significant discoveries for the stress+r-mTBI group versus the control group 
are denoted by “+”. In panels B-D, statistically significant discoveries versus the control 
group are denoted by “*”.  
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The 3-chamber test was used to assess social interaction and social memory after 
RUS and r-mTBI.  At the acute timepoint, as expected, control mice showed increased 
preference for the stranger mouse over the empty cage (One sample t-test: t(10) =3.577, 
p=0.005, Figure 3.13A), while mice receiving stress-only, r-mTBI-only, and stress+r-
mTBI showed no preference for the stranger mouse over the empty cage (One sample t-
test: p> 0.05, Figure 3.13A).  All the groups showed no preference for the stranger mouse 
over the empty cage, when retested for social interactions at the 3-month timepoint (One 
sample t-test: p> 0.05, Figure 3.13A). In the subsequent social memory test,  no group 
differences were observed at the acute timepoint (One sample t-test: p> 0.05, Figure 
3.13B).  However, at the 3-month timepoint, control animals and stress-only animals 
showed a preference for stranger 2 over stranger 1 (One sample t-test: t(9) =6.5, p=0.0001 
for controls, t(9) =3.2 p=0.001 for the stress-only group, Figure 3.13B), while r-mTBI and 
stress+r-mTBI groups spent equal time with both strangers (p>0.05, Figure 3.13B). The 
lack of preference for stranger 2 over stranger 1 in the social memory test suggests that 
social memory was impaired in r-mTBI and stress+r-mTBI animals (One sample t-test: p> 
0.05, Figure 3.13B). 
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Figure 3.13. Effect of stress and r-mTBI on social interactions and social memory at 
the acute timepoint and at 3 months after the second RUS.  In the social interaction 
test, only the control group showed increased preference for stranger1 relative to the empty 
cage at the acute timepoint (A).  All groups showed no preference for stranger1 when 
retested at 3 months after the second RUS (A).  In the social memory test, all groups failed 
to show a preference for stranger2 at the acute timepoint (B).  However, at the 3-month 
timepoint, control and stress-only groups showed increased preference for stranger2 over 
stranger1.  In (A), the ratio between time spent around stranger1 cage to total time spent 
around stranger1 and the empty cage was calculated for each animal to evaluate social 
interactions, while in (B), the ratio between time spent around stranger2 cage (new never 
seen mouse) to the total time around both strangers was calculated to evaluate social 
memory (social novelty recognition). Data in A and B were analyzed using One sample t 
test. 
 
Experiment 2. No dysregulation in baseline HPA-axis markers after repeated 
exposure to RUS.  
A single exposure to the RUS paradigm is associated with chronic HPA axis 
dysregulation (low baseline plasma corticosterone levels in stressed animals) as per our 
previous model characterization (Algamal et al. 2018). In order to understand the effects of 
repeated RUS exposure on the HPA-axis, I first measured baseline plasma 
adrenocorticotropic hormone (ACTH) and corticosterone levels at 3 months after second 
RUS.  Surprisingly, no significant changes were observed in baseline plasma ACTH or 
corticosterone levels after repeated exposure to RUS at the chronic timepoint (p>0.05, 
(p>0.05, Figure 3.14A and 3.14B). In addition, baseline ACTH and corticosterone levels 
did not change after r-mTBI (p>0.05, Figure 3.14A and 3.14B). Similarly, baseline 
plasma cortisol, norepinephrine and neuropeptide Y levels did not change after stress 
and/or r-mTBI (p>0.05, Figure 3.14C-E). No changes in the levels of corticosterone, 
cortisol, norepinephrine and NPY were observed in any group at the acute timepoint 
(p>0.0, Figure 3.15). I then examined the regulation of glucocorticoids in the brain by 
measuring the expression levels of glucocorticoid receptor (GR), FK506 binding protein 
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51 (FKBP51) and corticotropin-releasing hormone (CRH) in the hypothalamus (Figure 
3.14). Levels of FKBP51 and CRH were downregulated in the hypothalamus of r-mTBI 
and stress+r-mTBI animals (t-test: t(9) =2.4, p=0.042, Figure 3.14G and 3.14H) at 3 
months after the second RUS. Exposure to RUS did not affect the expression of GR, 
FKBP51, or CRH in the hypothalamus (Figure 3.14F-H). 
 
 
Figure 3.14. Effect of stress and r-mTBI on HPA axis markers at 3 months after the 
second RUS. No changes in plasma levels of ACTH (A), corticosterone (B), cortisol (C), 
noradrenaline (D) or neuropeptide Y (NPY) (E) were detected at 3 months after the second 
RUS. Quantification of western blot images for GR (F), FKBP51 (G), and CRH (H) levels 
in the hypothalamus at 3 months after the second RUS. Levels of FKBP51 and CRH were 
reduced in r-mTBI and stress+r-mTBI groups relative to the control and stress-only groups, 
respectively.  Data A-F were analyzed using a One-Way ANOVA followed by two-stage 
linear step-up procedure of BKY to correct for multiple comparisons (n=4-6). Statistically 
significant discoveries versus the control group are denoted by “*”, while statistically 
significant discoveries for the stress-only group are denoted by “+”. 
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Figure 3.15.  Profiling of plasma stress markers at the acute timepoint. No changes in 
plasma levels of cortisol (A), corticosterone (B), noradrenaline (C) and neuropeptide Y (D) 
were observed at the acute timepoint. Data in A-D were analyzed using One-Way ANOVA 
followed by two-stage linear step-up procedure of BKY to correct for multiple 
comparisons. 3-5 plasma samples per group were used at the acute timepoint.  
 
Experiment 2. Effect of stress and r-mTBI on the immune system.  
To examine the effect of repeated RUS and r-mTBI on the peripheral immune 
system, I measured plasma cytokine levels at baseline and after ex-vivo stimulation of 
whole blood with lipopolysaccharide (LPS) at the chronic timepoint. At baseline, IL2 
levels were reduced in the stress groups (i.e. stress and stress+r-mTBI groups) relative to 
the control group (One-way ANOVA, F(3, 30) =3.7, p=0.023, with correction for multiple 
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comparisons, Table 3.1), while IL5 levels were reduced in r-mTBI groups (i.e. r-mTBI and 
stress+r-mTBI groups) relative to the control group (One-way ANOVA, F(3, 30) =3.1, 
p=0.041, with correction for multiple comparisons, Table 3.1). Additionally, baseline 
plasma IL10 levels were reduced in all stress and/or r-mTBI  groups (One-way ANOVA, 
F(3, 30) =4.3, p=0.012, with correction for multiple comparisons, Table 3.1) relative to the 
control group. Baseline levels of other cytokines were not significantly altered (Table 3.1). 
In the ex-vivo whole blood challenge, IL1b, IL10, TNFa, IL6, and IL12 levels were 
increased in all treatment groups after incubation with LPS for 6 hours (RM-Two-Way 
ANOVA: interaction p>0.05, main LPS effect, p<0.0013, stress and/or r-mTBI effect, 
p>0.05 Figure 3.16E-I). Although the levels of TNFa showed an elevated trend in the 
stress-only animals relative to control animals after LPS stimulation (Figure 3.16I), RM-
Two-way ANOVA analysis showed no main stress and/or r-mTBI  effect. 
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Table 3.1. Effect of stress and/or r-mTBI on cytokines levels in brain and plasma  
Asterisks denote statistical significance (∗p < 0:05). 
Baseline cytokine levels (mean ± SEM) at 3 months after the second RUS  
Plasma (pg/mL) p  Hippocampus (pg/mg protein) p 
 Control 
r-
mTBI Stress 
Stress
+ r-
mTBI 
 Control 
r-
mTBI Stress 
Stress
+ r-
mTBI 
 
IFg 
1.85 
± 0.30 
1.58 
± 0.14 
1.30 ± 
0.12 
1.24 
± 0.09 
0.08 
1.91 
± 0.9 
1.18 
± 0.23 
1.554 
± 0.77 
2.75 
± 1.37 
0.68 
TNFa 
8.74 
± 0.82 
7.52 
± 0.59 
8.28 
± 1.57 
6.4 
± 0.76 
0.38 
0.049 
± 0.09 
0.06 
± 0.09 
0.052 
± 0.07 
0.053 
± 
0.056 
0.61 
IL1b 
0.101 
± 0.03 
0.081 
± 0.01 
0.079 
± 0.02 
0.072 
± 0.01 
0.44 
24.68 
± 3.57 
19.71 
± 4.05 
18.64 
± 
1.878 
21.65 
± 3.12 
0.61 
IL2* 
0.505 
± 0.09 
0.387 
± 0.05 
0.272 
± 0.06 
0.248 
± 0.05 
0.02 
43.73 
± 12.2 
21.29 
± 
10.61 
25.15 
± 5.98 
31.2 
± 4.9 
0.41 
IL4 
0.015 
± 
0.008 
0.026 
± 
0.008 
0.022 
± 0.01 
0.04 
± 0.01 
0.27 
13.56 
± 1.93 
15.95 
± 4.13 
16.91 
± 1.8 
12.92 
± 2.09 
0.63 
IL5* 
0.664 
± 0.04 
0.473 
± 0.07 
0.609 
± 0.08 
0.507 
± 0.03 
0.05 
19.03 
± 2.27 
19.39 
± 2.74 
22.58 
± 1.02 
20.47 
± 
1.382 
0.68 
IL6 
14.65 
± 4.3 
25.28 
± 7.9 
11.42 
± 1.8 
8.05 
± 1.3 
0.30 
1.585 
± 0.35 
1.191 
± 0.14 
1.423 
± 0.27 
1.04 
± 
0.047 
0.33 
IL10* 
16.12 
± 2.3 
11.08 
± 1.1 
10.56 
± 0.65 
10.8 
± 0.68 
0.01 
281.3 
± 
32.05 
346.8 
± 
36.25 
292.6 
± 
27.08 
294 
± 
17.16 
0.45 
IL12 
2.9 
± 1.7 
2.7 
± 2.0 
7.6 
± 4.5 
4.2± 
1.9 0.71 
057 
± 0.33 
0.155 
± 
0.155 
0.09 
± 0.09 
0.71 
± 0.29 
0.30 
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Figure 3.16. Effect of stress and r-mTBI on LPS-induced cytokine production in 
whole blood. Plasma levels of IFg (A), IL2 (B), IL4 (C), and IL5 (D) were not altered after 
incubating whole blood with LPS for 6 hours. On the contrary, the production levels of 
IL1b, IL10, IL6, IL12, and TNFa were significantly increased 6 hours after LPS 
stimulation. No stress or r-mTBI effects were observed in any group after LPS stimulation. 
Data in A-I were analyzed using repeated measures Two-Way ANOVA followed by two-
stage linear step-up procedure of BKY to correct for multiple comparisons (n=5-6). 
 
Experiment 2. Stress augments r-mTBI-dependent microgliosis and astrogliosis in the 
corpus callosum   
To assess the effect of stress on inflammatory markers associated with repetitive 
mTBI, brain tissue from different treatment groups was immunostained for GFAP and Iba1 
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at 3 months following the second RUS. In the corpus callosum, r-mTBI was associated 
with increased GFAP levels relative to control animals, while stress+r-mTBI animals 
showed increased GFAP levels relative to r-mTBI-only and control animals (Two-Way 
ANOVA: interaction F(6, 36) = 7.92, p<0.0001, with correction for multiple comparisons, 
Figure 3.17A). Similarly, Iba1 levels were increased in the corpus callosum of stress+r-
mTBI mice relative to r-mTBI-only mice, with both groups showing significantly higher 
levels than controls (Two-Way ANOVA: interaction F(6, 36) = 9.126, p<0.0001, with 
correction for multiple comparisons, Figure 3.17B). No significant changes in GFAP or 
Iba1 immunostaining were observed in the cortex or the hippocampus after stress or r-
mTBI (Figure 3.17A and 3.17B). Representative images for GFAP and Iba1 staining are 
depicted in Figure 3.18.  I also quantified the levels of neurofilament heavy chains (NF-H) 
and medium chains (NF-M) to explore the impact of r-mTBI on axonal injury. While there 
was no change in the hippocampal levels of NF-H (Figure 3.17C, P>0.05), NF-M levels 
were elevated in the r-mTBI group, but not in the stress+r-mTBI group (One-way 
ANOVA, F(3, 17) =5.5, p=0.0081, with correction for multiple comparisons, Figure 
3.17D). Rep 
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Figure 3.17. Effect of stress on brain injury markers at 3 months after last injury. 
Quantitative assessments of Iba1 and GFAP immunostaining in different brain regions are 
depicted in panels A and B, respectively.  Levels of Iba1 (A) and GFAP (B) were 
upregulated at 3 months after the last injury in the corpus callosum of r-mTBI and stress+r-
mTBI animals. Stress increases microgliosis and astrogliosis in injured animals as 
demonstrated by increased levels of Iba1 (A) and GFAP (B) immunostaining in the 
stress+r-mTBI group relative to the r-mTBI-only group.  No changes in GFAP or Iba1 
were observed in the cortex or the hippocampus (A, B). Quantification of hippocampal 
neurofilament heavy chain (C), neurofilament medium chain (D), at 3 months after the 
second RUS using western blotting.  Levels of hippocampal neurofilament medium chain 
(D) were increased in r-mTBI-only group relative to controls.  Data in A-B were analyzed 
using Two-Way ANOVA followed by two-stage linear step-up procedure of BKY to 
correct for multiple comparisons (n=5-6). Data C-D were analyzed using a One-Way 
ANOVA followed by two-stage linear step-up procedure of BKY to correct for multiple 
comparisons (n=4-6).  Statistically significant discoveries versus the control group are 
denoted by “*”, while statistically significant discoveries versus the r-mTBI group are 
denoted by “&”. 
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Figure 3.18.  Representative GFAP and Iba1 immunostaining images form each study 
group. 
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Experiment 2. Reduced spine density and chronic alterations in synaptic plasticity 
markers after r-mTBI and/or stress exposures. 
Variations in dendritic spine density and morphology have been reported after 
stress. To examine the chronic effects of repeated RUS and r-mTBI on spine density, I 
used the Golgi-cox staining method to quantify the number of spines per 10 𝑢m dendritic 
length in the prefrontal cortex and in the hippocampus at 3 months after the second RUS.  
Figure 3.19A shows representative images from the Golgi-stained hippocampal CA1 
neurons. Stress and/or r-mTBI did not change spine density in the prefrontal cortex (One-
way ANOVA, P>0.05, Figure 3.19B).  However, stress and/or r-mTBI resulted in a 
reduction in spine density in hippocampal CA1 pyramidal neurons (One-way ANOVA, 
F(3, 14) =4.45, p=0.0215, with correction for multiple comparisons, Figure 3.19C). I then 
examined the expression levels of notable markers/mediators of neuroplasticity using 
immunoblot analysis of hippocampal lysates. GluN2A/GluN2B ratio and the levels of  
CAMKIIa were downregulated with stress and/or r-mTBI relative to controls (One-way 
ANOVA, F(3, 16) =5.4, p=0.009, with correction for multiple comparisons, Figure 3.19H, 
respectively) and  (One-way ANOVA, F(3, 16) =6.62, p=0.004, with correction for 
multiple comparisons, Figure 3.19I, respectively). GluNR1 levels were downregulated in 
all groups relative to controls at the acute timepoint (One-way ANOVA, F(3, 13) =6,01, 
p=0.0008, with correction for multiple comparisons, Figure 3.20A) and upregulated in 
stress+r-mTBI groups relative to controls at the 3-months timepoint (One-way ANOVA, 
F(3, 16) =4.04, p=0.0258, with correction for multiple comparisons, Figure 3.19G) at the 
3-month timepoint.  Levels of PSD-95 showed a tend towards reduction only in the stress 
group (One-way ANOVA, F(3, 16) =4, p=0.004, with correction for multiple comparisons, 
Figure 3.19J) at the 3-month timepoint. The levels of other neuroplasticity markers such 
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as GluN2B, P-JNK/JNK and P-AKT/AKT were not significantly altered after RUS and r-
mTBI (P> 0.05, Figure 3.19 and 3.20).  
 
Figure 3.19. Effect of stress and r-mTBI on spine density and a number of synaptic 
markers at 3 months after the second RUS. Representative dendritic segments of the 
hippocampal CA1 region (A). Quantification of spine density in the PFC (B) and CA1 of 
the hippocampus (C). Stress, stress+r-mTBI and r-mTBI groups showed reduced spine 
density only in the hippocampal CA1 region when compared to the control group. 
Quantification of Western Blot images for GluN2B (D), GluN2A (E), GluN1 (F), 
GluN2A/GluN2B ratio (G), CAMKIIa (H), PSD-95 (I), the ratio of p-AKT/AKT (J), and 
P-JNK/JNK (K) in the hippocampus at 3 months after the second RUS. Data in B-L were 
analyzed using a One-Way ANOVA followed by two-stage linear step-up procedure of 
BKY to correct for multiple comparisons (n=4-6). Statistically significant discoveries 
versus the control group are denoted by “*”. 
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Figure 3.20. Effect of stress and r-mTBI on a number of hippocampal synaptic 
plasticity markers at the acute timepoint. Quantification of GluN1 (A), GluN2B (B), 
and PSD-95 (C) levels in the hippocampus at the acute timepoint. Levels of GluN1 were 
significantly reduced in the stress, r-mTBI and stress+r-mTBI groups compared to the 
control group. Data A-C were analyzed using a One-Way ANOVA followed by two-stage 
linear step-up procedure of BKY to correct for multiple comparisons (n=4-5). Statistically 
significant discoveries versus the control group are denoted by “*”. 
 
Experiment 2. Effect of stress and r-mTBI on neurotrophic signaling markers.  
BDNF levels in the hippocampus were not altered at 3 months after exposure to 
RUS and r-mTBI (p>0.05, Figure 3.21A), while BDNF precursor (ProBDNF) levels were 
only increased in the r-mTBI group (One-way ANOVA, F(3, 34) =7.23, p=0.0007, with 
correction for multiple comparisons, Figure 3.21C). I did not find any detectable changes 
in levels of BDNF receptor (TrkB) or proBDNF receptor (P75NTR) in the hippocampus at 
3 months after the second RUS (One-way ANOVA, p>0.05, Figure 3.21B and 3.21D). 
Interestingly, there was an effect for the combination of stress and r-mTBI on hippocampal 
P75NTR expression levels at the acute timepoint (One-way ANOVA, F(3, 34) =7.23, 
p=0.0007, with correction for multiple comparisons, Figure 3.22D).  No changes in 
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BDNF, proBDNF or TrkB levels were detected at the acute timepoint (One-way ANOVA, 
p>0.05, Figure 3.22). 
 
 
Figure 3.21.  Effect of RUS on hippocampal neurotrophic factors and receptors at 3 
months after the second RUS.  Quantification of hippocampal TrkB (A), P75NTR (C), 
and ProBDNF (D) levels using western blotting. Levels of hippocampal BDNF were 
quantified using ELISA (B). Hippocampal ProBDNF levels were upregulated only in the r-
mTBI group at 3 months after the second RUS. No changes in TrkB, BDNF or P75NTR 
were observed at the 3-month timepoint. Data in A-D were analyzed using One-Way 
ANOVA followed by two-stage linear step-up procedure of BKY to correct for multiple 
comparisons (n=4-6). Statistically significant discoveries versus the control group are 
denoted by “*”. 
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Figure 3.22.  Effect of RUS on hippocampal neurotrophic factors and receptors at the 
acute timepoint.  Levels of hippocampal BDNF were quantified using ELISA (A). 
Quantification of hippocampal TrkB (B), ProBDNF (C) and P75NTR (D) levels using 
western blotting. P7NTR levels were downregulated in the stress+r-mTBI group at the 
acute timepoint (C).  No changes in TrkB, BDNF, or ProBDNF were observed at the acute 
timepoint.  Data in A-D were analyzed using One-Way ANOVA followed by two-stage 
linear step-up procedure of BKY to correct for multiple comparisons (n=4-6). Statistically 
significant discoveries versus the control group are denoted by “*”. 
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Discussion.  
At the outset of this study, my goal was to first explore the behavioural and 
biological outcomes of exposure to repetitive mTBI and our RUS paradigm. From previous 
work, I explored this relationship by combining our 5 hit mTBI model to our 21-day RUS 
paradigm and demonstrated moderate behavioral effects of mTBI on stress related 
behavioral phenotypes. While this r-mTBI model reliably produces robust long-lasting 
spatial memory deficits in injured animals (Mouzon et al. 2012, 2014), a single exposure to 
the RUS paradigm was associated with moderate changes in stress-coping behavior and 
recall of cued fear memories at the chronic timepoint (Algamal et al. 2018). Thus, in this 
chapter, I extended this work, by focusing on the role of exposures to ‘multiple episodes’ 
of the same stressful event, as experienced by combat soldiers who undergo multiple 
deployments, or civilians exposed to multiple episodes of the same traumatic event (e.g. 
domestic violence, torture, or first-time responders).    
To that end, I administered our 21day-RUS paradigm on two occasions (separated 
by a few months) to intensify the stress procedures and combined this with two separate 
exposures to our 5hit mTBI paradigm, respectively.   
In this chapter, I presented a detailed characterization of the long-term 
consequences of recurrent and combined exposure to our well-characterized models of 
repeated unpredictable stress (RUS) (Algamal et al. 2018) and mTBI (Mouzon et al. 2012, 
2014).  Repeated stress or mTBI alone caused unique and distinct behavioral and 
neurobiological alterations long after the last exposure to mTBI or RUS.  Combining both 
exposures resulted in complex domain-dependent outcomes with no overall additive or 
opposite effects. Animals receiving repeated RUS alone showed several PTSD-like 
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behaviors such as acute weight loss, acute anxiety, long-term recall of contextual and cued 
fear memories, and chronic passive stress-coping behavior. Moreover, repeated RUS alone 
was associated with remodeling of dendritic spines and changes in several synaptic 
plasticity signaling markers in the hippocampus 3 months after the second RUS.  The 
unique r-mTBI traits were typified by persistent spatial and social memory deficits, 
microgliosis, astrogliosis and axonal damage.  Combined exposure to repeated r-mTBI and 
RUS resulted in an apparent amelioration of stress-related behaviors in the cued fear 
memory and forced swim tests at the 3-months timepoint.  However, these observations 
should be interpreted carefully due to the confounding effects of variable locomotion 
between study groups.  Animals in the comorbid group showed additional TBI-related 
deficits represented by hyperactivity and, spatial and social memory deficits at the chronic 
timepoint.  Additionally, stress+r-mTBI mice had synergistic effects on injury dependent 
astrogliosis and microgliosis in the corpus callosum and mitigated the mTBI-dependent 
increase in pro-BDNF in the hippocampus.   
Previously I showed that animals exposed to a single episode of our 21-day RUS 
paradigm around 3 months of age, demonstrate recall of cued fear memories, passive 
stress-coping behavior, low baseline plasma corticosterone and ACTH levels and reduced 
hippocampal BDNF levels at 6 months after the last exposure. Here, I hypothesized that 
exposure to the 21-day RUS paradigm at 3 months of age with re-exposure at 6 months of 
age would augment stress-related behavioral and neurobiological phenotypes examined at 
a similar post-exposure timepoint from our previous investigation (i.e. 3 months after the 
last-exposure).  At the behavioral level, animals re-exposed to RUS showed the same 
phenotypes reported after a single exposure.  However, I also observed strong recall of 
contextual fear memories 3 months after the second RUS, which was not observed in the 
132 	
previous single exposure paradigm (Algamal et al. 2018).  In contrast to my initial 
hypothesis, I found that re-exposure to RUS resulted in a reduction in the key 
neurobiological markers observed after a single RUS exposure.  Stress-only animals 
showed no change in baseline plasma corticosterone and ACTH levels (Figure 3.19) and 
no change in hippocampal BDNF levels relative to control animals (Figure 3.21) at 3 
months after the second RUS.  The noticeable change in stress-coping strategies in the 
forced swim test suggests that HPA axis functionality is further altered after re-exposure to 
RUS.  Additional experiments measuring corticosterone levels immediately after stress or 
after suppression with dexamethasone are required to better understand the complexity of 
HPA axis involvement in the current model.  
A number of clinical and preclinical studies have suggested that mTBI is 
implicated in the development of PTSD or PTSD-like behavior (Bryant et al. 2009; Elder 
et al. 2012; Kennedy 2007). A study conducted on civilians showed that patients who 
survived a mild TBI were more likely to develop PTSD than patients with no brain injury 
(Bryant et al. 2009).  Similar results were reported from a study within the military 
population, where mTBI was linked to increased self-reported post-traumatic symptoms 
(Kennedy et al. 2010).  In animals, exposure to different mTBI types, such as blast (Elder 
et al. 2012), weight drop (Meyer et al. 2012) or fluid percussion (Reger et al. 2012) 
injuries, was associated with increased fear memory recall and anxiety-like behavior 
multiple days after the injury.  In all of these studies, the injury was administered before 
fear conditioning and in the absence of any additional stress procedures (Elder et al. 2012; 
Meyer et al. 2012; Reger et al. 2012). 
Studies examining symptom severity in co-morbid PTSD and TBI patients relative 
to PTSD alone have shown mixed findings. Patients with co-morbid PTSD and mild to 
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severe TBI had fewer intrusive memories than patients with PTSD alone (Hibbard et al. 
1998). On the contrary, Simonović et al., reported more detachment and hyperarousal 
symptoms in patients with co-morbid PTSD and mild TBI compared to those with PTSD 
alone (Simonović et al. 2011).  A study by Kwon et al. is among the few preclinical studies 
investigating the consequences of combined exposure to mTBI and traumatic stress in 
animal models. Kwon et al. reported acute and transient anxiety in a group receiving 
unpredictable stress and a single blast injury relative to animals exposed to unpredictable 
stress alone (Kwon et al. 2011).  In another study, Klemenhagen et al. found that repetitive 
concussive traumatic brain injury and post-injury foot shocks had synergistic effects in 
tests of social recognition and stress-coping behavior with no injury effects on recall of 
fear memories (Klemenhagen et al. 2013).  
In the current study, cued fear memory recall was diminished in animals receiving 
repeated RUS and r-mTBI relative to RUS-only animals. Similar findings were observed at 
3 and 6 months after a single exposure to RUS and/or r-mTBI (Figure 3.4). Genovese et 
al. reported similar findings showing an overall decrease in the expression of conditioned 
fear in rats exposed to inescapable electric shocks and blast overpressure injury relative to 
rats receiving shocks alone (Genovese et al. 2013). It is important to note that in our 
current study the injury was delivered 1 hour after RUS, whereas in the study by Genovese 
et al., the injury was delivered 22 hours after fear conditioning. One explanation for the 
mitigation of PTSD-related behavior when mTBI is applied post-exposure is that the 
memory of the foot-shock is erased due to the impact of TBI-dependent retrograde 
amnesia. Nevertheless, retrograde amnesia cannot completely explain our findings because 
stress+r-mTBI animals showed increased freezing behavior during the first minute of the 
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test at the 3-month timepoint (Figure 3.9B-E), suggesting that the memory of the cue is 
intact.    
As demonstrated in Figure 3.9, stress+r-mTBI animals travelled longer distances in 
the OF test relative to animals in other study groups. This increase in their locomotor 
activity was negatively correlated with the immobility time in the cued fear memory test at 
the chronic timepoint (Figure 3.10). This correlation suggests that the increased 
locomotion in the comorbid group accounts for the decreased freezing in the cued fear 
memory test at the 3-month timepoint.  
Increased locomotion in the open field has been attributed to behavioral 
disinhibition both in a mouse model of Alzheimer’s disease (Tg2576 transgenic mice) 
(Gil-Bea et al. 2007) and in animals receiving 7 days of restraint stress (Ito et al. 2010). 
Interestingly, I have previously reported disinhibition or impulsive behavior in r-mTBI 
animals at 12 months after the last injury as demonstrated by increased time spent in the 
open arms and an increased number of entries into the open arms in the EPM (Mouzon et 
al. 2014).  
I didn’t observe a significant increase in open arm time or entries after r-mTBI in 
the current study possibly because the change in the lighting conditions. In our previous 
work by Mouzon et al., animals were tested in the EPM under bright light conditions, 
while in the current study animals were tested in the EPM in dark conditions (1 LuX).  I 
choose to do these experiments in dark conditions, since these procedures facilitate 
observing the anxiety-like behavior. In bright conditions, control mice usually spend 5% -
10 % of the time in the open arms, which leaves very little margin to detect anxiety-like 
behavior.  
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The decreased freezing in the cued fear memory test in stress+rm-TBI animals 
compared to stress-only animals is most likely driven by r-mTBI-induced impulsive 
behavior or hyperactivity and caution should be used to avoid interpretation as strictly a 
deficit in cued fear memory recall. Likewise, the hyper-locomotion after r-TBI could also 
be responsible for the decreased immobility time in r-mTBI animals in the FST (Figure 
3.9I) and (Figure 3.7) for the single exposure preliminary study. Similar observations were 
reported in Tg2576 transgenic mice showing a significant decrease in immobility time in 
the forced swim test that was inversely correlated with locomotor activity in the Open 
Field (Gil-Bea et al. 2007). There was no correlation between the distance travelled by 
stress+r-mTBI animals in the open field and their immobility time in the FST at the 
chronic timepoint (data not shown), suggesting that the observed FST behavior involves 
additional mechanisms.  These results emphasize the importance of examining the effect of 
study treatments on locomotion before interpreting the findings of behavioral testing in 
rodents.  
Peripheral inflammation has been implicated in the pathogenesis of TBI and PTSD 
with multiple reports of altered cytokine levels in the plasma (Acosta et al. 2013; Gill et al. 
2009; Wang et al. 2017). I reported the following changes in baseline plasma cytokine 
levels at the chronic timepoint: IL-2 levels were reduced in all stress groups, IL-5 levels 
were reduced in all r-mTBI groups, and IL-10 levels were reduced in all stress and/or r-
mTBI groups relative to the control group. IL-2 possesses a number of proinflammatory 
biological activities such as supporting the proliferation and survival of T cells, while IL-5 
triggers the growth and differentiation of B cells and eosinophils (Kouro and Takatsu 
2009). IL-10 is a potent anti-inflammatory cytokine that prevents the production of cell-
mediated immunity or Th1 cytokines such as IL-2 and IFN-γ, and humoral immunity or 
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Th2 cytokines such as IL-4 and IL-5 (Mosser and Zhang 2008). Therefore, our findings 
may underlie an imbalance between Th1 and Th2 immune response after stress and r-
mTBI. The impact of PTSD and mTBI on plasma cytokine levels in human patients is not 
clear. IL-2 levels were reduced in earthquake survivors and in middle-aged war veterans 
with PTSD (Jergović et al. 2014) relative to their age-matched healthy subjects. In 
contrast, veterans with PTSD  had higher levels of  salivary IL-2 relative to veterans 
without combat-related PTSD (Wang et al. 2016). Similarly, some reports showed 
decreased IL-10 levels in veterans with PTSD (Wang et al. 2016), while others showed 
increased IL-10 levels in PTSD patients relative to healthy controls (de Oliveira et al. 
2018). 
 Some studies reported an increase in IL-6 and TNFa production in whole blood 
from PTSD patients after ex vivo stimulation with LPS (Gil 2010; Gola et al. 2013). I 
performed similar experiments on fresh blood collected from our study groups. The 
response to LPS stimulation appeared similar in all study treatments, although some 
interesting trends resembling the clinical findings were observed for TNFa and IL-6 in the 
stress-only group (Figure 3.16). 
Spatial learning deficits after r-mTBI have been connected to changes in brain 
structures such as the hippocampus (Prasad and Bondy 2015). Hippocampal and PFC 
volume reduction and synaptic loss are also implicated in PTSD pathogenesis (Sherin and 
Nemeroff 2011). Multiple preclinical animal models reiterate the human findings and show 
the deleterious effects of stress and TBI on neuronal structures in the PFC and 
hippocampus (Ito et al. 2010; McEwen et al. 2016; Pitman et al. 2012; Wolf and Herringa 
2016). In the current study, I focused on the hippocampus as a primary site for 
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pathobiology since both stress and r-mTBI seem to affect hippocampal-related functions 
such spatial and contextual memories.  
Synapses are the junctions between neurons that facilitate communication and 
information processing in the brain. More than 90% of excitatory synapses are localized on 
the dendritic spines (Engert and Bonhoeffer 1999). Synaptic plasticity (long-term changes 
in the synapses in response to increased or decreased surrounding neuronal activity) is 
involved in the formation and retention of memories and is often accompanied by changes 
in the number and shape of dendritic spines (Frankfurt and Luine 2015; Li et al. 2004). 
Exposure to repeated RUS and r-mTBI alone or in combination decreased the number of 
dendritic spines in the CA1 of the hippocampus, but not in the PFC (Figure 3.19). Similar 
effects of stress and mTBI on hippocampal dendritic spines have been previously reported 
(Gao et al. 2011; Qiao et al. 2016; Shors, Falduto, and Leuner 2004; Winston et al. 2013). 
A study using 10 days of immobilization stress reported dendritic atrophy and debranching 
in the CA3 pyramidal neurons (Vyas et al. 2002), while another study using controlled 
cortical impact in mice showed a reduction in dendritic spines in the ipsilateral dentate 
gyrus at 24 (Winston et al. 2013) and 72 (Gao et al. 2011) hours after injury. Remodeling 
of hippocampal dendritic spines has implications for acquisition, consolidation and 
retrieval of spatial memories (Frankfurt and Luine 2015; Li et al. 2004; Luine, Wallace, 
and Frankfurt 2011; Mahmmoud et al. 2015). This was demonstrated in a study that found 
decreased spine density in the CA1 region of the hippocampus correlated with spatial 
memory deficits in an object placement task in aged rats (Luine et al. 2011).   
Synaptic plasticity in the cortex and the hippocampus is primarily mediated by N-
methyl-D-aspartate (NMDA) receptor signaling, which are a class of glutamatergic 
excitatory receptors  (Engert and Bonhoeffer 1999; Ultanir et al. 2007). NMDA receptors 
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are tetrameric structures containing two essential GluN1 subunits and two GluN2 subunits 
(Sanz-Clemente, Nicoll, and Roche 2013). Age, brain region and memory consolidation 
are known to regulate the expression of different NMDA receptor subunits (Sanz-Clemente 
et al. 2013). At early developmental stages, GluN1 and GluN2B are the main components 
of NMDA receptors expressed at synapses. GluN2A replaces GluN2B as the primary 
GluN2 subunit with aging in what is known as developmental switch (Newcomer, Farber, 
and Olney 2000). Evidence suggests that the ratio of GluN2A to GluN2B increases with 
induced synaptic plasticity or memory consolidation in adult  brains (Baez, Cercato, and 
Jerusalinsky 2018; Cui et al. 2013; Liu et al. 2007). At the 3-month timepoint, the ratio of 
hippocampal GluN2A/GluN2B was decreased in all study groups (Figure 3.19H), 
suggesting a chronic change in the maturity of synapses after stress and/or r-mTBI. In 
addition to the changes in GluN2, GluN1 levels were also reduced with stress and/or r-
mTBI at the acute timepoint (Figure 3.20) and increased in stress+r-mTBI group at the 
chronic timepoint (Figure 3.19) relative to the control group. Behavioral and long-term 
memory deficits have been reported after knocking-down the GluN1 subunit in rat 
hippocampus by an amplicon vector expressing a specific GluN1-antisense RNA sequence 
(Adrover et al. 2003; Cercato et al. 2017; Cheli et al. 2006). Downregulation of 
hippocampal GluN1 levels at the acute timepoint could be attributed to an earlier plastic 
change in the hippocampus after RUS or r-mTBI, while the increased levels at the chronic 
timepoint may represent an adaptive homeostatic mechanism to restore GluN1 levels. 
Activation of GluN2A subunits has neuroprotective and cell survival effects, while 
activation of GluN2B appeared to have opposite effects (Song et al. 2007). In addition, 
treatment with NMDA receptor antagonist prevented stress-induced spine changes in the 
hippocampus of male and female rats (Shors et al. 2004). The chronic engagement of 
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NMDA receptors was also demonstrated at the level of downstream postsynaptic proteins 
CMKIIa and PSD95 (Figure 3.19). 
After a TBI, BDNF levels increase to lessen the impact of secondary injury, 
provide neuroprotection, and restore brain connectivity (Kaplan, Vasterling, and Vedak 
2010). Increased BDNF levels has been reported in the cortex and the hippocampus of 
injured animals (Griesbach et al. 2002) and in the CSF of TBI patients (Failla, Conley, and 
Wagner 2016). In animal models of stress, prolonged exposure to glucocorticoids decrease 
BDNF levels in the hippocampus, causing dendritic retraction and remodeling (Kaplan et 
al. 2010). ELISA analysis of total BDNF levels in hippocampus homogenate did not show 
significant group differences. However, the BDNF precursor, ProBDNF, was upregulated 
in the hippocampus of r-mTBI-only animals at the 3-month timepoint. These findings 
support other reports showing increased BDNF signaling after mTBI. Interestingly, 
ProBDNF levels were not increased in the group receiving stress+-r-mTBI, suggesting an 
opposite effect for stress and r-mTBI on BDNF signaling.  
These results demonstrate that animals exposed to stressful trauma develop 
persisting traits that reflect critical aspects of PTSD symptomatology as defined by the 
DSM-5. Unique traits were also observed with the comorbid presentation of mTBI and 
trauma. The chronic timepoints examined here are particularly relevant to multiple 
persistent symptomology in the human condition.  T anticipate that this model will be a 
useful platform to explore the neurobiology of PTSD and repetitive mTBI.  
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Chapter 4. Exploring the impact of RUS on HPA axis regulation 
and function 
Introduction  
Physiological responses to stressful or life-threatening events involve the activation 
of the autonomic nervous system and the hypothalamic-pituitary-adrenal (HPA) axis.  
While the autonomic responses are immediate and transient, the HPA axis reaction starts 
several minutes after stress and is critical to restore homeostasis (Mifsud and Reul 2016) 
(MCEWEN 2004). 
The paraventricular nucleus of the hypothalamus responds to stress by releasing 
corticotropin-releasing hormone (CRH) into the portal circulation. Binding of CRH to its 
receptor in the anterior pituitary results in the secretion of adrenocorticotropic hormone 
(ACTH) which in turn stimulate the adrenal cortex to release cortisol (corticosterone in 
rodents) into the blood circulation.  Circulating glucocorticoids exert several physiological 
functions to facilitate arousal during a stress response including, energy mobilization (e.g.  
gluconeogenesis) and maintenance of heart rate and blood pressure.  In addition, 
glucocorticoids play a role in the acquisition of new memories and regulating homeostasis 
(Ulrich-Lai and Herman 2009).  To avoid overactivation of the HPA axis, cortisol binds 
glucocorticoid receptors in the pituitary and the hypothalamus preventing further release of 
CRH and ACTH (Leistner and Menke 2018).   
Mineralocorticoid receptor (MR) and Glucocorticoid receptor (GR) are the main 
binding sites for glucocorticoids in the brain. The affinity of glucocorticoids to MR is 10-
fold higher than to GR in rodent brain tissue, and at baseline levels, glucocorticoids occupy 
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more than 80% of MR (Reul, van den Bosch, and de Kloet 1987). During exposure to 
stressful stimuli and HPA axis activation, whereby glucocorticoid levels become 
significantly upregulated, occupation of GR by glucocorticoids significantly increases (de 
Kloet, Oitzl, and Joëls 1993; De Kloet and Reul 1987; Reul et al. 1987).  Thus, it is 
believed that MR mediates tonic actions (background activity) of glucocorticoids under 
physiological conditions, while GR mediates the negative feedback regulation mechanisms 
(De Kloet and Reul 1987).   
Dysregulation of these feedback mechanisms is implicated in the pathogenesis of 
several psychiatric disorders such as depression and posttraumatic stress disorder (PTSD ) 
(Leistner and Menke 2018). PTSD patients show increased CRH levels in cerebrospinal 
fluid (CSF) and decreased baseline plasma cortisol levels (Yehuda 2001).  It is 
hypothesized that the often reported low baseline cortisol levels in PTSD patients are due 
to enhanced negative feedback sensitivity to glucocorticoids.(Yehuda et al. 1993, 1995).  
This hypothesis is  supported by the increased sensitivity to dexamethasone (selective GR 
agonist) suppression reported in PTSD subjects (Yehuda et al. 1993). In addition, the GR 
co-chaperone FK506 binding protein 5 (FKBP5) was downregulated in the red blood cells 
and the brains of PTSD patients (Averill et al. 2017; Yehuda et al. 2009).  As FKBP5 is 
known to play a significant role in regulating GR sensitivity, this finding supports the 
notion of impaired HPA axis negative feedback mechanisms in PTSD.  
As detailed in Chapter 2, our newly developed PTSD mouse model demonstrates 
several chronic HPA axis alterations resembling human PTSD.  These changes include low 
baseline plasma corticosterone and ACTH levels and reduced expression of FKBP5 in the 
hypothalamus at a chronic timepoint (Algamal et al. 2018).  Our stress procedures relied 
on repeated unpredictable stress (RUS) that was followed by social isolation (SI), which is 
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a critical concurrent factor in patients known to increase vulnerability and risk for PTSD 
(Andrews, Brewin, and Rose 2003; Daskalakis, Yehuda, and Diamond 2013; Ullman and 
Filipas 2001; Zoladz et al. 2008).   
Note: Our RUS paradigm, as described in Chapters 2 and 3 and Algamal et al. 
2018, included SI as one of the stressors; however, as the work in this chapter delves into 
the separate effects of SI at this point I use RUS+SI when referring to the paradigm 
employed in Chapters 2 and 3, to distinguish from SI alone. 
Here, I further explore the role of HPA axis regulation and function in our model at 
a sub-chronic timepoint, one month after RUS. The first goal of the study was to examine 
the function of two key components of the HPA axis, namely the role of the pituitary and 
adrenal glands using in vivo Dexamethasone/CRH and Dexamethasone/ACTH tests, 
respectively, in stressed mice (receiving RUS and SI) compared to controls (unstressed 
mice).   
Secondly, I examine the functionality of central glucocorticoid receptor (GR) in 
RUS+SI mice under physiological and acute stress challenge conditions, with emphasis on 
negative feedback mechanisms involving FKBP5. In these experiments, as social isolation 
has been shown to be a major driver of HPA axis abnormalities in both clinical and 
preclinical studies (Hawkley et al. 2013), I included SI mice as an additional control group 
to address the contributory role of social isolation in our combined RUS+SI paradigm. 
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Materials and Methods 
Animals 
C57BL/6 male mice (aged 9 weeks) were purchased from Jackson Laboratories 
(Bar Harbor, Maine) and housed in standard cages (3 per cage) at ambient temperature.  
Mice were allowed to acclimate for three weeks before starting any experiments.  All the 
procedures were carried out under a protocol approved by the Roskamp Institute IACUC 
(Protocol #91).  
 
Experiment 1 
This experiment involved two study groups; 1) Repeated unpredictable stress 
(RUS) in addition to social isolation group (RUS+SI group) and 2) group-housed controls 
(Control group).   
 
Repeated unpredictable stress (RUS) 
RUS procedures were implemented as described previously in Chapter 2 and in 
(Algamal et al. 2018).  In brief, 12-week old mice in the RUS+SI group received daily 
unstable social housing with an unfamiliar mouse, 10 unpredictable exposures to predator 
odor (TMT) under restraint on 10 different days, and 5 inescapable foot-shocks in 5 on 
different days.  RUS+SI animals were singly housed until the end of the study (Day 1-Day 
56).  Group-housed mice control mice (n=18) were conditioned to the trauma context and 
cues without receiving the foot-shocks.  
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Dexamethasone-CRH test 
Baseline plasma corticosterone levels were measured 1 week before the actual test.  
On the test day (Day 56), control (n=18) or RUS+SI (n=22) mice were injected i.p. with 
0.09 mg/kg, Dexamethasone (DEX (Sigma)) at 11:00 AM, followed by an i.p. injection of 
0.2 mg/kg Corticotrophin Releasing Hormone (CRH (Sigma)) or Saline at 5:00 PM. A 
blood sample was collected from the tail vein (see below) immediately before CRH 
injection (i.e. 6 hours after injecting dexamethasone, (After DEX)).  Another blood sample 
was collected 30 min after CRH injection for corticosterone and ACTH measurements 
(After CRH). 
 
Dexamethasone-ACTH  
The adrenal function was assessed in the same cohort of mice using the DEX-
ACTH test.  This test was performed 3 weeks after the DEX-CRH test and using similar 
procedures (Day 77).  Animals were injected i.p. with 0.09 mg/kg DEX at 11:00 AM, 
followed by an i.p. injection of 0.1 mg/kg, ACTH (Sigma) or Saline at 5:00 PM. Blood 
samples were collected immediately before the injection of ACTH or saline (After DEX) 
and 30 min after ACTH injection (After ACTH) or Saline (After Saline).  
 
Low dose Dexamethasone challenge 
The same cohort of mice received a low dose dexamethasone suppression test 1 
month after the DEX-ACTH challenge.  Control and RUS+SI animals were injected i.p. 
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with 0.02 mg/kg DEX or saline at 11:00 AM, followed by a single blood collection at 5:00 
PM.  
 
 
Figure 4.1. Timeline of the study procedures.  In experiment 2, animals from different 
study groups were euthanized at 2 hours (Day 28) or 2 days (Day 30) after the FST.  
Abbreviations; RUS (Repeated unpredictable stress), Social Isolation (SI), DEX 
(Dexamethasone), Fear memory testing (FMT), Open Field (OF), Elevated Plus Maze 
(EPM), and the forced swim test (FST).  
 
Experiment 2 
Experiment 2 was performed on a new independent cohort of mice as depicted in 
Figure 4.1. The experiment involved three study groups; 1) RUS in addition to social 
isolation group (RUS+SI group), 2) social isolation-only group (SI group) and 3) group-
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housed controls (Control group).  RUS procedures were implemented as described in 
Experiment 1 and Chapter 2. After exposure to RUS, animals were singly housed until the 
end of the study (Day 1-Day 30).  Group-housed mice (n=22) were conditioned to the 
trauma context and cues without receiving the foot-shocks, as described in experiment 1.  
On day 1 of the study timeline (i.e., at the end of the RUS procedures), 11 mice out of the 
22 previously group housed Control mice were singly housed until the end of the study (SI 
group), while the other 11 remained undisturbed (Control group). 
 
Behavioral testing  
Behavioral testing started at day 21 after the stress/control paradigm as depicted in 
Figure 4.1.  Mice received contextual and cued fear memory testing (FMT), Open Field 
test (OF), Elevated Plus Maze (EPM) and the Forced Swim Test (FST) followed by 
euthanasia at either 2 hours (n=5-6) or 2 days after the FST (n=5-6).  All the behavioral 
procedures were conducted as described previously (Algamal et al. 2018). 
 
Acute stress reactivity in the periphery  
The FST was the last behavioral test in the study timeline and was additionally 
used to examine the effect of acute stress on HPA axis regulation.  Blood samples were 
collected 13 days before (Baseline) and 15 min after the FST (Response) by tail bleed.  
Corticosterone recovery after stress was measured in blood samples from animals 
euthanatized at 2 hours after the start of the FST (Recovery).   
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Blood collection  
The tail bleed procedures involved collecting a few blood drops (10-20 µL) from a 
small incision in the lateral tail vein at days 14 (Baseline) and 28 (Response).  All tail 
bleed procedures were performed in a room next to the housing room and completed in 
less than 5 minutes.  Blood samples from euthanized animals were collected by cardiac 
puncture after 3 min of isoflurane anesthesia. All blood samples were centrifuged at 3,000g 
for 5 min, and plasma samples (clear supernatant fraction) were flash frozen in liquid 
nitrogen and stored at −80 °C. 
 
ELISA 
All ELISA kits were used as per manufacturers’ instructions. The 
Adrenocorticotropic Hormone (ACTH) ELISA was purchased from Cloud-Clone Corp 
(Katy, Texas), while the Corticosterone ELISA was purchased from Arbor Assays (Ann 
Arbor, Michigan).  
 
Brain tissue preparation and isolation of nuclear and cytoplasmic fractions 
To examine the regulation of glucocorticoid receptor after an acute stressor, 
animals were euthanized and brain and plasma were collected at either 2 hours or 2 days 
after the FST. Brain tissue collected 2 hours after the FST was used to examine the acute 
stress-related changes in protein expression levels (n=5-6 per group), while tissue collected 
2 days after the FST was used to examine the recovered-baseline expression levels of 
relevant markers (n=5-6 per group,).  
148 	
Animals were transferred to the euthanasia room at least 90 min before sacrifice to 
allow for HPA axis recovery after transfer. After anesthesia and blood collection by 
cardiac perfusion, brains were extracted and dissected into pituitary, hypothalamus, and 
hippocampus and immediately flash frozen in liquid nitrogen and kept at −80 °C.  
To isolate the nuclear and cytoplasmic enriched fractions from the hypothalamus, 
tissue was weighed and homogenized in Phosphate Buffered Saline (PBS) containing 
proteinase and phosphatase inhibitors (PPI) (Thermofisher) using a probe sonication.  6 µL 
of PBS+PPI were added to each 1 mg of tissue.  50 µL of homogenized samples were 
mixed with equal volumes of PBS+PI containing 1.5M NaCl and spun at 21,000 g for 10 
minutes (min) followed by the collection of the supernatants containing the cytosolic and 
nuclear fractions. To separate the enriched nuclear fraction, 25 µL methanol was added to 
the supernatant solution under gentle vortexing followed by vigorous vortexing and 15 min 
incubation on ice.  Samples were then spun at 21,000 g for 15 min followed by collection 
of the supernatants (containing the cytosolic fraction) and the pellet (nuclear fraction).  The 
nuclear fractions were obtained by resuspending the pellets in 100 µL (25 mM 
Triethylammonium bicarbonate (TEAB) containing 0.05% sodium Deoxycholate (SDC)).  
The cytosolic enriched fractions were obtained by mixing the remaining supernatant 
solution with 325 µL methanol under gentle vortexing followed by vigorous vortexing and 
15 min incubation on ice. Samples were then spun at 21,000 g for 15 min followed by 
discarding the supernatant and collecting the pellet (cytosolic fraction) which was then 
dissolved in 100 µL 25 mM TEAB with 0.05% Deoxycholat (SDC).  The pituitary was 
homogenized directly in 100 µl of M-PER protein extraction reagent without fractionation, 
due to the small amount of starting material.  
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Western blotting 
Western blot experiments were conducted as described previously (Ojo et al. 2016).  
In brief, homogenized or fractionated samples were centrifuged at 15,000g for 10 minutes 
(min) and tissue supernatants were collected.  Supernatant fractions were denatured at 
99 °C by boiling in Laemmli buffer (Bio-Rad) containing dithiothreitol (DDT).  Samples 
were subsequently resolved on 4-15% gradient polyacrylamide criterion gels (Bio-Rad).  
After electro-transferring, polyvinylidene difluoride membranes, the membranes were 
blocked in 5% milk made in Tris-buffered saline and subsequently immunoprobed for 
different brain-specific primary antibodies overnight (Supplementary Table 1).  After three 
washing steps, membranes were probed with horseradish peroxidase-linked secondary 
antibodies (Supplementary Table 1).  Bio-Rad stain-free technology was used to quantify 
total protein for the hypothalamic fractions, while Anti-GAPDH antibody was used as a 
housekeeping protein and loading control for the pituitary lysates.  Signal intensities were 
quantified by chemiluminescence imaging with the ChemiDocTM XRS (Bio-Rad).  
 
Statistical Analysis 
The choice of the appropriate statistical test was made after assessment of normal 
distribution using the Shapiro-Wilk normality test. RM-Two-way ANOVA was used to 
examine statistical significance in body weight measurements, DEX-CRH and DEX-
ACTH tests.  All western blot analysis and baseline corticosterone measurements in 
Experiment 1 were analyzed using One-Way ANOVA.  All ANOVA were followed by 
pairwise comparisons with correction for multiple comparisons using the two-stage linear 
step-up procedure of Benjamini, Krieger and Yekutieli (BKY) (Benjamini, Krieger, and 
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Yekutieli 2006) to control the false discovery rate.  All analyses were performed with 
Graph Pad prism version 7.0 statistical software (La Jolla, California). Grubbs’ test was 
applied to identify statistical outliers. 
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Results 
Experiment 1. RUS+SI mice show attenuated response to CRH stimulation in the 
DEX-CRH test.  
Dexamethasone (DEX) is a synthetic glucocorticoid acting mainly on GR located 
in the anterior pituitary, with limited availability in other brain regions due to rapid 
clearance by multidrug resistant transporters (Meijer et al. 1998).  At a sufficient dose, 
DEX will bind GR in the pituitary, thereby suppressing the release of ACTH which in turn 
will result in a decrease in circulating plasma corticosterone levels.  To examine the HPA 
axis negative feedback regulation at the level of the pituitary, I performed the 
dexamethasone-CRH test.  At one month after RUS, baseline plasma corticosterone levels 
were lower in RUS+SI mice relative to the group housed controls (t-test: t(39) = 2.9, p = 
0.006, Figure 4.2A).  The DEX-CRH test was administered one week after the collection 
of baseline values. Mice were given a high dose of dexamethasone (0.09 mg/kg) at 11:00 
am in the morning.  Six hours after DEX injections, plasma corticosterone levels were 
equally suppressed in control and RUS+SI animals as compared to their baseline levels 
(p > 0.05, Figure 4.2B). Immediately after this blood collection (6 hours after DEX), CRH 
was injected intraperitoneally followed by another blood collection 30 min later to 
determine the response to this DEX-CRH test.  RUS+SI animals showed significantly 
lower plasma corticosterone levels compared to controls (RM-Two-Way ANOVA: 
interaction F(1, 38) = 4.195, p=0.047, main CRH  effect F(1, 38) = 452.4, p<0.0001  main 
RUS+SI effect F(1, 38) = 3.95, p=0.05 with correction for multiple comparisons, Figure 
4.2B), and no significant change in plasma ACTH levels (t-test, p > 0.05, Figure 4.2C).  
Because ACTH levels were normal after the challenge, this suggests that the pituitary 
response to CRH stimulation is similar in control and RUS+SI animals.  
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Experiment 1. RUS+SI mice show attenuated response to ACTH stimulation in the 
DEX-ACTH test.  
Mice were left undisturbed for three weeks after receiving the DEX-CRH test and 
then received the DEX-ACTH test (Eiler and Oliver 1980).  The purpose of the test is to 
assess the response of the adrenal glands to exogenous ACTH after the suppression of 
endogenous ACTH and corticosterone with DEX.  The same dexamethasone dose used in 
the DEX-CRH test was applied to suppress endogenous ACTH and corticosterone levels 
followed by injection of 0.1mg/kg ACTH or Saline after 6 hours. Plasma corticosterone 
levels were equally suppressed in control and RUS+SI animals 6 hours after DEX injection 
(p>0.05, Figure 4.6D). 30 min after ACTH injection, plasma corticosterone levels were 
significantly elevated in both groups in response to ACTH stimulation.  However, the 
adrenal response in RUS+SI animals was significantly attenuated as demonstrated by 
lower plasma corticosterone levels in the RUS+SI group relative to control at 30 min after 
ACTH injection (RM-Two-Way ANOVA: interaction F(1, 17) = 11.94, p=0.003, main 
ACTH effect F(1, 17) = 413.4, p<0.0001, main RUS+SI effect F(1, 17) = 6.35, p=0.022 with 
correction for multiple comparisons, Figure 4.2D).  Saline injection also caused a 
pronounced increase in corticosterone levels after dexamethasone suppression (RM-Two-
Way ANOVA: interaction F(1, 17) = 2.19, p=0.164, main Saline effect F(1, 17) = 78.77, 
p<0.0001, main RUS+SI effect F(1, 17) = 1.9, p=0.18 with correction for multiple 
comparisons, Figure 4.2E).  However, the overall increase in corticosterone levels after 
saline injection was two-fold lower than the ACTH-induced increase, thus suggesting that 
the administered ACTH dose was primarily responsible for the stimulation of the adrenal 
glands. 
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Figure 4.2.  Decreased HPA axis responsiveness after CRH and ACTH stimulation in 
stressed animals. The DEX-CRH stimulation test was administered 5 weeks after RUS. 
(A) Baseline plasma corticosterone levels measured 1 week before the DEX-CRH 
stimulation test. (B) Plasma corticosterone levels 6 hours after suppression with DEX 
(After DEX) and 30 min after a subsequent stimulation with CRH (After CRH). (C) 
Plasma ACTH levels 30 min after CRH stimulation in the DEX-CRH stimulation test. The 
same group of mice were used in the DEX-ACTH stimulation test at 9 weeks after RUS. 
(D) Plasma corticosterone levels 6 hours after suppression with DEX (After DEX) and 30 
min after a subsequent stimulation with ACTH (After ACTH). (E) Same as (D) except for 
the use of saline injections after DEX suppression instead of ACTH. In A-C, n=18-22, 
while in D-E, n=6-11. All Data were analyzed using a student t-test. Asterisks denote 
statistical significance as follows *p<0.05, **p<0.01. 
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Experiment 1. Low dose DEX suppresses plasma corticosterone levels in RUS+SI 
mice and control mice.  
One month after administering the DEX-ACTH challenge, control and RUS+SI 
received the low-dose dexamethasone suppression test (0.02mg/kg as compared to the 
0.09mg/kg of the previous tests). Control and RUS+SI mice showed comparable 
corticosterone suppression levels at 6 hours after i.p. injection of 0.02 mg/kg DEX (Two-
Way ANOVA: interaction F(1, 32) = 0.05, p=0.8214, main DEX effect F(1, 32) = 8.41, 
p=0.0067, main RUS+SI effect F(1, 32) = 2.773, p=0.11with correction for multiple 
comparisons, Figure 4.3.  
 
 
Figure 4.3. Performance of each study group in the low-dose dexamethasone suppression 
test. Plasma corticosterone levels in control and RUS+SI mice 6 hours after an injection of 
saline or 0.02 mg/kg DEX. Bar graphs depicting control and RUS+SI mice receiving saline 
are outlined with black lines, while bar graphs depicting control and RUS+SI mice 
receiving DEX have green border lines.  Asterisks denote statistical significance as follows 
*p<0.05.   
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Experiment 2. Decreased basal and stress-induced plasma corticosterone levels in 
socially isolated and RUS mice.  
PTSD patients show low plasma cortisol levels in response to the Trier Social 
Stress Test (TSST), which examines the reactivity to social and psychological stress under 
laboratory settings in humans (Pierce and Pritchard 2016; Wichmann et al. 2017).  To 
examine the stress-reactivity in RUS+SI mice, I measured plasma corticosterone levels in 
response to an acute heterotypic stressor (forced swim).  I also assessed stress reactivity in 
mice receiving only SI to examine if our findings can be reproduced by SI alone, as the 
role of SI in our paradigm remains undetermined.  All groups showed a stress response as 
demonstrated by increased corticosterone levels 20 min after initiating the FST relative to 
their respective baseline values (Two-Way ANOVA: interaction F(4, 74) = 1.25, p>0.05, 
main acute stress effect F(2, 74) = 45.43 with correction for multiple comparisons, Figure 
4.4A).  Plasma corticosterone levels were lower in SI and RUS+SI mice relative to control 
mice at baseline and 20 minutes (Response) after the forced swim test (Two-Way 
ANOVA: interaction F(4, 74) = 1.25, p>0.05, main treatment effect F(2, 74) = 5.01, p=0.009 
with correction for multiple comparisons, Figure 4.4A).  All groups showed similar 
corticosterone levels at 2 hours after the FST (Recovery) (Two-Way ANOVA, p>0.05).  
Recovery ACTH levels showed a trend towards increase in the RUS+SI mice relative to 
control and SI groups (One-way ANOVA, F(2, 11) =3.53, p=0.065, with correction for 
multiple comparisons, Figure 4.4B). 
156 	
 
Figure 4.4.  Effect of RUS and social isolation on reactivity to acute stress. (A) 
Baseline plasma corticosterone levels were measured 10 days before the forced swim test 
(Baseline). Plasma corticosterone levels were measured 20 min (Response) and 120 min 
(Recovery) after initiating the forced swim. (B) Plasma ACTH levels 120 min after the 
cessation of forced swim (Recovery). Data in A was analyzed using Two-Way ANOVA 
followed by the two-stage linear step-up procedure of Benjamini, Krieger and Yekutieli 
(BKY) to control the false discovery rate, while data in B was analyzed using One-Way 
ANOVA. n=11-14 in baseline and stress response measurement while n=5-6 in all 
Recovery measurements. Asterisks denote statistical significance as follows *p<0.05.   
 
Experiment 2. Social isolation and RUS differentially regulate stress-induced 
expression of HPA axis markers in the hypothalamus 
I have previously shown the RUS+SI mice show a downregulation in the GR 
regulatory protein FKBP5 at 6 months after RUS (Algamal et al. 2018).  To better 
understand GR functionality in RUS+SI and SI mice under physiological condition and 
following HPA axis activation, I measured the protein expression levels of the GR and its 
associated proteins in the hypothalamus and the pituitary in response to acute stress 
challenge. Animals euthanized at 2 hours and 2 days after the FST were used to examine 
the stress-induced and baseline expression levels of relevant HPA axis markers, 
respectively.  Activation of GR involves the translocation of the receptors from the 
cytoplasm to the nucleus followed by binding to glucocorticoid responsive elements (GRE) 
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to activate gene expression (Fries, Gassen, and Rein 2017).  Hence, I obtained the nuclear 
and cytoplasmic fractions from the hypothalamus in order to examine the effect of acute 
stress on GR translocation in RUS+SI mice.  In each fraction, the expression levels of GR, 
FKBP and CRH were measured at baseline, and after acute stress, using western blotting.  
No changes were observed in the cytoplasmic GR levels at baseline or in response to acute 
stress or treatment (p>0.06, Figure 4.5A), although there was a trend towards increased 
cytoplasmic GR levels in RUS+SI animals relative to control and SI animals.  In the 
hypothalamic nuclear fraction, baseline levels of GR were lower in RUS+SI relative to 
controls. In addition, nuclear GR levels were higher in all groups in response to acute 
stress with the relative levels after stress being lower in SI and RUS+SI animals compared 
to controls (Two-Way ANOVA: interaction F(2, 27) = 1.863 p=0.18, main acute stress effect 
F(1, 27) = 52.6, p<0.001  main treatment effect F(2, 26) = 5..14, p=0.012 with correction for 
multiple comparisons, Figure 4.5D).  
FKBP5 levels were reduced in the cytoplasmic fraction of SI mice relative to 
controls and RUS+SI mice after acute stress (Two-Way ANOVA: interaction F(2, 26) = 2.78, 
p=0.984, main acute stress effect F(1, 26) = 0.67, p=0.41  main treatment effect F(2, 26) = 4.3, 
p=0.023 with correction for multiple comparisons, Figure 4.5B). Additionally, nuclear 
FKBP5 levels were down regulated in control and RUS+SI mice after acute stress, while it 
remained elevated in SI mice after acute stress (Two-Way ANOVA: interaction F(2, 26) = 
0.87, p=0.42, main acute stress effect F(1, 26) = 9.237, p=0.0052  main treatment effect F(2, 
26) = 0.1, p=0.9 with correction for multiple comparisons, Figure 4.5E).  
Two-way ANOVA showed no changes in the hypothalamic cytoplasmic and 
nuclear levels of CRH at baseline and in response to acute stress at the examined timepoint 
(p>0.05, Figure 4.5C and 4.5F). However, examining the group differences after acute 
158 	
stress using One-way ANOVA showed that nuclear CRH levels were reduced in the 
RUS+SI group relative to SI after acute stress (One-way ANOVA, F(2, 13) =6.31, p=0.012, 
with correction for multiple comparisons, Figure 4.5F) 
 
 
Figure 4.5. Effect of acute stress on HPA axis regulation in the hypothalamus at 1 
month after RUS. Quantification of western blot images in the cytoplasmic and nuclear 
enriched fractions in response to acute stress in the hypothalamus. A, B, and C depict the 
effect of acute stress on cytoplasmic levels of GR, FKBP5, and CRH, respectively, while 
D, E, and F depict the effect of acute stress on nuclear levels of GR, FKBP5, and CRH, 
respectively. Data were analyzed using One-Way ANOVA followed by two-stage linear 
step-up procedure of BKY to control the false discovery rate (n=5-6). Statistically 
significant findings versus the control group are denoted by *, while statistically significant 
findings versus the SI group are denoted by #. 
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Experiment 2. Social isolation and RUS differentially regulate stress-induced 
expression of HPA axis markers in the pituitary  
I then examined the expression levels of MR, GR, FKBP5, CRH, and its type1 
receptor CRH-R1 in whole cell lysates from the pituitary. Cellular fractionation of pituitary 
could not be achieved due to the small tissue size.  No changes were observed in pituitary 
GR levels at baseline or in response to acute stress (p>0.05, Figure 4.6A). FKBP5 levels 
were downregulated in the RUS+SI group relative to the SI group at baseline and relative 
to the control group after acute stress (Two-Way ANOVA: interaction F(2, 24) = 2.78, 
p=0.08, main acute stress effect F(1, 24) = 5.4, p=0.0289  main treatment effect F(2, 24) = 4.19, 
p=0.027 with correction for multiple comparisons, Figure 4.6B). No significant change 
was observed in Two-way ANOVA of pituitary CRH and or its receptor CRH-R1 levels.  
However, One-Way ANOVA showed increased CRH-R1 levels in the RUS+SI group 
relative to control and SI groups after acute stress (One-way ANOVA, F(2, 11) =9.162, 
p=0.0045, with correction for multiple comparisons, Figure 4.6D). No differences between 
study groups were observed in the pituitary levels of GR, MR or CRH at one month after 
RUS (Two-Way ANOVA, p>0.05, Figure 4.6). 
I also examined the effect of acute stress on high affinity glucocorticoid receptors 
(MR) in the pituitary.  After acute stress, the levels of pituitary MR were downregulated to 
the same levels, across all groups relative to their baseline values, with no difference 
between the groups at either baseline or in response to acute stress (p>0.05, Figure 4.6E). 
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Figure 4.6. Effect of acute stress on HPA axis regulation in the pituitary of RUS and 
SI mice. Quantification of pituitary GR (A), FKBP5 (B), CRH (C) (CRH-R1) (D) and MR 
(E) levels at baseline and after acute stress using western blotting. Data were analyzed 
using One-Way ANOVA followed by two-stage linear step-up procedure of BKY to 
control the false discovery rate (n=4-6). Statistically significant results versus the control 
group are denoted by *, while statistically significant results versus the SI group are 
denoted by #. 
 
Experiment 2. Body weight deficits after exposure to RUS or chronic social isolation. 
Socially isolated mice (SI) showed decreased body weight relative to the control 
group after 27 days of social isolation, while animals exposed to RUS in addition to social 
isolation (RUS+SI) showed decreased body weight at the end of the RUS paradigm (Day 
1), which persisted after 27 days of social isolation) (RM-ANOVA: interaction F(8, 128) = 
5.14, p<0.0001, with correction for multiple comparisons, Figure 4.7A).  RUS+SI and SI 
mice showed similar bodyweights at Day 27 (p> 0.05, Figure 4.7A). 
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Figure 4.7. Effect of RUS and social isolation on body weight, anxiety and stress-
coping behavior. Changes in mice bodyweight relative to baseline after RUS and SI (A). 
Performance of each group in the contextual fear memory test (B). Anxiety-like behavior 
was assessed by examining the number of entries to the OF center zone (C), total time 
spent in open arms of the EPM (D), and the number of entries to the open arms of the EPM 
(E). Immobility time and immobility frequency in the FST are depicted in panels (F) and 
(G), respectively. Data in A was analyzed using RM-Two-way ANOVA, while data in (B-
G) were analyzed using One-Way ANOVA followed by two-stage linear step-up 
procedure of BKY to control the false discovery rate. (n=11-14). Statistically significant 
findings versus the control group are denoted by *. 
 
Experiment 2. Combined exposure to RUS and social isolation is associated with 
anxiety-like behavior one month after RUS.  
In our previous characterization of the RUS paradigm, recall of contextual fear 
memories and anxiety-like behavior was demonstrated at an acute timepoint, but not at the 
3-months or the 6-months timepoints (Chapter 2 and (Algamal et al. 2018)).  Our findings 
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at the chronic timepoints were not conclusive, because the same cohort of mice was 
subjected to retesting at all timepoints. In the current study, all behavioral testing was 
performed once at approximately one months after RUS (Day 21 to Day 28 of the study 
timeline).  
RUS +SI mice showed increased % freezing time in the trauma context relative to 
control and SI mice (One-Way ANOVA, F(2, 33) = 14.29, p<0.0001, with correction for 
multiple comparisons, Figure 4.7B).  To examine the chronic effects of RUS on anxiety, I 
performed the Open Field (OF) and Elevated Plus Maze (EPM) tests at one month after 
RUS without any prior testing at Day 42.  As depicted in Figure 4.7, avoidance behavior 
was observed only in the stress group (RUS+SI) as evident by decreased open arm time 
(One-way ANOVA, F(2, 27) =3.58, p=0.041, with correction for multiple comparisons, 
Figure 4.7D) , and open arm entries (One-way ANOVA, F(2, 27) =5.28, p=0.012, with 
correction for multiple comparisons, Figure 4.7E).  No changes were observed in the total 
distance travelled (F) or not-moving time (H) in stressed animals relative to controls (One-
way ANOVA, p>0.05, Figure S1C and S1D). No change in the FST immobility time was 
observed between study groups (One-way ANOVA, p>0.05, Figure 4.7F).  However, the 
immobility frequency was increased in stress and SI animals relative to the control group 
suggesting that they share similar stress coping strategies (One-way ANOVA, F(2, 30) 
=7.5, p=0.002, with correction for multiple comparisons, Figure 4.7G). 
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Discussion 
Imbalance in HPA axis regulation is implicated in a number of affective disorders 
including PTSD in which it often presents as low baseline plasma cortisol levels 
(Deslauriers et al. 2018; Pitman et al. 2012; Yehuda 2001). In this Chapter, I explored the 
mechanisms of HPA axis regulation in our PTSD mouse model.  As previously described 
in Chapter 2, this model has been extensively characterized at 6 months after exposure to 
repeated unpredictable stress (RUS). Here, I performed studies at the earlier timepoint of 
one month after RUS, where I anticipated the demonstration of persistent and prominent 
subchronic behavioral abnormalities in our model and a suitable time-window for 
assessing theragnostic effects in our model in anticipation of future studies exploring novel 
therapeutic approaches in drug discovery.  
A number of explanations for the blunted HPA axis after PTSD have been 
proposed including enhanced negative feedback sensitivity at the level of the 
pituitary(Yehuda et al. 1993). I examined the pituitary negative feedback regulation 
mechanisms in RUS+SI mice in vivo using the DEX-CRH test. DEX was first given to 
supress endogenous release of ACTH since  DEX acts mainly on the pituitary. As a result 
of ACTH supression, circulating glucorticoids levels decreased accordingly. CRH was 
then injected to stimulate the pituitary to release ACTH which in turn increased the 
synthesis and release of glucorticoids. Decreased plasma glucocorticoid levels in response 
to CRH stimulation may indicate a hypofunctional pituitary or adrenal gland and can also 
arise due to inceased sensitivity of GR to dexamethasone. Control and RUS+SI animals 
showed similarly suppressed corticosterone levels after a high dose dexamethasone, and 
lower corticosterone levels in response to CRH stimulation in RUS+SI animals (Figure 
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4.2B). Low corticosterone levels after CRH stimulation can be attributed to impaired 
pituitary or adrenal functions. However, the normal or slightly elevated ACTH levels in 
RUS+SI animals after CRH stimulation suggested that the low plasma corticosterone 
concentration cannot be explained by pituitary hypofunction (Figure 4.2C). If the pituitary 
function were impaired due to enhanced sensitivity to dexamethasone suppression or 
decreased overall ability to release ACTH, plasma ACTH levels should have been lower in 
RUS+SI mice after CRH stimulation. Therefore, these findings suggested that the adrenals 
are irresponsive to ACTH stimulation. To further check this hypothesis, I retested the same 
cohort of mice in the combined DEX-ACTH stimulation test. Similarly, a high dose DEX 
was given to prevent the release of any endogenous ACTH from the pituitary followed by 
ACTH or saline injection. Consistent with our hypothesis, RUS+SI animals showed 
decreased plasma corticosterone levels after ACTH stimulation relative to the group-
housed controls (Figure 4.2D). Similar findings have previously been observed in a study 
examining the effects of chronic subordinate colony (CSC) housing- a form of 
psychosocial stress- on adrenal function (Reber et al. 2007). In this study, adrenal glands 
isloated from CSC mice failed to respond to multiple doses of ACTH stimulation in vitro 
(Reber et al. 2007). 
Alternatively, these findings can also be explained by increased sensitivity to 
dexamethasone supression at the level of the adrenal glands. Recent evidence has shown 
that GR are expressed in the adrenal cortex in rodents and humans (Walker et al. 2014). 
This finding suggests that glucocorticoids may be able to autoregulate their own synthesis 
and release via intra-adrenal mechanisms (Walker et al. 2014). Therefore, in our study, 
increased sensitivity of adrenal GR to dexamethasone may also account for the decreased 
corticosterone release in RUS+SI animals in the combined DEX_ACTH test.  
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High or low doses of DEX alone (Figure 4.2 and 4.3) were not associated with a 
significant change in HPA axis negative feedback sensitivity in RUS+SI animals relative 
to control animals.  Retesting the same cohort of mice in the HPA challenges is one of the 
limitations of this study, due to the possibility of inducing long-term plastic changes in the 
HPA axis after DEX and CRH administration (Touma et al. 2011). The DEX dose 
examined here before prior testing is high and so may have been efficient in completely 
suppressing corticosterone levels in all groups.  Additional studies using lower DEX doses 
in an independent cohort of mice are needed to clearly elucidate the sensitivity of GR to 
negative feedback regulation.   
Group-housing of laboratory mice is recommended and widely used to 
accommodate the social nature of rodents (Kappel, Hawkins, and Mendl 2017). Single-
housing or social isolation is considered a form of psychosocial stress in mice because of 
its impact on behavior, and the physiological and neuroendocrine systems (Arndt et al. 
2009). Early-life, juvenile or adult social isolation for a period of 2 to 8 weeks is associated 
with changes in HPA axis activity and stress-coping strategies (Boero et al. 2018; Gądek-
Michalska et al. 2017; Pisu et al. 2016).  Specifically, adult socially isolated mice show 
lower plasma corticosterone levels at baseline and higher levels in response to acute stress 
when compared to group housed control mice (Berry et al. 2012).  
In this study, socially isolated (SI) mice and RUS+SI mice showed similar changes 
in bodyweight, stress coping strategies and corticosterone stress response to acute stress.  
However, the abundance of GR and FKBP5 in the brain in response to acute stress was 
markedly different between RUS+SI and SI mice, indicating that the mechanisms 
regulating GR activity are different in both groups.  FKBP5 is a part of an ultra-short 
negative feedback loop that regulates the GR response to acute stress (Hubler and 
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Scammell 2004; Paakinaho et al. 2010). Under baseline conditions (normal corticosterone 
levels), GR is held in the cytoplasm as a multiprotein complex containing the co-
chaperones FKBP5 and heat shock protein 90 (HSP90). After acute stress, corticosterone 
levels increase and bind to cytoplasmic GR resulting in its transport to the nucleus after 
dissociation from chaperone proteins.  Activation of GR transcriptional activity by its 
binding to the glucocorticoid response element (GRE) in the nucleus increases the 
expression of FKBP5 and other regulatory proteins to block additional GR translocation 
(Merkulov, Merkulova, and Bondar 2017).  Although the involvement of cytoplasmic 
FKBP5 in translocation of GR is well established, little is known about the function of 
nuclear FKBP5 (Brkic et al. 2017). Some reports have suggested a role for nuclear FKBP5 
in increasing GR stability in the nucleus by protecting non-DNA-bound-GR from 
proteolysis (Tatro et al. 2009).  
Baseline GR levels were lower in RUS+SI animals relative to control mice in the 
nuclear fraction of the hypothalamus, suggesting a difference in subcellular localization of 
GR in our model (Figure 4.5D). This is also supported by the trend towards higher 
baseline levels of cytoplasmic GR in RUS+SI mice relative to control and RUS mice 
(Figure 4.5A). No change was observed in the subcellular baseline levels of FKBP5 in the 
hypothalamus suggesting that other mechanisms are involved. These mechanisms may 
involve changes in other chaperone proteins such as FKBP4 and HSP9 and may also 
underlie deficiencies in GR export from the nucleus. Interestingly, previous reports have 
shown that elevated FKBP4/FKBP5 ratio in the hippocampal nuclear fraction was 
associated with increased GR nuclear localization(Tatro et al. 2009).  
In response to acute stress in the Forced Swim Test, levels of GR were lower in 
both RUS+SI and SI mice relative to controls, while FKBP5 levels were higher in SI mice 
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relative to group housed controls in the hypothalamic nuclear fraction. I am unable to 
determine whether the decrease in nuclear GR was mainly due to alteration in nuclear 
translocation, as FKBP5 levels would have appeared higher in the cytoplasmic fraction. 
Given that cytoplasmic FKBP5 levels were lower in SI animals and unchanged in RUS+SI 
animals, this implicates interplay of other unknown regulatory mechanisms.  
A limitation of the current study is the analysis of only a single timepoint after 
acute stress (2 hours after forced swim stress). Additional experiments using multiple 
earlier timepoints are needed to clearly understand the exact mechanisms involved here.  
However, these results clearly suggest that that stress adaptation mechanisms are different 
in RUS+SI and SI animals.  Interestingly, anxiety-like behavior was only observed in 
animals exposed to RUS in addition to SI at one month after RUS (Figure 4.7). This 
finding also strengthens the validity of our chronic PTSD model, since the persistence of 
anxiety-like behavior could not be established in our previous characterization of the RUS 
model in Chapter 2. 
Here, I have shown that exposure to the RUS stress paradigm resulted in a number 
of HPA axis alterations including decreased plasma corticosterone concentrations in 
response to acute stress, DEX-CRH stimulation, and DEX-ACTH stimulation. In addition, 
the model also shows changes in GR subcellular localization in the hypothalamus of 
stressed mice implicating that GR sensitivity and HPA axis feedback are altered. The HPA 
axis alterations in this model, although not perfectly resembling human PTSD, are unique 
to an animal model of stress and will be valuable in understanding the complexity and 
intricate details of the HPA axis response to stress. Because of the heterogenous nature of 
PTSD, our findings may be relevant to the fraction of PTSD patients showing low baseline 
glucocorticoids levels accompanied by a slight alteration in pituitary function. In 
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agreement with previous reports (Leistner and Menke, 2018), my findings emphasise the 
importance of examining HPA axis function in response to acute stress to better engage 
GR.  Finally, I show that while social stress is a key factor for the persistence of symptoms 
in this model, the findings cannot be solely reproduced by social isolation stress. 
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Chapter 5. Effect of dexamethasone and/or 7,8 
dihydroxyflavone treatment on stress-related behavior in the 
RUS model 
Introduction 
The lack of progress in the psychopharmacologic treatment of post-traumatic stress 
disorder (PTSD) is an ongoing crisis due to its negative clinical, social and economic 
implications (Krystal et al. 2017). Current PTSD pharmacotherapy relies on a few FDA 
approved depression medications which offer only symptomatic relief and show limited 
efficacy (Krystal et al. 2017; McAllister 2009). As both military and civilian populations 
are increasingly exposed to traumatic stress, the identification of effective etiology-based 
treatments for the condition is a high priority. As presented in Chapter 1, valid preclinical 
PTSD animal models, showing long-lasting PTSD-like traits, are invaluable in that respect 
because they enable fast and efficient testing of potential drugs. 
In Chapter 2 and Chapter 4, I showed that exposure to repeated unpredictable stress 
(RUS) and subsequent social isolation were effective in demonstrating several chronic 
PTSD-related phenotypes in a mouse model. These chronic traits were observed in 
multiple systems, most noticeably in the HPA axis and BDNF signaling.    The HPA axis 
changes included decreased plasma corticosterone levels at baseline and after acute stress 
(Figure 2.8 and 4.4), altered GR subcellular localization in the hypothalamus (Figure 
4.5), and increased pituitary CRH-R1 levels in response to acute stress (Figure 4.6). In 
addition, hippocampal BDNF levels were significantly reduced at 6 months after RUS 
(Figure 2.10) and possibly at 10 days after RUS (A trend towards reduction, Figure 2.14). 
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Here I examine if pharmacological targeting of these two systems individually or in 
combination would be effective in restoring homeostasis in stressed animals. Because 
hippocampal BDNF levels were downregulated 6 months after RUS, I used the orally 
available BDNF receptor (TrkB) agonist 7, 8-dihydroxyflavone (DHF) to restore BDNF 
signaling. To target the HPA axis, I used a low dose dexamethasone (DEX) for a month 
after RUS. DEX is a corticosterone analogue with higher receptor affinity and limited 
central availability, therefore treatment with a low DEX dose should be mainly supportive 
for the peripheral glucocorticoid function.  Interestingly, a single low dose of DEX was 
effective in accelerating the extinction of fear memories in humans and rodents with 
mechanism involving altered GR sensitivity in the amygdala during fear extinction 
(Michopoulos et al. 2017; Sawamura et al. 2016). Therefore, this study will also examine 
the consequences of chronic administration of low-dose DEX on fear memory recall and 
other on stress-related behavior to further validate our model. DEX and DHF were 
administered alone or in combination in drinking water for a month followed by behavioral 
testing and target engagement studies.  
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Materials and Methods 
Animals 
I used C57BL/6 male mice aged 12 weeks old at the time of exposure to RUS to 
investigate the impact of our therapeutic interventions on stress-related behaviors. The 
RUS procedures were implemented as described in Chapter 2 followed by a month of drug 
administration in drinking water starting at day 3 after RUS.As depicted in Figure 5.1, the 
experiment involved one vehicle treated control group (C-VEH, n=10) and 4 stress groups 
(n=9-10 per group) receiving either vehicle (S-VEH), Dexamethasone-only (S-DEX), 
DHF-only (S-DHF), or a combination of both (S-DEX+DHF). 
 
Figure 5.1. Study timeline. Treatment started 3 days after the end of the RUS procedures. 
All animals were euthanized after @ one month of treatment.   
 
Drugs 
7, 8-dihydroxyflavone (Tokyo Chemical Industry Co., Ltd., Tokyo, Japan) was 
dissolved in 100% dimethyl sulfoxide DMSO (Sigma) to generate a stock solution at 500 
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mg/mL. The stock solution (1 ml) was gently added to 1000 ml of water that contained 1% 
sucrose and sonicated for 30 min. The final concentration of DHF given to mice in 
drinking water was 0.5 mg/mL. Water soluble dexamethasone was purchased from Sigma 
and dissolved directly into the vehicle solution (1% sucrose, 0.1% DMSO) to a final 
concentration of (0.12 µg/mL) in drinking water. Estimating that each animal drinks 5-7 
mL per day, this concentration approximates 20-40 µg/kg for 15-18-week-old mice. The 
drinking water containing either DHF, DEX, DEX+DHF, or vehicle was replaced every 2 
days. Water bottles were weighed in each replacement cycle to estimate the average water 
consumption by each animal. The dose of DHF examined here was adapted from previous 
studies showing improved cognitive functions using a dose of 1 mg/mL in mouse models 
of psychosis and fragile X syndrome (Han et al. 2016; Tian et al. 2015). However, due to 
the immediate precipitation of DHF when dissolved at a concentration of 1mg/mL, the 
dose was reduced to 0.5 mg/mL followed by the sonication procedures described earlier to 
improve DHF vehicle solubility. These procedures resulted in a clear to slightly turbid 
DHF solution that was subsequently given to mice as drinking water.  Several studies 
reported a much lower dose (0.08 mg/ mL) to be also effective in rodent models of stress, 
TBI and Rett Syndrome (He et al. 2016; R. A. Johnson et al. 2012; Sanz-García et al. 
2016).  To ensure that DHF treatment was associated with maximum TrkB receptor 
activation, I used the maximum reported, yet soluble, dose of DHF I can prepare. 
Behavioral testing.  
Behavioral assessment started 19 days after RUS, while mice were still receiving 
treatments, and included the Open Field test, contextual and cued fear memory testing, the 
forced swim test (FST) and the Elevated Plus Maze (EPM) (Figure 5.1). Animals were 
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tested in the FST twice with a 48 hours interval. All behavioral procedures were 
implemented as described previously in Chapter 2. 
 
Euthanasia 
Animals were euthanized 7 days after the last behavioral test (Day 35). The 
collection of plasma and brain tissue was followed as described previously in Chapter 2 
and as previously published (Algamal et al. 2018).  
 
Statistics 
Freezing scores in the cued fear memory tests and the immobility time in the forced 
swim test were analyzed using Repeated measure Two-Way ANOVA. All other 
experiments were analyzed using One-Way ANOVA.  All ANOVA experiments were 
followed by Two stage linear set up procedure of Benjamini, Krieger and Yekutieli (BKY) 
(Benjamini et al. 2006) to correct for multiple comparisons by controlling the false 
discovery rate (q=0.05). Grubb’s test was used to identify outliers. 
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Results 
DHF supplementation reverses anxiety-like behavior in stressed animals. 
The average weekly intake of drinking water was monitored to ensure that all 
animals were receiving similar drug dosages. The weekly water consumption for C-VEH 
mice was lower than all animals in the stress groups, with no significant changes across 
stressed groups regardless of treatment (Figure 5.2) (RM-Two-Way ANOVA: main 
treatment effect F(4, 42) = 6.88, p=0.0002, with correction for multiple comparisons, 
Figure 5.2A). Treatment had no effect on body weight, since all stressed animals had 
lower bodyweights at euthanasia relative to the C-VEH group (One-Way ANOVA, F(4, 
40) = 4.22, p=0.006, with correction for multiple comparisons, Figure 5.2B). 
 
 
Figure 5.2.  The average weekly intake of drinking water by each treatment group.  
(A) Average weekly drinking water consumption in each treatment group. (B) Body 
weights (% baseline) after one month of treatment (i.e. at euthanasia). Data in A was 
analyzed using RM-Two-Way ANOVA, while data in B was analyzed using One Way 
ANOVA.  
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S-VEH animals showed anxiety-like behavior as demonstrated by decreased center 
zone entries relative to C-VEH animals in the Open Field test (One-Way ANOVA, F(4, 
41) = 4.96, p=0.0024, with correction for multiple comparisons, Figure 5.3B. DHF 
treatment reversed the anxiety-like behavior observed in S-VEH group, since entries to the 
Open Field center zone were not statistically significant  between S-DHF or S-DHF+DEX 
animals and C-VEH animals. In addition, S-DHF+DEX group showed increased center 
zone entries relative to S-VEH animals suggesting that combined DEX and DHF are 
possibly more effective. DEX treatment did not reverse the anxiety-like behavior in 
stressed animals, because both S-DEX and S-VEH animals showed a decrease in Open 
Field center zone entries relative to C-VEH. Immobility time in the open field test was 
increased only in S-VEH animals relative to C-VEH (One-Way ANOVA, F(4, 40) = 4.62, 
p=0.0037, with correction for multiple comparisons, Figure 5.3C). Therefore, all treatment 
groups seem to reduce Open Field immobility time. All stressed animals showed decreased 
locomotor activity in the open field relative to C-VEH animals with no drug effects 
observed (One-Way ANOVA, F(4, 40) = 8.335, p<0.0001, with correction for multiple 
comparisons, Figure 5.3D). No change was observed in the time spent in the open field 
center zone between different study groups (One-Way ANOVA, p=0.45, Figure 5.3A).   
I also assessed anxiety behavior in the EPM test. No significant treatment effects 
were observed in time spent in the open arms (One-Way ANOVA, p >0.05, Figure 5.3E), 
entries to the open arms (One-Way ANOVA, p >0.05, Figure 5.3F), number of dose dips 
(One-Way ANOVA, p >0.05, Figure 5.3G), or the total distance travelled in the EPM 
(One-Way ANOVA, p >0.05, Figure 5.3H). Although there was a trend towards reduced 
number of nose dips in the open space in S-VEH animals relative to C-VEH, no significant 
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differences were found in One-Way ANOVA analysis. This was probably attributed to the 
high variability in animals’ performance in the EPM.  
  
 
Figure 5.3. Effect of DEX and/or DHF intake on anxiety-like behavior after one 
month of treatment. Anxiety-like behavior was assessed in the Open field test at Day 19 
after RUS and in the Elevated Plus Maze at Day 28 after RUS. Average time spent in the 
Open Field center zone is depicted in (A), while the number entries to center zone area is 
depicted in (B). The total immobility time and distance travelled in the Open Field are 
depicted in C and D, respectively. The time spent the EPM open arms, number of entries to 
the EPM, number of nose dips in the EPM the open area and total distance travelled in the 
EPM are depicted in E, F, G, and H, respectively. Data were analyzed using One-Way 
ANOVA followed by BKY method to correct for multiple comparisons. Asterisks (*) 
denote statistically significant results relative to the C-VEH group, while ($) denote 
statistically significant results relative to the S-VEH group.  
 
DEX intake decreases freezing response to the fear conditioning context.  
The effect of DEX and/or DHF treatment on fear memory recall was examined at 
one month after RUS as depicted in Figure 5.1. DEX treatment attenuated contextual fear 
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memory recall as evident by increased freezing times in S-VEH and S-DHF animals 
relative to C-VEH, S-DEX, and S-DEX+DHF animals in the contextual fear memory test 
(One-Way ANOVA, F(4, 40) = 5.77, p=0.0009, with correction for multiple comparisons, 
Figure 5.4A). All treatment groups showed minimal freezing when placed in a novel 
context (No cue) 1 hour after the contextual fear memory test (p>0.05, Figure 5.4B). A 
tone (Cue) was turned on after 3 min of habituation in the new context to examine the cued 
fear memory response. All stress groups showed increased freezing time relative to the 
control group after tone introduction (RM-Two-Way ANOVA: interaction, F(4, 40) = 
13.62, p<0.0001 main treatment effect F(4, 40) = 10.99, p<0.0001, with correction for 
multiple comparisons, Figure 5.4B). Interestingly, S-DEX animals showed reduced 
freezing time relative to S-VEH animals after tone introduction (Figure 5.4B). 
 
 
Figure 5.4.  Effect of DEX and/or DHF intake on recall of fear memories after one 
month of treatment. The performance of each treatment group on contextual (A) and cued 
(B) fear memory tests. Data in A was analyzed with One-Way ANOVA, while data in B 
was analyzed with RM-Two Way ANOVA. Asterisks (*) denote statistically significant 
results relative to the C-VEH group, while ($) denote statistically significant results 
relative to the S-VEH group. 
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All treatment groups showed similar stress coping behavior when examined in the 
FST (RM-Two-Way ANOVA, p>0.05, Figure 5.5). 
 
Figure 5.5.  Effect of DEX and DHF intake on stress coping strategies. The 
performance of each treatment group in the forced swim test is depicted in Figure 5.5 as 
follows; (A) immobility time, (B) immobility frequency, (C) struggling time, and (D) 
struggling frequency. RM-Two Way ANOVA was used to analyze the data. 
 
Effect of DEX and/or DHF on baseline plasma corticosterone levels and TrkB 
phosphorylation in the hippocampus 
To examine the effects of chronic DEX administration (20 µg /kg) on HPA axis 
suppression, I measured baseline plasma corticosterone levels at euthanasia. Baseline 
plasma corticosterone levels were lower in S-DEX and S-DEX+DHF animals relative to 
C-VEH and S-VEH animals (One-Way ANOVA, F(4, 41) = 7.76, p<0.0001, with 
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correction for multiple comparisons, Figure 5.6.6B). Surprisingly, S-VEH animals showed 
higher baseline corticosterone levels relative to C-VEH animals (p=0.0156, Figure 5.6B) 
in contrast to what I have reported previously. Plasma corticosterone levels in control 
animals at euthanasia appeared to be lower than to their levels prior to vehicle 
administration (Figure 5.6A). No change in the levels of P-TRKB or BDNF were observed 
in the hippocampus of all treatment groups (p>0.05, Figure 5.7). 
 
 
Figure 5.6. Effect of DEX and DHF intake on baseline corticosterone levels. A blood 
sample was drawn from control and stressed animals by tail bleed at day 10 of the ongoing 
RUS procedures and before treatment. (A) Pre-treatment baseline corticosterone levels 10 
days after the start of the RUS paradigm (B) Baseline plasma corticosterone levels at 
euthanasia (i.e. after one month of treatment). Data in A was analyzed using a student test, 
while data in B was analyzed using One-Way ANOVA followed by BKY procedures to 
correct for multiple comparisons. Asterisks (*) denote statistically significant results s 
relative to the C-VEH group, while ($) denote statistically significant results relative to the 
S-VEH group.   
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Figure 5.7.  Effect of treatment on P-TrkB and BDNF levels in the hippocampus. 
Quantification of western blot images for P-TrkB (A), and BDNF from the hippocampus. 
Data was analyzed using One-Way ANOVA.  
181 	
Discussion 
Herein, I examined the effects of combined treatment with an HPA axis regulator 
(DEX) and a TrkB receptor agonist (DHF) on neurobehavioral outcomes in mice at one 
month after RUS.  Chronic DHF intake was associated with improvements in anxiety-like 
behavior and no effect on body weight or recall of fear memories. On the other hand, 
chronic DEX intake was associated with reduced freezing response to the trauma context 
and no effect on body weight, or anxiety-like behavior.  These findings show beneficial 
outcomes for a combination therapy regulating the HPA axis and BDNF signalling. 
A single dose of DEX has been previously demonstrated in humans to facilitate 
fear extinction and discrimination in PTSD patients when administered the night before a 
fear extinction session (Michopoulos et al. 2017). In mice, injection of a low DEX dose 4 
hours before cued fear memory recall trials was associated with enhanced fear extinction 
(Sawamura et al. 2016).  In addition, the DEX-induced changes in fear extinction was 
dose-dependent and may have involved epigenetic regulation of FKBP5 expression in the 
amygdala (Sawamura et al. 2016) 
In the current experiment, chronic administration of DEX attenuated freezing 
response in the contextual and cued fear memory test relative to the vehicle treated stressed 
mice. These findings suggest that DEX effects on fear extinction are maintained after 
chronic low dose administration and therefore provide further validation to our model.  
The low DEX dose used here was effective in supressing the HPA axis (Figure 5.6) 
relative to vehicle treated stressed mice. Interestingly, DHF alone was also effective in 
reducing corticosterone levels relative to stressed animals receiving vehicle suggesting that 
DHF effects may be partially mediated by HPA axis adjustments. The interaction between 
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the BDNF/TrkB system and HPA axis is well-established (Chen et al. 2012; Daskalakis et 
al. 2015; Jeanneteau et al. 2012). Intracerebroventricular BDNF injections upregulates 
CRH expression in the hypothalamus and increases plasma corticosterone concentrations 
(Givalois et al. 2004; Naert et al. 2006). In addition, increased glucocorticoids levels due to 
acute or chronic stress is known to downregulate BDNF levels and decrease TrkB 
phosphorylation in the hippocampus (Kunugi et al. 2010).   In Chapter 2, I showed that 
BDNF and corticosterone levels were decreased in the hippocampus at 6 months after 
RUS. It is important to note that corticosterone levels were most likely elevated during the 
RUS procedures and possibly during the early days of social isolation. Therefore, the 
negative alterations in the hippocampus in our model, including reduced BDNF levels, can 
be possibly be attributed to initial elevation in corticosterone levels. 
DHF has shown therapeutic potential in several animal studies of BDNF-related 
disorders such as Alzheimer’s disease(Liu, Chan, and Ye 2016), Parkinson’s disease (Jang 
et al. 2010), psychosis (Han et al. 2016), Rett syndrome (R. A. Johnson et al. 2012), and 
depression (Chang et al. 2016). In the context of  PTSD, administration of DHF 8 hours 
prior to a spatial memory task prevented the immobilization-induced memory deficits in 
rats (Sanz-García et al. 2016). The reversal of the stress-associated behavior in the open 
field test by DHF (supported also by similar trends in the EPM) indicates that DHF 
administration partially recovers the unstressed phenotypes. Interestingly, polymorphism 
in BDNF gene (Val66Met) resulting in deficits in its secretion from neurons have been 
previously reported to increase anxiety-like behavior in mice (Chen et al. 2007).No change 
was observed in p-TrkB or BDNF levels in whole hippocampal homogenates, so activation 
of TrkB receptor under the current experimental procedures could not be confirmed.  
Additional screening for different TrkB phosphorylation sites in the hippocampus and 
183 	
other brain regions, particularly in isolated fractions such as synaptosomes, and activation 
of downstream signaling targets, is required to thoroughly explore target engagement of 
DHF in the brain. The goal of the treatment study presented here was to further validate 
our model and emphasize the involvement of the HPA axis and BDNF signaling in the 
behavioral alterations observed after RUS. Future experiments should be planned to 
explore the impact of different pharmacological agents, dosages and routes of 
administration to ensure maximum drug delivery to the brain. In addition, exploring the 
outcomes at more chronic timepoints and after longer treatment durations is imperative to 
ensure better translational outcomes. 
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Chapter 6. Discussion and future directions 
Summary of research findings 
PTSD is a debilitating condition affecting the lives of 13 to 24 million Americans 
and 2 to 4 million in the United Kingdom.  The number of PTSD patients is expected to 
increase in both military personnel and civilians because of ongoing military interventions, 
refugee crises and the increasing number of terrorist attacks and mass violence (Richter-
Levin et al. 2018).  The past decade has witnessed a growing awareness and 
acknowledgment of the gravity of this condition and its detrimental consequences.  
However, no disease-modifying drugs are currently available due in part to our current lack 
of understanding of the pathophysiology of PTSD (Krystal et al. 2017).  PTSD develops in 
a fraction of individuals after exposure to a significant stressful event (Kessler et al. 1995) 
and is accompanied by a number of changes in the HPA axis such as low baseline 
glucocorticoid levels and increased sensitivity to feedback regulatory mechanisms 
(Daskalakis, Lehrner, and Yehuda 2013; Yehuda 2001; Yehuda et al. 1995).  Because the 
changes in the HPA axis are persistent, and correlate with PTSD symptom severity, stress 
homeostasis mechanisms are thus believed to be chronically impaired in PTSD (Fragkaki 
et al. 2016; Nijdam et al. 2015; Watkins et al. 2016).  Several ethical and methodological 
challenges preclude the study of these mechanisms in humans, therefore preclinical animal 
research provides an alternative platform that is better suited to conduct such studies under 
controlled conditions. The challenge, however, is to develop an easily reproducible stress 
procedure capable of generating maladaptive responses that disrupts stress regulatory 
mechanisms in animals, which persists many months after the last stress exposure.  In 
addition, for these procedures to be etiologically relevant to human PTSD and demonstrate 
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construct/face validity, they must also result in multiple chronic PTSD-like behavioral 
phenotypes.  The first aim of this thesis was to address these challenges by examining the 
chronic effects of a combination of social, physical and psychological stress procedures in 
mice.  Our stress paradigm combined multiple types of traumatic exposures including 
predator odor under restraint, footshocks, social instability and social isolation.   
I have demonstrated in chapter 2 that our stress model generated a number of 
PTSD-associated behavioral changes that were correlated with decreased baseline plasma 
corticosterone and ACTH levels and diminished FKBP5 expression in the hypothalamus.  
These results implicate a blunted HPA axis function, which is a key neurobiological 
finding in human subjects with PTSD.  This model also shows a chronic reduction in 
hippocampal CA1 volume and BDNF levels in addition to early, short-term changes in 
amygdaloid synaptic plasticity markers.   
A number of interesting questions emerged from the findings in chapter 2, which 
were mainly recorded at 6 months after RUS. The first set of questions is centered around 
the HPA axis findings: 1) Why would animals exposed to our stress procedures show low 
baseline plasma corticosterone levels? Is there an attenuation in the pituitary response to 
CRH stimulation from the hypothalamus? Additionally, since FKBP5 levels were lower in 
the hypothalamus, is the GR negative feedback sensitivity altered in the hypothalamus and 
possibly other brain regions? The second set of questions concerns the time-dependent 
changes observed in several stress-related markers after RUS exposure. 
To address the first set of questions, I conducted HPA axis challenges on stressed 
mice at one month after RUS, as described in chapter 4. The combined dexamethasone 
suppression and CRH stimulation test is often used to examine pituitary function and has 
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been shown to have better sensitivity in diagnosing pituitary-related disorders relative to 
the dexamethasone suppression test (Leistner and Menke 2018). Stressed animals showed 
normal plasma ACTH levels and lower plasma corticosterone levels in response to the 
DEX-CRH test. This indicated that the pituitary response is normal, and the attenuation in 
corticosterone may be due to decreased adrenal responsiveness. Stressed animals also 
showed lower corticosterone levels in response to the DEX-ACTH test, which examines 
adrenal function. These findings lead us to the conclusion that the observed low baseline 
corticosterone levels are likely due to mild adrenal insufficiency in stressed animals.  My 
findings can also be explained by increased sensitivity of adrenal GR autoreceptors to 
dexamethasone suppression.  I opted to use the combined DEX-ACTH test to ensure that 
endogenous corticosterone and ACTH levels are suppressed. However, additional 
experiments using only ACTH stimulation without DEX administration or prior testing 
would help us to better understand the adrenal function in stressed mice. Stressed animals 
showed decreased nuclear localization of GR receptors in the hypothalamus at baseline and 
after acute stress relative to control animals (Chapter 4), further implicating an impaired 
negative feedback mechanism and possibly prolonged chronic HPA axis activation in the 
hypothalamus. The source of this overactivation remains elusive but may be partly 
attributed to dysregulation in the input from the prefrontal cortex and limbic regions such 
as the amygdala and hippocampus involved in the allostatic management of stress. 
Interestingly, CRH-R1 levels were upregulated in stressed animals after acute stress 
challenge and circulating ACTH levels showed a trend towards an increase, which is 
consistent with central HPA axis hyperfunction. Taken together, our data suggest that there 
is decreased glucocorticoid negative feedback at the level of the hypothalamus resulting in 
prolonged HPA axis activation. However, due to the attenuated adrenal response to ACTH 
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stimulation, this HPA axis hyperactivation does not seemingly result in an increase in 
circulating plasma corticosterone levels, possibly owing to impaired ACTH mobilization 
of corticosterone from its precursors or inadequate GR autoreceptor feedback mechanism 
in the adrenal gland. This unique stress response is an important finding to advance our 
understanding of stress disorders in general, and it could also be relevant to the 
subpopulation of PTSD patients who demonstrate low baseline plasma corticosterone 
levels but a normal response in the dexamethasone suppression test.   
The second topic that emerged from chapter 2 was the time-dependent changes 
observed in several markers. For instance, synaptic plasticity markers such as CAMK, 
PSD95, and GluN1 were altered in the amygdala at only the acute timepoint (10 days after 
RUS), while levels of other markers, such as hypothalamic FKBP5 and hippocampal CRH, 
were altered only at 6 months. These observations are probably driven by the differential 
effects of RUS and social isolation on these markers. The changes in amygdala synaptic 
markers could be transient and exclusively dependent on some of the stress procedures 
applied during RUS, such as restraint stress, TMT exposure, and footshocks. Therefore, a 
number of these markers were dysregulated at the acute timepoint but did not persist for 
any chronic period after RUS cessation. On the contrary, it is possible that social isolation 
(SI) is essential for the downregulation of FKBP5 in the hypothalamus and upregulation of 
hippocampal CRH, as these alterations were not observed at the acute timepoint (i.e. when 
mice had only experienced 10 days of SI).  
Since one of the primary goals of developing this mouse model is utilization in 
drug discovery studies, I performed our treatment studies at one month after RUS exposure 
to minimize the lag time in future drug screening experiments. Examining the stress effect 
at the one-month timepoint is a valid representation of the chronic nature of stress given 
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that the DSM-5 criteria mandate the persistence of PTSD symptoms for at least one month 
in humans. In addition, because the average lifespan of mice is 30-40 times shorter than 
that of humans, persistence of behavioral deficits in mice for more than one month 
represents a longer relative duration in their life. In chapter 5 I performed a pilot treatment 
study aiming to restore hippocampal BDNF levels and recover normal HPA axis function 
which were chronically affected in our model. Animals were either given DEX, DHF 
(TrkB receptor agonist) or a combination of both to examine the impact of these treatments 
on stress-related behaviors. The choice of daily continuous exogenous supply of 
compounds in drinking water, particularly for DEX, was designed to correct alterations in 
tonic and pulsatile actions of corticosterone in our model, as diurnal fluctuations in the 
circadian rhythm of corticosterone is known to affect its allostatic regulation of stress. 
Chronic DEX treatment attenuated the recall of contextual fear memories, while DHF 
improved their anxiety-like behavior. The combination group emerged as the best modality 
in restoring homeostasis.  This study exemplifies the utility of our model in future PTSD 
treatment studies. 
Mild traumatic brain injury is a worldwide public health problem, with at least 41 
million people affected per year (Gardner and Yaffe 2015). Mild traumatic brain injury is 
known to increase the risk for psychiatric disorders and neurodegenerative diseases, 
especially with repeated exposures. Active duty soldiers often suffer from comorbid mTBI 
and PTSD, which can be clinically challenging to diagnose due primarily to the 
heterogeneity and clinical overlap shared by both conditions. In addition, the impact of 
mTBI on PTSD symptom severity is not clearly understood. This emphasizes the critical 
need to develop a relevant animal model to examine the chronic consequences of comorbid 
PTSD and TBI. In chapter 3, I examined the impact of repetitive mild TBI (r-mTBI) on the 
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behavioral outcomes in our stress paradigm. Repetitive mild traumatic brain injury 
procedures (5 injuries with a 48-hour inter-injury interval) were administered concurrently 
with the 21-day RUS procedures to reproduce the nature of trauma endured by soldiers 
during a single deployment. The impact of repeated deployment on the severity of PTSD 
and mTBI, either individually or comorbidly, has received little attention in either clinical 
or preclinical studies. Therefore, I also examined the effects of repeat exposure to the 
procedures of RUS and r-mTBI on the chronic behavioral and neurobiological outcomes in 
mice.  
I observed that after repeated exposure to RUS, stressed animals showed intensified 
contextual and cued fear memory recall and deficits in long-term recall of spatial memory. 
Exposure to the 5-injury r-mTBI model in combination with RUS, either once or twice, 
was associated with very similar outcomes, including: spatial memory impairments and 
reduced immobility time in the cued fear memory and forced swim tests relative to stressed 
animals. The changes in cued fear memory stress-coping behavior after r-mTBI may be 
driven by the hyperlocomotor activity observed after r-mTBI and may also involve an 
underlying complex behavior arising from the interaction between two opposite behavioral 
domains. Furthermore, I reported complex biological outcomes after repeated RUS and r-
mTBI that involved reduced spine density and dysregulation in NMDA receptor levels 3 
months after exposure to stress or r-mTBI. A summary of the findings presented in this 
thesis is presented in Tables 6.1 and 6.2. 
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 Fear memory 
recall 
Anxiety-like 
behavior 
Stress-coping 
strategies 
Spatial 
memory 
One RUS 
Exposure 
Contextual (one 
month after RUS, 
abrogated by DEX 
treatment) 
Cued (6 months 
after RUS) 
One month 
after RUS 
(abrogated by 
DHF 
treatment) 
Passive 
stress-coping 
at 6 months 
after RUS 
No change 
One RUS+r-
mTBI 
Exposure 
Contextual (No 
recall at any 
timepoint) 
Cued(only at the 
acute timepoint) 
No change 
relative to 
control 
animals 
No change 
relative to 
control 
animals 
r-mTBI-
related 
deficits at 6 
months after 
RUS 
Two  RUS 
Exposures  
Contextual (3 
months after the 
second RUS) 
Cued((3 months 
after the second 
RUS) 
Acute 
timepoint 
Passive 
stress-coping 
at 3 months 
after the 
second RUS 
Deficits in 
long-term 
spatial 
memory 
recall at 3 
months after 
initial training 
Two RUS+r-
mTBI 
Exposures 
Contextual (3 
months after the 
second RUS) 
Cued (Acute 
timepoint) 
No change 
relative to 
control 
animals 
No change 
relative to 
control 
animals 
r-mTBI-
related 
deficits at 3-
months after 
the second 
RUS 
Table 6.1. A summary of the main behavioral experiments presented in this thesis. 
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 HPA axis function Hippocampus 
structure 
BDNF Synaptic 
plasticity  
One RUS 
Exposure 
Low baseline plasma 
corticosterone levels 
(14, 30, and 180 
days after RUS) 
Low ACTH levels at 
6 months after RUS 
Low plasma 
corticosterone levels 
in response to acute 
stress, DEX/CRH 
and DEX/ACTH 
Decreased 
hippocampal 
CA1 volume at  
6 months after 
RUS 
Decreased 
hippocampal 
BDNF levels 
at 6 months 
after RUS 
No change in 
hippocampal or 
amygdalar 
markers at 6 
months after 
RUS 
Acute changes in 
the amygdalar 
markers (10 days 
after RUS) 
Two  RUS 
Exposures  
No change in 
corticosterone or 
ACTH levels at the 
acute timepoint and 
at 3 months after 
RUS 
Reduced spine 
density in the 
hippocampus 
(CA1) at 3 
months after 
the second 
RUS 
No change in 
hippocampal 
BDNF levels 
Reduced PSD95, 
CAMKII, 
GLUN2A/GlUN
2B ratio at 3 
months after the 
second RUS 
(hippocampus) 
Two 
RUS+r-
mTBI 
Exposures 
No change in 
corticosterone or 
ACTH levels at the 
acute timepoint and 
at 3 months after 
RUS  
Reduced spine 
density in the 
hippocampus 
(CA1) at 3 
months after 
the second 
RUS 
No change in 
hippocampal 
BDNF levels 
Reduced 
CAMKII, 
GLUN2A/ 
GlUN2B ratio at 
3 months after 
the second RUS 
(hippocampus) 
Table 6.2. A summary of the main neurobiological findings in this thesis.  
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Study limitations and future directions  
The work presented in this thesis to has significantly extended the existing 
literature, however I acknowledge that there are a few limitations in the current model and 
therefore will be proposing additional experiments to address these in the future.  
 
Addressing individual variability  
 Not all individuals exposed to a traumatic event develop PTSD, which can be 
explained by individual variability in stress resiliency attributed to genetic and epigenetic 
factors, particularly prior risk factors, such as childhood abuse or lack of social support. To 
account for the variability in stress response in our model, additional experiments using 
larger sample sizes should be planned. Subsequently, animals exposed to the RUS 
paradigm should be subdivided into susceptible and resilient groups based on their 
cumulative scores in multiple behavioral experiments. This approach is very similar to the 
procedures used to diagnose PTSD in humans, such as PCL-5 and CAPS, in which an 
individual is assigned a score based on the cumulative symptom severity. Biomarker 
discovery and genetic experiments can then be conducted on subgroups to explore the 
differences between the two populations. As depicted in Figures 2.4E and 2.4F, there are 
3 or 4 animals that show significantly higher freezing scores within the RUS group at 3-
month and 6-month timepoints, which suggests that our model can potentially be utilized 
to explore individual variability in response to stress. 
Another limitation to our studies is the lack of a clear understanding of the impact 
of each stressor on the observed phenotypes. In chapter 4 I showed that social isolation 
alone can produce HPA axis alterations that are very similar to the ones observed in our 
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RUS model, and therefore it is a key component in our stress procedures. In addition, the 
ability of stressed mice to recall fear memories 6 months after RUS (Chapter 2) also 
suggests that our fear conditioning procedures are critical to the paradigm. However, the 
impact of the 10 repeated exposures to TMT under restraint and unstable social housing 
during the 21-day RUS paradigm is not clear. Additional experiments comparing the 
outcomes of exposure to the RUS paradigm with and without any of these components 
should help elucidate their impact and possibly reduce the duration of the RUS paradigm. 
For example, if the deficits observed after our stress paradigm are comparable using 5 or 
10 exposures to TMT under restraint, the paradigm duration can be shortened to 14 days 
instead of 21, which would decrease the delay between stress exposures and testing, 
facilitating more high throughput studies in the future.   
Exploring the impact of sustaining an earlier mTBI on stress-related phenotypes 
In chapter 3, I examined the impact of concurrent exposure to r-mTBI and RUS on 
the behavioral outcomes in both conditions. In the context of human PTSD and TBI, these 
experiments are valuable in understanding the complexity of symptoms presentation in the 
comorbid condition. However, our experiments did not examine whether prior mTBI 
increases the risk to PTSD. This issue is highly relevant to the military, due to high number 
of mTBI sustained by soldiers during training prior to deployment.  To address this issue in 
our model, future experiments should involve receiving the 5-hit-mTBI model one or three 
months before exposure to the RUS paradigm followed by behavioral and molecular 
analysis at extended timepoints. Although few preclinical studies have examined the 
effects of earlier TBI on fear conditioning and anxiety-like behavior in stress models 
(reviewed in Chapter 1), none of these studies were performed on a chronic timescale like 
the studies presented here.  
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Chronic hypopituitarism, or decreased pituitary function, has been reported in 
approximately 16% of mTBI patients (Tan et al. 2017). The exact mechanism by which 
hypopituitarism evolves after mTBI, and it is effect on recovery times, is not clearly 
understood (Tanriverdi and Kelestimur 2015). Because a single exposure to the RUS 
model resulted in a significant change in HPA axis function, future studies should also 
examine the pituitary function after r-mTBI alone and after combined exposure to r-mTBI 
and RUS. These studies should be done after an acute stressor or HPA axis challenge to 
clearly elucidate the r-mTBI-related alterations. Because behavioral testing of laboratory 
animals is known to activate the HPA axis and increase the levels of plasma corticosterone 
(Arndt et al. 2009), attenuation in pituitary function and subsequent decrease in plasma 
corticosterone levels may affect the behavior of r-mTBI animals. These studies may also 
shed the light on the disinhibition behavior observed after r-mTBI.  
Understanding the role of FKBP5 in regulating GR activation. 
FK506 binding protein (FKBP5) has received a lot attention after the discovery of 
its contribution to GR resistance, observed in squirrel monkeys(Denny et al. 2000; 
Reynolds et al. 1999). Although squirrel monkeys show 50 times higher free cortisol levels 
than humans, no signs of hypercortisolism are observed in these animals due to FKBP5 
overexpression (Binder 2009; Hartmann et al. 2012; Merkulov et al. 2017). Multiple 
reports have shown that changes in FKBP5 polymorphisms leading to dysregulation in its 
functionality are involved in several stress and anxiety disorders, including PTSD (Binder 
2009). The role of cytoplasmic FKBP5 in the translocation of GR receptors and its 
implications in GR resistance have been extensively studied. However, several questions 
regarding the function of nuclear FKBP5 and the role of the single nucleotide 
polymorphisms associated with FKBP5 in mood disorders remain unanswered. In chapter 
195 	
4, I showed unique alterations in FKBP5 levels in stressed and socially isolated mice that 
can potentially be used to understand FKBP5 functions. These experiments were limited 
because I have only examined a single timepoint after acute stress (forced swim). A clearer 
understanding of regulation of the GR ultra-short feedback loop involving FKBP5 can be 
achieved by sampling mRNA and protein expression levels of different components of that 
loop (GR, FKBP51, FKBP52, HSP90) at different timepoints after acute stress or with 
variable intensity of the acute stressor (longer forced swim durations). The rate of 
expression can then be extrapolated and compared in control and stressed animals to 
highlight the differences. In addition, experiments exploring SNPs in the FKBP5 gene and 
posttranslational modifications and changes in FKBP5 expression levels in susceptible and 
resilient mice can also be conducted either at baseline or after acute stress. A 
comprehensive analysis of these data can help elucidate the functions of FKBP5, especially 
in the context of suitability and resilience to PTSD. This work can also be corroborated by 
conducting cell culture studies in iPSC derived hypothalamic cell lines from PTSD patients 
harboring related genetic polymorphisms, exposed to different elevated corticosterone 
concentrations to mimic an acute stress response.  
In conclusion, the work presented in this thesis provides a laboratory PTSD model 
with face and construct validity, paving the way for future studies to better understand the 
pathophysiology of PTSD and providing a relevant platform for interrogation of novel, 
targeted, therapeutic approaches which are urgently needed to combat the current and 
growing PTSD patient population. 
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